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3Abstract
The Wilms tumour antigen is a promising target for T cell-based tumour
immunotherapies. Vaccines against WT1 peptides tested in cancer patients
showed immunological and molecular responses. However, the clinical
responses observed were partial and it is currently not known whether
physiological levels of WT1 expression in some healthy tissues results in
the deletion or tolerance induction of WT1-specific T cells. In this PhD
project, TCR gene transfer into purified haematopoietic stem cells (HSCs)
was used to study the thymic development of WT1-specific T cells and their
fate in the periphery. Lentiviral constructs containing the genes for an HLA-
A2 allorestricted, murinised WT1 TCR or the genes for a control, viral
peptide-specific, LMP2 TCR, were generated. The conditions for
lentivirally-transduced HSC transplants were optimised. The results
obtained from WT1 TCR tranduced HSC transplants in HLA-A2Kb
transgenic mice demonstrated that thymocytes expressing this high-avidity
WT1 TCR were positively selected into CD8 T cells and emerged in the
recipient’s periphery. WT1-specific T cells exhibited a memory, CD44hi
phenotype correlating with rapid antigen specific killing, proliferation and
cytokine secretion of WT1-specific T cells in the absence of vaccination.
LMP2-specific T cells exhibited a naive-like, CD44low phenotype without
any antigen specific function. WT1-specific T cells persistent long-term in
the periphery of transplanted mice, and no autoimmunity was noted. The
results presented in this thesis show for the first time that T cell specificity
for a tumour-associated, self-antigen did not result in tolerance induction,
4but instead mediated the spontaneous generation of functionally
competent, memory phenotype T cells.
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Chapter 1 – General Introduction
1.1 Commitment to the T cell lineage and Early T cell development
1.1.1 From HSC to T cell precursor in the thymus
T cells, unlike all other haematopoietic cells require a specialised organ, the
thymus, dedicated to their development. T cell progenitors derived from HSCs
are imported from the blood into the thymus via the blood vessels near the
corticomedullary junction, (Petrie and Zúñiga-Pflücker, 2007) in a periodic
fashion(Donskoy et al., 2003, Foss et al., 2001). However, the nature of the
extrathymic T cell progenitors that seed the thymus is not yet conclusively
decided. Early thymic progenitors (ETPs) are the most immature thymocytes,
but a number of progenitor cells in BM and blood feature as candidates for the
actual T cell progenitors that enter the thymus and give rise to ETPs.
A model of T cell lineage development long-thought to be true was based on
the identification of common lymphoid and common myeloid progenitors (CLPs
and CMPs) in the BM on methylcellulose cultures (M. Kondon et al Cell 1997,
A Galy et al Immunity 1995, K. Akash et al Nature 2000) and suggested that
lymphoid progenitors separate from myeloerythroid progenitors early on in
haematopoiesis. According to this, the cells that settle in the thymus and
eventually differentiate into T cells would either be CLPs or their progeny and
as such should only be able to develop into T, B and NK cells. However, in
recent studies where single cell ETP cultures on OP9:OP9-Delta ligand 4
(DL4) stroma that can support both lymphoid and myeloid development,
showed that ETPs could differentiate towards either of the two lineages given
the right conditions (Wada et al., 2008, Bell and Bhandoola, 2008). These
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studies therefore disputed the established dichotomy between lymphoid and
myeloid lineage commitment and instead proposed a model were ETPs arise
from multipotent progenitor cells with T, B and myeloid potential.
The newly established model instead suggests that Notch1 signalling in the
thymus drives the commitment towards the T cell lineage by repressing gene
expression programs characteristic of other lineages. In vitro studies in OP9
and OP9-DL1 stroma cell cultures have shown that Notch1 signals
sequentially restrict the lineage potential of progenitor cells as these move
from the DN1 to the DN3 stage (Schmitt et al., 2004). However, the
involvement of Notch1 signalling in T cell lineage commitment was known even
earlier. In 1999 Pui et al using BM chimera experiments where donor BM cells,
were retrovirally transduced to express a constitutively active form of Notch1,
demonstrated that this resulted in the development of immature αβ T cells in
the BM while B cell lymphopoiesis was blocked (Pui et al., 1999). The reverse
was observed in the absence of Notch1 signalling in developing thymocytes in
a study by Radtke et al published the same year; in BM chimeras reconstituted
with induced Notch1-/- BM cells, T cell development was blocked early before
the DN2 stage. Instead thymocytes derived from these progenitors appeared
to differentiate into phenotypically normal, immature B cells within the thymus
(Radtke et al., 1999).
Recent evidence provided independently by two groups (Hozumi et al., 2008,
Koch et al., 2008), identified DL4 ligand as the partner for the Notch1 receptor
expressed in developing thymocytes which is necessary and sufficient to
impose T cell lineage commitment. Both groups by located the site of DL4
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expression to be in the thymic epithelial cells of the cortex, using DL4 antibody
and cytokeratin staining in immunohistochemistry analysis. They also
generated foxN1Cre:DL4 floxed mice to conditionally switch off DL4
expression in thymic epithelial cells. As this resulted in a block in T cell
development at the DN2 stage and in the ectopic development of immature B
cells in the thymus, it recapitulated the phenotype of mice bearing Notch1-/-
BM progenitors described above and provided the functional evidence for the
significance of DL4 expression by the thymic microenvironment, in T cell
lineage commitment and development. In accordance with these results, the
studies rejecting the long-established dichotomy between lymphoid and myelo-
erythroid lineages, reported that the myeloid potential of ETPs was most
clearly manifested in the absence of Notch1 signalling (Bell and Bhandoola,
2008, Wada et al., 2008).
1.1.2 The transition of DN thymocytes to CD4+CD8+ DP thymocytes
The transition between the DN2 to DN3 stages of T cell development primarily
depends on V(D)J recombinations of the Tcrγ, Tcrδ and Tcrβ gene loci,
directed by RAG1 and RAG2 (Mombaerts et al., 1992b, Shinkai et al., 1992)
which make up the lymphoid-specific recombinase RAG. Following successful
TCRβ VDJ rearrangement the pre-TCR complex, consisting of the rearranged
TCRβ chain, an invariant pre-TCRα chain (pTα) and the CD3 molecule
(Groettrup et al., 1993, Saint-Ruf et al., 1994) is assembled on the cell surface
of developing thymocytes. Notch 1 signalling plays a decisive role at this stage
of T cell development as well. In mice where the Notch1 gene was specifically
inactivated at the DN2 stage, V-DJ rearrangement of the TCRβ genes was
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impaired and resulted in a block at the pre-TCR checkpoint (Wolfer et al.,
2002).
The analysis of T cell development in TCRβ-/- mice (Mombaerts et al., 1992a),
as well as in pTα deficient mice (Fehling et al., 1995), showed that the
expression of both of these components of the pre-TCR complex on DN3
thymocytes is necessary for the proliferation and survival of thymocytes
committed to the TCRαβ lineage, as well as for their differentiation into
CD4+CD8+ DP T cells. The pre-TCR signalling which mediates this process,
called β-selection, has been shown to be ligand-independent in studies with
transgenic mice expressing a truncated form of TCRβ and pTα lacking their
extracellular domains (Irving et al., 1998). As β-selection is a developmental
checkpoint that tests the productive outcome of the TCRβ locus rearrangement
but not the specificity of this molecule, intuitively it is not surprising that an
extracellular interaction is not required for the signalling that drives
differentiation to the next stage. However, autonomous pre-TCR signalling
alone does not seem to be sufficient in driving differentiation to the DP stage,
as isolated DN3 cells fail to differentiate in vitro in the absence of a supporting
thymic microenvironment (Petrie et al., 1990). More recent data from studies
where Rag2-/- thymocytes - arresting in the DN3 stage - were transduced with
the genes for a TCRβ chain and subsequently cultured in OP9 or OP9-DL1
stroma cultures, showed that only in the presence of Notch1 signalling, TCRβ
gene transfer could mediate β-selection and the differentiation of Rag2-/- DN3
thymocytes into DP cells (Ciofani et al., 2004). It was therefore concluded that
cooperative signals from Notch1 and pre-TCR are required during β-selection.
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1.1.3 From pre-TCR to TCR expression on developing DP thymocytes
β-selection is followed by a transient downregulation of recombinase activity to
block further TCRβ gene rearrangement and in this way ensure that a single
TCRβ chain is expressed in each T cell. This process which is a classic
example of allelic exclusion is followed by a proliferative burst and the
differentiation of developing DN cells into CD4+ CD8+ Double Positive (DP)
cells migrating to the thymic cortex. Once these cells become quiescent DP
thymocytes, RAG1 and RAG2 activity resume and Tcr α- chain locus
rearrangement is established (Wilson et al., 1994, Petrie et al., 1995). The aim
of the recombination events at this site is not only to generate productive
rearrangements of the TCR α chain locus, but also to provide a TCRα chain
which when coupled to the already selected TCRβ chain gives rise to a self-
MHC restricted TCR. Nevertheless, if a newly formed TCRαβ specificity fails to
recognise self-p:MHC complexes on cortical Thymic Epithelial cells (cTECs), it
is still possible for such a DP thymocyte to be rescued as gene rearrangement
at this locus resumes giving rise to a different TCRα chain. A number of
attempts of forming an appropriate specificity are possible in the 4-5 days that
the cell spends in the thymic cortex.
The first evidence that allelic exclusion at the TCRα chain locus is not as
stringent as in the case of the TCRβ locus came about following a study by
Von Boehmer’s group published in 1992. The authors looked into the
expression of a transgene and endogenous TCRα chains in TCR Tg mice, at
different stages of thymocyte development. T cells expressing the transgenic
class I-restricted HY TCR were destined to commit to the CD8 lineage. The
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introduced TCR, as in most TCR Tg mice, was expressed earlier than in the
physiological T cell development. In this system the authors observed that
while the introduced TCRαβ heterodimer was expressed in CD8 SP cells, the
few CD4 SP thymocytes that were detected expressed the Tg TCRβ chain
paired with an endogenous TCRα chain. This was the case even though the
Tg TCRα chain was still produced and was present intracellularly in those
cells. These results, in combination with the observation that RAG1 and RAG2
activity only ceased after a thymocyte is positively selected, allowed them to
conclude that unlike the case of the Tcrβ locus, productive α chain
rearrangement is not enough to signal the end of the recombination events at
this site. Instead, it continues until the developing thymocyte assembles a
positively selecting TCRαβ heterodimer (Borgulya et al., 1992).
The main events in T cell lineage commitment and early T cell development
are schematically represented in figure 1.1.
Figure 1.1 Schematic Representation of early T cell development and T cell
lineage commitment.
T cell progenitors home to the thymus and enter this organ through the High
Endothelial Venules (HEV) that are present in the corticomedullary junction. Notch 1
signalling in the thymus progressively represses other haematopoietic lineage fates,
including the B cell lineage, driving in this way T cell lineage commitment.
TCR expression is a stepwise process in T cell development. RAG expression
drives V(D)J recombinations at the TCR locus commensing at the DN2 stage. A
rearranged TCR chain pairs with an invariant pre-TCR chain (pT ) at the DN3
stage, forming the pre-TCR. Signalling through the pre-TCR confirms successful
TCR chain rearrangement and together with Notch1 signalling mediates -
selection and the transition of DN3 thymocytes to the DP stage. At the DP stage,
TCR chain locus rearrangement takes place and pairing of a succesfully
rearranged TCR chain with the previously selected TCR chain results in the
expression of a complete TCR molecule on the cell surface. Positive selection
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Figure 1.1 (continued)
occurs at this point, assessing the expressed TCR for its ability to recognise
peptides on the self-MHC complex. if a newly formed TCR molecule fails to be
positively selected TCR chain rearrangement restarts to produce a different
TCR molecule. This process can be repeated a few times to allow the positive
selection of DP T cells, followed by migration to the medulla where negative
selection is generally thought to take place.
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1.2 T cell development and Central Tolerance
The aim of positive selection is to identify immature DP T cells expressing
TCRs with intermediate affinity for self-peptide:self MHC complexes (self-
p:MHC) and induce them to differentiate into mature single positive (SP) CD4
or CD8 thymocytes. Once developing thymocytes reach the SP stage,
specificity for self p:MHC has the opposite effect and leads to their deletion, a
process called negative selection. Negative selection, one of the major
mechanisms of central tolerance, ensures that autoreactive T cells are purged
from the circulating T cell repertoire to avoid autoimmune damage on healthy
tissues. In this simplified description of positive and negative selection, the
paradox that has troubled scientists over the years quickly becomes apparent.
Recognition of self is what seems to positively select DP T cells in the cortex,
but also what appears to delete them as SP T cells in the medulla. A number
of groups took up addressing this contradiction and 3 main theories have
emerged from these studies, namely the altered peptide, the affinity and the
avidity models of thymocyte selection.
1.2.1 The altered peptide model of thymic selection
The altered peptide model suggested that the peptides displayed by APCs
mediating positive selection in the cortex differ both from those presented in
the medulla where self-Ag recognition leads to cell death, as well as from
those that mature T cells would encounter in the periphery. In that way the
cells that successfully go through positive selection are not doomed to be
deleted in the next step of thymic development, but at the same time they are
also unlikely to cause autoimmunity as they are not positively selected on the
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same self-peptides that they see in the periphery (Marrack and Kappler, 1987).
A schematic illustration of the altered peptide model is shown in figure 1.2. The
same group proposing this model went on to test it by isolating and comparing
peptides from MHC class II proteins in the spleen and the thymic cortical
epithelium. Their data showed that there was no fundamental difference in
self-peptides presented by MHC class II by the two different cell types and
consequently the altered peptide hypothesis was rejected (Marrack et al.,
1993).
Figure 1.2 Schematic diagram of the altered peptide model of positive and
negative thymic selection. The altered peptide model predicted that in the thymic
medulla, generally accepted to be the site of negative selection, the peptides
presented would consist of peripheral tissue antigens but would be different from the
peptides presented to developing thymocytes in the thymic cortex, the site of positive
selection. In this way, self p:MHC recognition in the cortex would allow positive
selection, whereas self p:MHC recognition in the medulla (where the self p pool is
different from the cortex) would drive thymic deletion.
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1.2.2 The affinity model of thymic selection
The affinity model of positive and negative selection, first suggested by Sprent
and co-workers (Lo et al., 1986) on the other hand, has been supported by a
substantial amount of data by different groups and has been widely accepted.
As illustrated in figure 1.3, this model suggests that thymocytes expressing
TCR with no or very low affinity for self p:MHC die by neglect, whereas very
high affinity contacts lead to death through negative selection. In 1996, Alam et
al used a cloned OVA-specific TCR, in plasmon resonance experiments that
allowed them to measure the kinetics of TCR-p:MHC interactions with different
positive and negative selecting ligands in fetal thymic organ cultures (FTOCs).
The purpose of this experiment was to correlate the affinity of each p:MHC
ligand to the selection outcome. They were able to clearly demonstrate that
positive selecting affinities were always up to 1-log lower than negative
selecting affinities (Alam, 1996).
Figure 1.3 The affinity model of thymic selection. The simplest form of the affinity
model of thymic selection suggests that positive and negative selection are both
decided by the affinity of the TCR-self p:MHC interaction, irrespective of the location
of this interaction and whether it takes place between T cell and cTEC, mTEC, or BM-
derived APCs. An intermediate affinity interaction allows developing T cells to be
positively selected. If the affinity of the interaction is too low, then developing T cells
die by neglect whereas if the interaction is of too high affinity the cells are deleted to
prevent autoreactive T cell specificities from emerging in the periphery.
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1.2.3 The avidity model of thymic selection
The avidity model predicts that the quantity of interacting TCR-self p:MHC
together with the quality of the individual interactions decides whether a
thymocyte is positively or negatively selected. It came about following two
studies demonstrating that the administration of negative selecting peptides at
extremely low doses could result in positive selection of the relevant
developing T cells (Sebzda, 1994, Ashton-Rickardt, 1994). The data provided
by Alam et al, could be in agreement with both models.
However, an elegant study published in 2006 by Daniels et al has provided
further evidence in favour of the affinity model. This group studied positive and
negative selection of OT-I transgenic DP thymocytes in FTOCs in the presence
of different OVA variant ligands exhibiting a hierarchy of affinities for this TCR.
As the affinity of the ligands for the TCR was measured by Tetramer binding,
this assay was performed on live cells and the data obtained took into account
the participation of the CD8 co-receptor in the TCR-p:MHC complex
interaction. Since among the ligands the least potent negative selector was
only 1.5 times more potent than the strongest positive selector, the authors
were able to show that very slight increases in the affinity of the TCR-p:MHC-
CD8 interaction, but importantly not in the amount of added peptide, resulted in
a shift from positive to negative selection. It was therefore appropriate to
conclude that only a very narrow range of positively selecting autoreactive
affinities could allow developing T cells to escape negative selection (Daniels,
2006).
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1.2.4 The altered peptide model returns and complements the affinity
model.
Despite the great amount of evidence in support of the affinity model, on its
own this theory does not take into account the spatial and temporal
compartmentalisation of thymic selection processes and provides an
explanation for negative selection, but not for other central tolerance
mechanisms such as the deviation of autoreactive T cells to the Treg lineage.
Furthermore despite the sophistication of these studies, the peptides used
were never shown to be physiologically expressed and presented in cTECs or
indeed known to contribute to positive selection under natural conditions.
In this context, recent studies comparing the pathways through which MHC-
bound peptides are generated and presented in cortical TECs (cTECs),
medullary TECs (mTECs) and peripheral APCs put forward the idea that the
affinity model and the previously rejected altered peptide hypothesis for
positive and negative selection might actually complement each other (Klein et
al., 2009). In all cells, proteolysis that gives rise to the antigenic peptides
presented by MHC class I molecules is mediated by multicatalytic proteinase
complexes called proteasomes (Brown et al., 1991, Rock et al., 1994). These
cylindrical structures consist of 4 heteroheptameric rings, 28 subunits in total
and of these the β1, β2 and β5 subunits mediate the catalytic function. IFNγ-
induced versions of these particular subunits are present in immune cells.
These proteasomes are more efficient in producing antigenic peptides and are
called immunoproteasomes. Almost coincidentally, Murata et al came across
the gene for a different version of the β5 proteosome subunit. They established
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that this was exclusively expressed in the thymus and so they called it β5t (t for
thymus). Using immunostaining of mouse thymus sections for β5t, the Ly51
and UEA-I and CD11c markers of cTECs, mTECs and DCs respectively, they
were able to demonstrate that this newly discovered proteosomal subunit was
exclusively found in the thymic cortex and in particular was expressed in
cTECs (Murata, 2007). Immunoblot analysis of different thymic cell populations
not only confirmed these results but also revealed that cTECs mainly contain
thymoproteasomes defined as proteasomes containing β5t, β1i and β2i
subunits. Thymoproteasomes, unlike immunoproteasomes and proteasomes
were found to have weaker chymotrypsin-like activity and consequently are
expected to cleave proteins in a different fashion. This suggests that an altered
pool of peptides might be available and be presented by cTECs during positive
selection, (than during negative selection). In the absence of the
thymoproteasome in β5t-/- knockout mice, thymic CD8 T cell development did
not progress beyond the DP stage and there was an associated dramatic
decrease in the size of the CD8+ T cell compartment. In view of these data
and the fact that cTECs are known to be instrumental in mediating positive
selection, the same group went on to further investigate the role of the
thymoproteasome at this stage of T cell development by crossing HY-TCR Tg
mice with β5t deficient mice.
Normally in female HY-TCR Tg mice, HY-specific CD8 T cells are positively
selected, while in male mice developing HY-specific T cells are deleted by
negative selection as they recognise the HY-self antigen. In the absence of β5t
in these mice, positive selection was highly impaired in female mice, whereas
negative selection in male mice remained unaffected. This proved the
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essential role of β5t in positive selection. Beyond these results, the authors
were able to show that the reduced numbers of CD8 T cells generated in β5t
deficient mice remained functional in response to TCR engagement, but
instead displayed an altered and diminished TCR repertoire compared to wild-
type mice and hence were unable to mount an effective immune response to
allogeneic and viral antigens (Nitta et al., 2010).
The importance of the thymoproteasome in positive selection, strongly
proposes a come-back of the altered peptide theory of positive and negative
selection, even if at this point the available technologies only allowed Nitta,
Murata and co-workers to speculate in the nature and uniqueness of the
peptide repertoire presented by cTECs facilitating positive selection.
The comeback of the altered peptide model and the well established affinity
model together, as illustrated in figure 1.4, provide an explanation as to how
recognition of self-antigen can result in the divergent developing T cell fates of
positive or negative selection. However, they do not give us an insight into the
nature and mechanisms by which peripheral self-antigens appear in the
thymus.
Figure 1.4 Schematic diagram of the current model of positive and negative
selection combining the altered peptide and affinity models. A combination of
the altered peptide and affinity models of positive and negative selection provides a
model that takes into account the spatial and temporal compartmentalisation of these
processes. In cTECs a distinct proteasome is present (the 5t-containing
thymoproteasome) and this cleaves proteins in a different fashion than proteasomes
present in mTECs and BM-derived APCs. Therefore, a different pool of self-peptides
is available in the cortex compared to the medulla. Self-Ag expression in the medulla
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Figure 1.4 (continued)
on the other hand, mirrors that of peripheral tissue self-Ags. In this way it becomes
possible that a TCR-self p:self MHC interaction in the cortex will allow the positive
selection of a developing T cell, but once this cell migrates to the thymic medulla the
affinity of the TCR-self p:self MHC interaction (where the self p in the medulla is
different from that in the cortex) decides whether the cell survives negative selection
or not.
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1.2.5 Clonal deletion – a focal point for central tolerance
Despite early seminal work in the 50s suggesting the presence of mechanisms
preventing autoimmunity, for years it was presumed that tolerance was
established merely by the inactivation of mature, autoreactive lymphocytes.
This hypothesis was based on in vitro experiments demonstrating the
presence of autoreactive clones in mature lymphocyte populations (Bruce
Smith and Pasternak, 1978, Glimcher and Shevach, 1982). In particular,
Glimcher and Shevach in their attempt to produce antigen specific T cell
hybridomas, came across a large population of cells exhibiting a response to
H-2-matched splenocytes, in the absence of the priming antigen. The authors
were able to identify the stimulatory self-antigen to be the I-Ad subregion of the
MHC complex. The very presence of self-MHC specific T cells with
autoreactive potential was later on used by Kappler et al to provide the first
strong evidence in favour of clonal deletion and central tolerance. In two
accompanying papers the authors first described a monoclonal antibody that
was reactive and could hence be used to identify TCRs containing the Vβ17α
chain (Kappler et al., 1987b). Having shown that a great proportion of Vβ17α T
cells were reactive to an IE class II MHC molecule, they then demonstrated
that such T cells were present in a mouse strain that lacks expression of the IE
molecule, but not in mice where this molecule was expressed. Further
experiments showing that Vβ17α+ T cells were absent in the periphery of mice
expressing the IE molecule, but present at normal levels up to a certain stage
in thymic T cell development allowed them to confidently conclude that the
clonal deletion of autoreactive immature thymocytes is an important tolerance
mechanism (Kappler et al., 1987a).
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The concept that immunological tolerance to self is largely obtained during
thymic T cell development was soon established. Whilst the consensus initially
was that the scope of central tolerance was restricted to self-antigen coming
from ubiquitously expressed proteins and from abundant blood-born self-
antigens, the 1990s saw a rising number of papers reporting the expression of
tissue-specific genes at very low levels in the thymus.
1.2.5.1 Peripheral Antigens are ectopically expressed in the thymus
The first publication to broach the idea that ectopic expression of tissue-
restricted antigens could be a physiological property of thymic stromal cells
came from Jolicoeur et al in 1994. This group utilised the rat insulin promoter
(RIP) to express a viral antigen (Tag) in pancreatic β islet cells and
characterise the antigen-specific T cells response against these cells in the
presence of different amounts of antigen. They were surprised to find that
irrespective of the amount of antigen expressed, Tag-specific T cells were
profoundly tolerant to the β cell antigen and subsequently examined transgene
and endogenous insulin gene expression in the thymus, to find that these and
other pancreatic genes were indeed expressed at low levels intrathymically
(Jolicoeur et al., 1994). This report was followed by numerous others showing
the “ectopic” expression of tissue-specific parenchymal peptides conferring a
protective advantage against corresponding autoimmune conditions, both in
mouse and human (Egwuagu et al., 1997, Vafiadis et al., 1997, Pugliese et al.,
1997, Heath et al., 1998, Sospedra et al., 1998). Klein et al went further to
show that the expression of CRP, an acute inflammatory phase inducible
protein, is expressed in the thymus even when it is not expressed
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peripherally(Klein et al., 1998), providing in this way evidence that thymic
expression of peripheral antigens is not only independent of the location of
each antigen, but also of the time at which antigens are expressed.
Each of these and other studies reporting promiscuous gene expression in the
thymus identified different thymic cell subsets as the ones where this
phenomenon was taking place. In 2001 Derbinski et al shed light on this
controversy with the publication of a comprehensive analysis of promiscuous
gene expression (PGE) in highly purified thymic stromal cell subsets,
combining density fractionation and cell sorting techniques. Their findings
showed that all of the genes assessed were expressed in mTECs, while some
of those were also present in either of the other 3 cell subsets, cTECs, DCs
and macrophages. However, the thymic expression of 50% of the genes
analysed was exclusive to mTECs. Interestingly they also showed that the
promiscuous expression of any particular antigen was limited to 100-1000
mTECs per thymus and on analysing mTECs at the single cell level only a
minor fraction of those exhibited PGE (Derbinski et al., 2001).
A year later Anderson M.S. et al, went on to answer the question of what
drives this phenomenon. They followed up on developments of the late 1990s
relating to the identification of Autoimmune Regulator (AIRE) as the single
gene defect causing the rare autoimmune condition Autoimmune
Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED) (Nagamine
et al., 1997, Rosatelli et al., 1998) and the localised and exclusive high level
expression of this gene in the thymus and in particular in mTECs (Heino et al.,
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1999). Their working hypothesis was that loss of AIRE expression in mTECs
would result in the prevention or modification of PGE in these cells.
Firstly they produced BM chimeric mice to control the expression of aire in
haematopoietic (radiosensitive) and TECs (radioresistant) cells and were able
to show that autoimmunity only occurred when the radioresistant TECs were
Aire-/-. Then to directly assess whether this autoimmunity was due to a related
change in PGE in TECs, they probed 12000 mouse genes in mTEC RNA
preparations from Aire-/- and WT mice using labelled complementary RNA. A
link was indeed strongly suggested as the expression of a substantial number
of genes, including previously identified promiscuously expressed genes was
silenced or significantly repressed in these cells in the absence of Aire. As 2
known autoantibody-targets in patients with APECED syndrome were shown to
be abolished in Aire-/- MECS, this was the first data directly implying that
absence of Aire impedes the thymic expression of a particular self-Ag and
subsequently results in the escape of the corresponding autoreactive T cells in
the periphery which cause autoimmunity(Anderson, 2002). However, the first
formal evidence to substantiate this link was presented by DeVoss et al a few
years later.
DeVoss et al pursued the cause of spontaneous autoimmune uveitis in Aire-/-
mice, the eye being one of the organs targeted by autoimmunity in this setting.
Sera from Aire deficient mice, previously shown to contain autoantibodies
specific for the photoreceptor layer of the retina (Anderson et al., 2002), were
used to immunoblot whole-eye extract identifying the Interphotoreceptor
retinoid binding protein (IRBP) as the main target Ag. Quantitative RT PCR on
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cDNA from WT and Aire-/- purified thymic stroma cells showed that IRBP was
expressed in the thymus in an aire-dependent fashion. Finally, to prove that
autoimmune uveitis in aire deficient mice was linked to the absence of IRBP
expression in the thymus, DeVoss et al crossed IRBP-/- with Aire-/- mice.
Double knockout animals did not show any evidence of autoimmunity against
the eye, while other organs usually targeted by autoreactive cells in aire-/-
mice where still affected. These results illustrated that, in the absence of Aire,
autoimmune uveitis is an IRBP-specific response (DeVoss et al., 2006).
1.2.5.2 Models of Promiscuous Gene Expression (PGE) in the thymus
Interestingly despite the clear link between Aire and PGE, regulation of the
latter at the cellular and molecular level is not based on a straightforward
relationship between the two. Derbinski et al performed a detailed gene
expression analysis in each of the progressively more differentiated subsets of
mTECs, defined and FACS sorted on the basis of varying expression levels of
lectin UEA binding sites, CD80 and MHC class II molecules. Comparison of
global gene expression performed by microarray analysis and RT-PCR in the
different thymic cell populations confirmed that mTECs are the cells
specialising in PGE and the authors were able to show that strikingly almost
every single tissue was represented by the expression of at least one tissue
restricted Ag (TRA) in these cells. On examining the expression of casein β
and testis lipid binding protein, the former a gene expressed in the mammary
gland of female mice in late pregnancy and the latter a gene expressed in
male mice in the testes, the levels of each of these two proteins in mTECs did
not differ among male and female animals. With this experiment the authors
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demonstrated that PGE is not subject to the normal tissue-, sex- and
development gene regulations.
They then went on to show that PGE of 21 out of 22 genes studied and Aire
expression correlated with increasing CD80 expression levels on mTECs. As
the authors worked on the presumption that progressively differentiated
mTECs are marked by increasing levels of CD80, they concluded that their
results were clearly in favour of a terminal differentiation model of PGE. This
model proposed that as mTECs matured and differentiated they expressed
increasing levels and numbers of peripheral Ags in a cumulative fashion. A
contrasting model to interpret the same results was then proposed by Farr et
al. This group had a different view on the differentiation profile of mTECs and
suggested a progressive restriction model of PGE where the earliest thymic
epithelial progenitors are not yet committed to the thymic lineage and are
multipotent. Therefore, multiple conserved transcriptional programmes are still
able to be active and consequently a broad spectrum of peripheral Ags is
expressed in immature mTECs. As these progenitors then mature their
developmental potential is progressively restricted and most of the
transcriptional programs sequentially become silenced. Subsequently each
mTEC commits to one of numerous terminally differentiated cell gene
expression profiles, expressing a discrete set of TRA according to the
peripheral lineage fate it has taken. Consequently all mature mTECs put
together compose a mosaic of peripheral tissue antigen expression in the
thymus (Gillard and Farr, 2005).
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This disagreement was addressed with an elegant study by Gray et al,
published in 2007. As one model was predicting that PGE is prominent in the
terminally differentiated subset of mTECs and the opposing model was
suggesting that this was a property of immature, uncommitted mTECs the
authors decided to investigate the differentiation state and the dynamic
relationship between different mTEC subsets distinguished by Aire and MHC
class II expression. To do this they first identified 3 subsets of TECs, the
cortical epithelial cells (CECs), the medullary epithelial cells expressing high
levels of CD80, and MHC class II (MEChi) and the medullary epithelial cells
expressing low levels of these two molecules (MEClo) and they confirmed by
intracellular staining that only a very small proportion of MEClo cells express
Aire while this molecule is highly expressed in 50-60% of MEChi cells. BrdU
incorporation and decay kinetics determined in in vivo experiments suggested
that Aire+ve MEChi cells are not cycling and are derived from proliferating
Aire-ve MEChi cells. The post-mitotic, most differentiated Aire+ve MEChi
subset appeared to also have a rapid turnover. Based on these findings the
authors wished to investigate the possibility that Aire promotes the apoptosis
of the MEChi cells that express it. They therefore transfected a MEC cell line
with an Aire-GFP fusion protein or the GFP protein alone, and assessed
proliferation and apoptosis of these cells by BrdU incorporation and Annexin V
FACS analysis respectively. Their results showed that Aire did not affect
proliferation but promoted apoptosis.
Overall, the authors felt that their results strongly supported the terminal
differentiation model and proposed an intriguing refinement to it. Aire-ve
MEClo cells differentiate to Aire+ve MEChi cells possibly through an Aire-ve
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MEChi intermediate stage and the Aire molecule induces apoptosis either
directly by turning on an apoptosis program or indirectly by upregulating
peripheral tissue antigen expression to the extent where protein synthesis
overwhelms the cells and causes death through ER stress (figure 1.5).
Whatever the mechanism, cell death of Aire+ve MEChi cells that express high
levels of peripheral tissue Ags, makes these Ags available for cross-
presentation by the DCs that are present in the medulla (Gray et al., 2007).
Clonal deletion is the hallmark of central tolerance. Shifting into the Regulatory
T cell (Treg) lineage has also been associated with self-antigen specificity of
developing CD4 T cells in the thymus. However, the mechanism behind
commitment to the Treg fate in the thymus remains controversial and as it is
not linked CD8 T cell central tolerance, it will not be discussed further.
Figure 1.5 Progressive differentiation model of Aire driven PGE. Aire-ve
medullary epithelial cells (MEC) differentiate to Aire+ve cells upregulating the
expression of MHC-II and CD8 at the same time. Aire expression induces apoptosis
of the terminally differentiated MECs. In the terminally differentiated stage, MECs
express great amounts of peripheral tissue Ags at this terminally differentiated stage
and a link has been suggested between protein overload and apoptosis induction.
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Figure 1.5 (continued)
The promiscuously expressed self-Ags are disseminated in the medulla following
the MECs death and obtained by BM-derived APCs for cross-presentation. This is
thought to facilitate negative selection.
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1.3 CD8 T cells in the periphery and Peripheral Tolerance
Despite the elaborate processes of central tolerance, it is well established that
some autoreactive T cells escape to the periphery. More often than not, such T
cells are comprised of cells with low-avidity self-specificities (Liu et al., 1995).
Rarely, high avidity, self-reactive specificities are found, if the Ag was not
presented in the thymus. It is therefore no surprise, that peripheral tolerance
mechanisms are employed to compromise the function of these T cells and
prevent autoimmunity. Clonal ignorance, deletion, anergy and suppression are
the 4 main mechanisms of peripheral tolerance. The latter spans central and
peripheral tolerance as Tregs that mediate suppression, can be generated
both in the thymus and in the periphery, but act in the periphery. Prior to
discussing peripheral tolerance, the parameters contributing to CD8 T cell
activation will be discussed.
1.3.1 Antigen processing and presentation to CD8 T cells
CD8 T cells recognise antigen presented to them on MHC class I molecules.
Intracellular proteins produced in the cytosol - viral, mutated as in a tumour
cell, and normal proteins - are degraded by proteasomes as part of a
continuous turnover process. Peptides longer than 7 amino acids are
transferred to the ER through two ATP-dependent peptide transporters, called
transporters associated with antigen processing (TAP). In the ER the amino
acids’ length is adjusted to 8-mers and 9-mers, the size of class I restricted
antigenic epitopes. In this organelle they also meet and bind to the MHC class
I molecules, forming a stable p:MHC class I complex which is subsequently
transferred to the cell surface. Naive, as well as memory CD8 T cells scan
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these complexes that are in fact a sample of the intracellular compartment of
each cell. While effector and memory CTLs can respond to p:MHC complexes
on any cell, naive CD8 T cells are more resilient to activation and require Ag
presentation by activated professional APCs.
1.3.2 Cross presentation and its role in T cell activation and peripheral
tolerance.
In the mid-70s Bevan et al immunised animals with allogeneic cells bearing
different minor and major histocompatibility antigen genes from the host and
observed that a number of CTLs specific for the donor minor antigens
presented on host MHC class I molecules were generated (Bevan, 1976).
These results revealed for the first time that class I antigens could somehow
be transferred from one cell to an APC which can then prime a CTL response.
The phenomenon of cross-presentation has been extensively studied since. In
the 1990s DCs and macrophages were identified as the specialised cells
capable of cross-presentation (Kovacsovics-Bankowski et al., 1993, Rock et
al., 1990, Rock et al., 1993), acquiring exogenous antigen through
phagocytosis (Shen et al., 1997) and macropinocytosis (Norbury et al., 1995).
Nevertheless, how extracellular proteins taken up in endosomes and
phagosomes, access the MHC I processing machinery which is typically found
in the cytosol, and how peptides derived from extracellular proteins meet the
MHC class I molecules to form the cross-presenting p:self MHC I molecules,
remain matters under investigation. Almost 10 years ago it was shown that the
necessary elements for peptide loading onto the MHC class I molecule,
classically thought to be exclusively found in the ER, are also found in
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phagosomes (Ackerman et al., 2003, Houde et al., 2003). The same year
Guermonprez et al showed that in the case of DCs - the APCs that are most
effective in cross-presentation - fusion of the ER to the phagosomes is what
provides the peptide loading machinery to the latter (Guermonprez et al.,
2003). The processes of direct class I antigen presentation and cross
presentation are described in the schematic diagram in figure 1.6.
Figure 1.6 Class I Antigen processing and presentation. Class-1 antigen
processing and presentation takes place in all cells expressing MHC class I
molecules and is the means to present the intracellular environment to CD8 T cells.
In the example shown on the left in the above diagram (1) a virally infected cell
produces viral peptide epitopes through the proteolytic degradation of viral proteins
by the proteasome. These viral peptides are transferred in the endoplasmic
rediculum (ER) through two ATP-dependent peptide transporters (TAP). In the ER
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Figure 1.6 (continued)
the class I epitopes bind to MHC class I molecules, forming a stable p:MHC class I
complex which is then transferred to the cell surface. Naive and memory CD8 T
cells can both recognise Ag presented in this way, however in the absence of co-
stimulation only previously primed, memory T cells are expected to produce a
functional, Ag-specific response. Cross-presentation, shown in (2) refers to the
processing and presentation of extracellular antigenic material by professional APCs
on class I, rather than class II molecules. It involves the uptake of extracellular
proteins by macropinocytosis and phagocytosis of dying, infected (or transformed)
cells. The mechanism by which the phagocytosed extracellular proteins then enter
the class I antigen processing and presentation pathway is unclear. Some studies
suggest that fusion of the ER to phagosomes facilitates Ag loading on class I
molecules. Cross-presentation of class-I peptides on professional APCs can
stimulate memory T cells, but also prime naive CD8 T cells which in this setting will
recognise Ag in the presence of co-stimulation. Primed CD8 T cells can then
migrate to the periphery as effector/memory T cells and respond to direct Ag
presentation by infected or transformed cells.
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Cross-presentation can be used to prime a CTL response, whilst it can also
orchestrate the containment of autoreactive T cell specificities that circulate in
the periphery. Kurts et al first reported that self-Ags, from constitutively
expressed proteins, can be cross-presented by professional BM-derived APCs
in the draining LNs of the organs expressing them and that this can lead to the
activation of autoreactive T cells (Kurts et al., 1996). They then went on to
study the fate of these autoreactive T cells that see their cognate Ag in the
periphery through cross-presentation. As their model-self Ag, OVA, was
expressed in kidneys, pancreas as well as in the thymus, they first
thymectomised and grafted a B6 thymus in their RIP-OVA Tg animals to avoid
OVA thymic expression. Then they replaced the BM of these mice with BM
cells from OT-I TCR Tg mice. The Tg self-Ag specific OT-I T cells that were
generated in the recipient animals, escaped thymic negative selection and
appeared to be activated in the periphery. However, despite their initial Ag-
specific proliferation they were subsequently gradually deleted and the mice
did not develop diabetes. Thus, cross-presentation was shown to also mediate
peripheral tolerance to self-Ags and this phenomenon was named cross-
tolerance (Kurts et al., 1997).
1.3.3 Requirements for CD8 T cell activation vs tolerance
When a CD8 T cell encounters its cognate Ag, with the exception of very low
affinity specificities that render such a meeting an insignificant event, a
decision is made as to whether the cell will be activated or tolerised. Therefore
studies aiming to elucidate the prerequisites of T cell priming have also
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contributed important information regarding the requirements for tolerance
following TCR - p:MHC interaction.
1.3.3.1 Co-stimulation is required for naive CD8 T cell activation
The 2 signal hypothesis for effective CD8 T cell priming is well established.
The first signal involves Ag recognition and engagement of the TCR with its
cognate p:MHC complex presented on a professional APC. Binding of co-
stimulatory receptors on the responding T cell, of which CD28 is the prototype,
with a choice of ligands such as CD80 and CD86 on the activated APC
presenting the Ag, leads to IL-2 production by the T cell. In that way, CD28
signalling conducts signal 2 which promotes the proliferation and survival of
primed T cells (Thompson et al., 1989, Harding et al., 1992). Co-stimulatory
receptor ligands are upregulated on the APCs with the provision of CD4 T cell
help when these cells simultaneously recognise a related class II Ag presented
on MHC class II on the same cell (Bennett et al., 1997). Alternatively, binding
of Toll-like Receptor and other Pattern Recognition Receptors to their
appropriate ligands found on the invading microbes can also result in the
maturation of APC.
1.3.3.2 The three-signal model of CD8 T cell activation and peripheral
tolerance
Incomplete activation in the absence of signal 2 is considered to be the major
cause of T cell anergy and deletion, and this was first shown for CD4 T cells. In
the case of CD8 T cells, signal 1 and 2 will only lead to a dampened Ag-
specific response if a third signal, in the form of IL-12 and IFNα, is not
provided. This concept was first put forward by Curtsinger JM et al in 1999.
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This group found that in vitro, IL-12 was essential for highly purified naive CD8
T cells to progress from being merely clonally expanded following signal 1 and
2 induction by artificial APCs, to becoming differentiated cytolytic effectors. In
vivo peptide immunisation experiments, demonstrated that administration of IL-
12 could replace adjuvant in stimulating an antigen specific CD8 T cell
proliferative response in vivo (Curtsinger et al., 1999). The role of IL-12 in
mounting a full blown CD8 T cell response that leads to the formation of a
memory population, was then confirmed with adoptive transfer of TCR Tg T
cells and peptide immunisation experiments in the presence of adjuvant or IL-
12 (Schmidt and Mescher, 1999). The contribution of signal 3 in the decision
between CD8 T cell activation versus tolerance was subsequently highlighted
in a later study by Curtsinger et al. The authors showed that IL12 not only was
necessary for antigen specific T cell differentiation into functional effector cells,
but also that CD8 T cells expanding in response to antigen and costimulation
alone remained unable to show in vivo functional activity upon restimulation in
the presence of all 3 signals and were therefore tolerised (Curtsinger et al.,
2003).
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1.3.4 Modes of peripheral T cell tolerance
1.3.4.1 Clonal ignorance
In the early 90s, Pircher et al used an LCMV TCR Tg model where the T cells
exhibited a range of reactivities to different LCMV virus variants to compare the
avidity of TCR-p:MHC interaction required to cause negative selection in the
thymus with that required to cause activation in the periphery. Their
experiments revealed that the avidity threshold for thymic deletion was lower
than for T cell activation and suggested that this “safety margin” between the
different strengths of TCR-p:MHC interactions required to induce each of these
two phenomena protects the periphery from low avidity self-Ag specific T cells
that evade central tolerance (Pircher et al., 1991).
The higher activation threshold of T cells in the periphery than in the thymus
can, to some extent, prevent the activation of autoreactive low affinity T cells
when these meet their cognate self-Ag in the periphery. Nevertheless, high-
affinity autoreactive T cells are also infrequently present in the periphery. The
physical separation of naive T cells from parenchymal cells that might express
their cognate Ag of such high affinity self-specificities is another protective
mechanism preventing autoimmunity. When in the blood naive T cells express
CCR7 which binds to the CCL21 and CCL19 chemokines, expressed by
lymphoid tissue, and leads them to migrate to the lymph node cortex. Naive T
cells also express a receptor for a lipid molecule called sphingosine 1-
phosphate (S1P). The expression of this receptor is downregulated upon T cell
activation in the LN. However, if TCR ligation does not take place this receptor
remains expressed and binds to S1P which is expressed in an increasing
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concentration gradient between lymphoid tissue and blood. Therefore, this
interaction mediates the return of the naive T cells to blood. Using a TCR Tg
mouse model, where all T cells were specific for the LCMV epitope GP -
expressed in the β islets of the pancreas - Ohashi et al demonstrated that GP-
specific T cells escaping central tolerance remained ignorant of their cognate
Ag in the periphery and caused no autoimmunity. This was the case even
though they were fully functional upon stimulation in in vitro and in vivo assays.
The authors therefore proved the hypothesis of clonal ignorance. Nonetheless,
once Tg mice were infected with the CMV virus, the previously ignorant GP-
specific T cells encountered their cognate Ag in the context of infection,
became fully activated and infiltrated the pancreas in an Ag-specific manner
consequently causing autoimmunity in the form of diabetes. Therefore, the
authors also proved that this clonal ignorance is an inherently unreliable mode
of peripheral tolerance. (Ohashi et al., 1991).
The ease with which clonal ignorance can be overcome is not surprising given
that even though naive T cells navigate only between blood and lymph nodes,
upon their passage through secondary lymphoid organs they scan APCs that
previously sampled the antigenic environment of parenchymal tissues and
maybe able to cross-present it. As mentioned above cross-presentation by
immature APCs, in the absence of co-stimulation and cytokines such as IL-12,
typically fail to prime naive T cells. However, it is often the case that certain
infections can precipitate autoimmune disease and one of the mechanisms
behind this phenomenon is thought to be cross-presentation of self-Ags by
APCs that have been activated by the microbial challenge (Mills, 2011).
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1.3.4.2 Deletion and Anergy
Peripheral tolerance induced by the cross-presentation of self-Ags mainly
derived from apoptotic cells, in the absence of inflammation, occurs through
either clonal deletion or anergy. Each of these two mechanisms are
considered to be more important in safeguarding the periphery from
autoreactive T cells than clonal ignorance. While numerous studies have
attempted to distinguish the different requirements driving one or the other,
both deletion and anergy are processes that can take place together in the
same experimental system or physiological situation.
1.3.4.2.1 Peripheral Deletion
Clonal deletion of autoreactive T cells in response to the cross-presentation of
their cognate Ag by professional APCs was described earlier in section 2.2.
The peripheral deletion of autoreactive T cells would obviously be the most
permanent solution in the body’s attempt to avoid autoimmune T cell damage.
However, it seems that this decision is not taken at the time that an
autoreactive CTL first encounters its cognate Ag(Redmond et al., 2003), but
rather depends on further antigenic exposure. A number of studies suggested
that deletion occurs when low-levels of the tolerising Ag are present
systemically and long term (Kurts et al., 1997, Mamalaki et al., 1993, Barron et
al., 2008, Redmond et al., 2005, Rocha et al., 1995).
Barron et al demonstrated that peripheral deletion of T cells encountering their
model self-Ag systemically in vivo depends on Bim-mediated apoptosis. By
subsequently knocking down Bim to prevent apoptosis they learned that
tolerance in these conditions was maintained because Bim-/- autoreactive T
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cells only survived to become anergic (Barron et al., 2008). This interesting
study suggested that clonal deletion in the periphery can sometimes be
disposable and replaced by anergy. However, a different study suggested that
while deletion prevents highly pathogenic autoreactive T cells -which could not
be otherwise contained by Treg-induced suppression- from causing
autoimmune damage, anergy is responsible for containing the remaining
autoreactive T cell specificities(Gavanescu et al., 2007)
1.3.4.2.2 CD8 T cell Anergy
Anergy is defined as a state of functional unresponsiveness, were proliferation
and IL2 production are defective on subsequent antigenic challenges even in
the presence of a full assembly of costimulatory signals (Schwartz, 2003). CD8
T cell anergy was first described in 1991 by Otten and Germain. In this in vitro
study the authors showed that TCR-p:MHC interactions under conditions
preventing co-stimulation by the APCs, abolished IL-2 production and
proliferation but had no effect on the cytotoxic function of CD8 T cells (Otten
and Germain, 1991).
Dubois et al in an in vivo model studying CD8 T cell peripheral tolerance
showed that initially responsive F5 Tg CD8 T cells, were rendered anergic by
repeated peptide injections as they did not proliferate and were also unable to
kill. Both functions were rescued with the addition of IL-2 in the cell culture
(Dubois et al., 1998). This was also one of a number of studies which
demonstrated that anergy is a transcriptionally active event requiring the
translocation of transcriptional activators to “turn-on” anergy-inducing genes.
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Activation of such genes has been shown to downregulate TCR signalling
pathways (Redmond and Sherman, 2005).
1.3.4.2.3 Inhibitory signals inducing anergy
Apart from the lack of co-stimulation, co-inhibitory signals are now known to
contribute to T cell hyporesponsiveness. Two structurally similar molecules,
CTLA-4 and PD-1 are present on T cells and play an important role in
suppressing the CTL response. CTLA-4, the expression of which is
dramatically increased following TCR engagement (Lindsten et al., 1993), is an
inhibitory homologue of CD28 and shares the same ligands with the latter. The
inhibitory role of CTLA-4 was clearly suggested in 1995, when two groups
showed that CTLA-4 -/- mice suffered a fatal lymphoproliferative disease
(Waterhouse et al., 1995, Tivol et al., 1995). The autoimmune nature of this
disease also hinted at a role for CTL4 in tolerance. The contribution of CTLA-4
to anergy induction has since been extensively studied. Greenwald et al,
utilised naive T cells from TCR Tg, CTLA4 -/- or CTLA4 competent mice in
adoptive transfer experiments to prove that T cells lacking CTLA4 remained
functional despite a tolerogenic stimulus. CTLA4 appeared to exert its
tolerigenic effects by mediating a cell cycle arrest (Greenwald et al., 2001).
Similarly to CTLA-4 the first evidence for the importance of PD-1 in peripheral
tolerance came from PD1-/- developing a lupus-like proliferative arthritis and
glomerulonephritis, as well as autoimmune dilated cardiomyopathy (Clay et al.,
1999a, Latchman et al., 2001). This molecule belongs to the immunoglobulin
superfamily, is expressed in T, B and myeloid cells (Agata et al., 1996) and
exerts its effects upon ligation to the PD Ligand 1 and 2 (PDL-1, PDL-2)
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expressed on APCs, lymphocytes and non-lymphoid tissues (Freeman et al.,
2000, Latchman et al., 2001). Probst et al investigated the effects of both these
molecules in peripheral tolerance using mixed BM chimeras of PD1-deficient
and Rag-DIETER mice (DC-specific inducible expression of T cell epitopes by
recombination' mice), and by blocking CTLA-4 signalling with a monoclonal
blocking antibody. In DIETER mice the expression of 3 Tg CTL epitopes can
be induced with the administration of Tamoxifen. Depending on the activation
state of the DCs the outcome of Ag presentation is either T cell activation or
tolerance(Probst et al., 2003). In the absence of either PD-1 or CTLA-4
signalling, not only peripheral tolerance was impaired, but the antigen-specific
CD8 T cells were genuinely primed under what would normally be tolerogenic
conditions; they proliferated and secreted IFNγ in an antigen specific manner
and were even able to clear an LCMV infection in vivo. PD-1 and CTLA-4
pathways seemed to have an additive effect in tolerance induction. These
results suggested that the balance between co-stimulatory and co-inhibitory
receptor-ligand interactions between T cells and APCs at the time of TCR
engagement, contributes to the decision between T cell activation and
tolerance (Probst et al., 2005).
1.3.4.2.4 CTL anergy linked to TCR and CD8 downregulation
In some cases, anergy appears to be linked with the downregulation of TCR
and CD8 molecules. Schonrich et al, came across this mode of CTL anergy
when studying peripheral tolerance induction in a monoclonal T cell population.
They created a class I restricted TCR Tg mouse and a Tg mouse expressing
the Tg TCR’s cognate Ag in very few peripheral tissues. Double transgenic
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mice derived from crosses between the TCR and Ag transgenic lines,
accepted skin grafts and allowed lymphoid tumour cells (EL4) expressing the
Ag to grow. Therefore, in this system tolerance was induced not only in the
possible absence of costimulation, but also in its presence. Phenotyping the
Tg T cells in these mice pointed at a different mechanism mediating T cell
hyporesponsiveness. Both CD8 and Tg-TCR expression were downregulated
among T cells of the double Tg, but not in the TCR Tg mice. Following ex-vivo
antigenic stimulation of FACS sorted Tg-TCR positive and negative T cells
from double Tg animals, TCR and CD8 expression was upregulated among
Tg-TCR negative T cells and Ag-specific cytotoxicity was recovered. These
data confirmed that Ag specific T cells were in fact present in the double Tg
mice but their TCR and CD8 phenotypes were altered under tolerogenic
conditions. Subsequently the authors also confirmed a correlation between
anergy and the expression levels of these two molecules (Schönrich et al.,
1991).
In a more recent study, where Gutermuth et al used a TCR Tg model of CD8 T
cell-mediated autoimmunity to explore self-peptide vaccination as the means
to diminish autoreactive responses, they were able to study CD8 and TCR
downregulation in the setting of peripheral tolerance further. In their model OT-
I TCR Tg mice crossed with mice expressing OVA in a number of epithelial
tissues and in the thymus, developed a lethal CD8 T cell driven autoimmunity.
Only 14% of these double transgenics escaped this fate spontaneously, but
upon prophylactic or even therapeutic injection with soluble OVAp the majority
were protected from autoimmunity and their survival was prolonged. Even
though thymic deletion was shown to play a part, great numbers of OT-I
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specific CD8 T cells were present in the LNs of spontaneously healthy or
treated healthy animals suggesting that peripheral tolerance mechanisms were
also involved in holding these cells at bay. FACS staining showed that the
majority of OTI-specific T cells in mice that remained healthy had
downregulated either the CD8 molecule or the Vα chain of the OTI TCR. Not
surprisingly, they were also shown to be anergic in terms of antigen-specific
proliferation in ex-vivo studies. Impaired OVA-pentamer staining only evident in
healthy double Tg mice, allowed the authors to attribute the observed T cell
hyporesponsiveness to the inability of these cells to bind to their cognate Ag
(Gutermuth et al., 2009).
1.3.5 Memory T cells
1.3.5.1 Classical T cell memory development
The establishment of peripheral tolerance is expected following the encounter
of a T cell with its cognate antigen under the tolerogenic conditions described
above. However, when T cells specific for foreign Ags are presented with the
corresponding epitopes on activated professional APCs, more frequently than
not the outcome of this interaction will be an effective immune response that
will clear the infection. Following antigenic clearance, the expanded population
of effector T cells contracts, leaving behind 5-10% of these cells which have in
the meantime differentiated to memory T cells (Jacob and Baltimore, 1999).
Memory T cells in general respond faster and more effectively, than naive T
cells, in a subsequent antigenic challenge even in the absence of co-
stimulation and cytokines.
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The event triggering memory T cell development and its timing within a primary
immune response have been studied extensively by numerous groups. In
2001, Kaech and Ahmed stimulated CFSE-labelled, naive, TCR Tg CD8 T
cells in vitro with a limited number of peptide-pulsed APCs and observed that T
cells continued to proliferate even after antigen clearance in the cell culture. In
another experiment they stimulated CFSE-labelled T cells in vitro for 24 hrs
only and then purified CD8 T cells from the cell culture prior to transferring
them into recipient Ag-free mice. In this in vivo system they confirmed that the
T cells continued to proliferate for a few days in the absence of Ag and 43
days after Adoptive Transfer (AT) the surviving cells exhibited memory T cell
function upon a secondary challenge. Therefore the authors concluded that
initial antigenic stimulation is enough to instruct the differentiation of naive T
cells into memory (Kaech and Ahmed, 2001).
A central issue however, remained unanswered from the above study
regarding the exact identity of the memory T cell progenitors. Opferman et al
reported that in AT experiments, memory CD8 T cells could only be generated
from effector T cells that had already divided more than five times in vitro
following their first antigenic encounter in vitro. They considered this to be
evidence that all antigen-reactive T cells follow a linear differentiation pathway
from naive to effector T cells during a primary response and subsequently a
low proportion of the effector T cells are selected to differentiate into memory T
cells (Opferman et al., 1999).
Sallusto et al first described the existence of 2 subsets of memory T cells in the
human system and the definitions they have provided for Central Memory
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(Tcm) and Effector Memory (Tem) T cells are still being used. Tem are CCR7
negative, CD62L low and migrate to sites of inflammation readily exhibiting
effector functions. In mice they correspond to CD62L negative CD44 low CD8
T cells. Tcm are CCR7 positive CD62L positive and therefore home to the LNs.
In mice this subset corresponds to CD44 positive CD62L positive T cells.
These were thought to be less functional, but able to rapidly differentiate to
effectors in a secondary antigenic challenge. In this same study the authors
sorted Tcm and stimulated them in vitro showing that 10 days later almost all
cells converted to an effector phenotype and function. In contrast repeating
this experiment with sorted Tem cells did not result in the conversion of these
cells to the Tcm phenotype. They therefore suggested that naive T cells
differentiated stepwise to Tcm and subsequently to Tem/effector cells (Sallusto
et al., 1999). However, as Sallusto et al pointed out this hypothesis was only
derived from in vitro experiments leaving open the possibility that memory T
cell differentiation is a more complicated issue.
A few years later Wherry et al further investigated the differentiation pathway of
CD8 memory T cells in an in vivo model infecting TCR Tg mice containing T
cells, specific for particular epitopes of LCMV or Listeria Monocytogenes (LM).
Unlike the initial description of Tcm and Tem by Sallusto et al, they showed
that both subsets showed similar functional responses in ex-vivo peptide re-
stimulation assays. Despite this, sorted, adoptively transferred Tcm were
markedly better than Tem at controlling both viral and bacterial infections in
vivo. In order to address the lineage relationship between these two memory
T cell subsets the authors again adoptively transferred sorted Tcm and Tem
into separate naive recipients to observe that 25 days later the former maintain
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their phenotype, whereas half of the transferred Tem converted to a Tcm
phenotype. The Tcm were additionally shown to have better antigen-driven
and homeostatic proliferation in vivo. Overall their results allowed Wherry et al
to propose a progressive differentiation model according to which Tem is an
intermediate cell type, rather than a different memory lineage, as antigen
specific T cells differentiate from effector to Tcm following an antigenic
stimulation (Wherry et al., 2003).
In 2007 Chang et al CFSE-labelled, naive P14 TCR Tg CD8 T cells and
adoptively transferred them into WT recipients that were infected with LM 24
hrs prior to the AT. 32 hrs after the transfer they FACS sorted undivided donor
T cells to examine them during their first division using live cell confocal
microscopy for the expression of various T cell signalling molecules. They
were in this way able to demonstrate an asymmetric distribution of these
molecules in naive T cells during their first antigen-driven cell division. With
subsequent AT experiments they showed that the daughter cells from this first
division, differed in function in a way that correlated to the effector or Tcm
phenotype they each exhibited. Therefore this group suggested that at the
beginning of an immune T cell response effector and memory T cells are
generated from the same naive cell rather than sequentially (Chang et al.,
2007). The same year in a technically impressive study Stemberger et al
attempted to provide a definitive answer to the question of memory T cell
subset origin by adoptively transferring a single naive OT-I T cell into recipient
mice. With their experiments, this group unequivocally demonstrated that the
full spectrum of effector and memory T cell subsets can be generated from a
single naive precursor. More recently, Gerlach et al also using a
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technologically advanced in vivo model, where individual naive T cells carried
unique genetic tags, confirmed the findings of Stemberger et al. One naive T
cell, was shown to give rise to both effector and memory CD8 T cell progeny
under different infection conditions and in different anatomical sites (Gerlach et
al., 2010). Even though all three studies – Chang et al, Stemberger et al and
Gerlach et al - discussed here clearly provide strong evidence in favour of
effector and memory T cells being derived from a single naive T cell, they do
not exclude a scenario where after the first division of a naive T cell the
effector daughter cell can give rise to memory T cells in subsequent cell
divisions.
1.3.5.2 Homeostatic proliferation and memory T cell development.
Antigen-driven memory T cell development following a primary immune
response is the classical paradigm of memory T cell development. However, it
is well established that homeostatic proliferation also leads to memory T cell
differentiation in a physiological as well experimental conditions and this
phenomenon is now called Lymphopenia-Induced Proliferation (LIP) – driven
memory development (Surh and Sprent, 2008). In 2000, two back to back
papers in Journal of Experimental Medicine described the cognate Ag-
independent generation of memory T cells in lymphopenia. Both groups
showed that these cells exhibited a Tcm-like phenotype and function, rapidly
secreting IFNγ and becoming cytotoxic in response to their cognate Ag both in
vitro and in vivo (Goldrath et al., 2000, Cho et al., 2000).
Cho et al studied the kinetics of LIP-driven memory development by
transferring CFSE labelled, naive TCR Tg T cells into Rag1-/- recipients and
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monitoring the phenotype of the dividing cells over a time course. In these
experiments they observed that naive T cells differentiated to memory without
passing through an intermediate effector stage. They also showed that whilst
cognate Ag was not required for memory development, expression of the
appropriate MHC by the host was needed, as the transfer of naive T cells into
allogeneic, NK-depleted Rag1-/- recipients did not allow the cells to proliferate,
let alone differentiate into memory T cells. Importantly, the authors also
showed that CD28 signaling and IL-2 were not required for LIP-driven memory
T cell development by using naive T cells from CD28-/- and IL-2-/- donor mice
(Cho et al., 2000). Goldrath et al performed similar experiments, but used
sublethally irradiated B6 mice instead of Rag1 -/- animals as recipients and
their results were mostly similar to Cho et al. However, they demonstrated that
in their system, but not in Rag1-/- hosts, the majority of memory cells
eventually reverted to a naive phenotype once the mice were no longer
lymphopenic (Goldrath et al., 2000).
A few years later, Min et al published a study highlighting the fact that the
physiologic lymphopenia of the neonatal period also supports LIP-driven
memory T cell development. The authors showed that AT of naive polyclonal
CD4 T cells in newborn mice supported LIP, promoting memory phenotype
development in 20% of the donor-derived T cells. In contrast to memory T cells
generated in response to an adult lymphopenic environment, memory T cell
development in the neonate was dependent on CD28 co-stimulation along with
the interaction with MHC class II molecules (Min et al., 2003).
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More recently, Haluszczak et al reported on a very exciting finding that
suggested a physiological contribution of LIP-driven T cell memory
development to the unprimed T cell repertoire. Using MHC class I tetramers
loaded with 3 different foreign peptide antigens, magnetic column separation
and FACS sorting they were able to isolate small numbers of nominal Ag-
specific CD8 T cells from unimmunised normal B6 mice. After transferring
them into syngeneic recipients that were neither immunised nor irradiated, they
were surprised to notice that both CD44hi and CD44low donor cells were
present. The authors then showed that these Ag-specific, but Ag-
inexperienced memory phenotype T cell were also present in unprimed
gnotobiotic mice strengthening the hypothesis that these cells were generated
through homeostatic mechanisms rather than due to cross-reactivity with any
commensal flora-derived Ags. They named these cells Virtual Memory (VM) T
cells. Phenotypic analysis of the VM T cells was consistent with an LIP-derived
memory CD8 T cell phenotype and their functional activity was superior to that
of their naive counterparts. In view of these results the authors concluded that
VM T cells contribute to the unprimed CD8 T cell repertoire and speculated
that they might have a role in primary immune responses especially in
situations of physiological lymphopenia such as the neonatal period
(Haluszczak et al., 2009).
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1.4 Tumour immunology
1.4.1 Tumour immunosurveilance and immunoediting
1.4.1.1Tumour Immunosurveilance
More than 50 years ago Burnet discussed the possibility that despite being of
the “body’s own pattern”, cancer cells might exhibit enough antigenic
differences from healthy tissues to trigger an immune response against them
which could clear the tumour before it even becomes clinically apparent. In this
publication the author even suggested that what might be required for the
effective treatment of cancer is to enhance the immune system in order for it to
be able to recognise these small differences, possibly by means of genetic
manipulation (Burnet, 1957).
This formed the tumour immunosurveillance hypothesis which was further
substantiated in the 1990s when Dighe et al demonstrated that IFNγ had a
central role in mediating the rejection of Meth A- carcinogen induced tumours.
As inoculating IFNγ sensitive or insensitive tumour cells in SCID mice lacking
lymphocytes, unlike in BalbC animals, showed no difference in tumour growth
it was clear that the IFNγ effect related to the tumour being recognised and
attacked by the adaptive branch of immunity (Dighe et al., 1994).
1.4.1.2 Tumour Immunoediting
In 2001, Shankaran et al presented a set of striking data where an absent
lymphocyte compartment either coupled or not with defective IFNγ signalling
resulted in increased susceptibility not only to carcinogen-induced malignancy,
but more importantly to spontaneous epithelial tumour formation. Even though
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these results clearly supported the tumour immunosurveilance hypothesis, the
authors where also interested whether the immune response to a tumour can
also influence its immunogenicity. To investigate this, they transplanted
carcinogen-induced tumours growing in WT and Rag2 deficient mice into
syngeneic immunocompetent mice and noticed that while tumours derived
from mice lacking a lymphocyte compartment only grew in 40% of the
transplanted animals, 100% of the transplanted tumours obtained from WT
animals grew progressively in their recipients (Shankaran et al., 2001).
Therefore, having documented that tumours arising in immunocompetent mice
become less immunogenic as they establish amidst an immune response
against them, the authors proposed an update to the tumour
immunosurveillance hypothesis introducing the concept of cancer
immunoediting. According to this, the immune system paradoxically can both
fight off cancer but in doing so sculpts it into a version evolved to escape its
defences.
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Schreiber et al have recently suggested that cancer immunoediting can be
seen as a process characterised by three consecutive phases. The elimination
step, being the first phase in any cancer’s natural history, incorporates the
tumour immunosurveilance hypothesis. In this phase, relatively sub-clinical
numbers of cancer cells are detected and destroyed by the immune system. A
cancer enters the next phase only if at least one transformed cell survives the
elimination phase. At that point, the immune system might still be able to keep
those few malignant cells at bay as the still clinically undetectable cancer
enters the equilibrium phase. The fact that tumour cells are genetically
unstable allows them to evolve through the immune selection pressure that
they are found under during this phase. They evolve into less immunogenic
cells, and in this way they escape the body’s defences, proliferate and
establish themselves into clinically detectable disease, this being the third
stage of cancer immunoediting (Schreiber et al., 2011).
Despite the more negative picture painted by the concept of tumour
immunoediting in comparison to the older more hopeful immunosurveilance
hypothesis, the advances in our knowledge of the interaction between cancer
and immunity, allow the development of a variety of tumour immunotherapies
aimed at modulating the patient’s immune system so that it can recognise
already immunoedited transformed cells and effectively clear them.
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1.4.2 Tumour Immunotherapy
1.4.2.1 Tumour Antigens
Tumour antigens can be broadly divided into tumour-specific (TSA) and
tumour-associated Ags (TAAs). TSAs are epitopes arising from mutated
proteins and are exclusively expressed and presented in tumour cells. They
represent good targets for T cell based cancer therapies as they can mark the
tumour cells as non-self. On the other hand TAA are expressed both in healthy
and transformed tissues, typically overexpressed in the latter. Many more TAA
than TSA have been identified over the years. Their obvious and important
disadvantage is that they are self-Ags and as such any T cell specificities
present against them are very likely to be tolerised either in the thymus or in
the periphery. Nevertheless, the very fact that they are more common and
often shared among different malignancies has the practical advantage that
one possible successful T cell based immunotherapy may be applicable for
more than one tumour type.
1.4.2.2 WT1 antigen and its role as a tumour immunotherapy target
The Wilms tumour antigen 1 (WT1) is a TAA overexpressed in nearly all
haematological malignancies (Menssen et al., 1995, Yong et al., 2008, Tamaki
et al., 1999) and in solid tumours such as breast, colon and ovarian cancer (Oji
et al., 1999, Oji et al., 2002). WT1 expression at low level is only observed in a
limited number of healthy tissues; in a subset of HSCs, renal podocytes,
ovarian granulosa cells and sertoli cells (Sugiyama, 2002, Oka et al., 2006).
Therefore, the prospect of only destroying transformed cells with a T cell based
immunotherapy directed against this TAA makes it a very appealing target.
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Apart from its pattern of expression in malignant and healthy tissues, WT1 has
further advantages as a TAA. Even though it was originally identified as a
tumour suppressor gene in the context of the paediatric Wilms tumour (Haber
et al., 1993, Haber et al., 1990, Santos et al., 1993), evidence for its role as an
oncogene are also present. Yamagami et al suggested that overexpression of
WT1 in most haematological malignancies has a role in the leukaemogenesis
process. To investigate this they synthesised WT1 antisense oligonucleotides
and in support of their hypothesis they were able to show that these molecules
specifically inhibited tumour cell growth both in leukaemic cell lines and fresh
leukaemic cells isolated from patient’s at the time of diagnosis (Yamagami et
al., 1996). Algar et al also cultured leukaemic cell lines with antisense
oligonucleotides obtaining similar results. In addition, they were able to
demonstrate that when WT1 protein expression was inhibited, the reduction in
cell growth was associated with an increased frequency of cells with apoptotic
features. As the WT1 gene was found not to be mutated in those cell lines,
they concluded that overexpression of the normal WT1 protein was important
to leukaemic cell viability and proliferation (Algar et al., 1996). Therefore,
targeting and eliminating tumour cells expressing WT1 could have a bold effect
on both the tumour load but perhaps more importantly on tumour growth. A
more recent study suggested an additional role for WT1 in solid tumour
metastasis, as siRNA knockdown of WT1 expression in serous ovarian
carcinoma cell lines interfered with cellular migration and hindered their
invasion into 3D collagen cultures (Barbolina et al., 2008). As this molecule
appears to be vital for the malignancies that overexpress it, it is unlikely that its
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expression will be downregulated as a tumour immune evasion mechanism
and this is an important advantage in the context of cancer immunoediting.
1.4.2.3 T cell based tumour immunotherapies
1.4.2.3.1 Vaccination
The identification of naturally occurring CTL clones recognising TSAs and
TAAs in a variety of malignancies encouraged research in the development of
vaccination strategies to enhance such populations in cancer patients. WT1-
specific T cells in particular were isolated for the first time from the blood of an
HLA-A2-positive healthy donor following numerous cycles of in-vitro
stimulations with wild type, class I-presented WT1 peptides (Freeman et al.,
2000). Based on this discovery, the same group performed WT1-DNA
vaccinations in mice to demonstrate that vaccination could generate detectable
numbers of WT1-specific CD8 T cells able to reject WT1-expressing tumour
cells in subsequent challenges (Oka et al., 2000a). Clinical trials with different
WT1-vaccination protocols including peptide, DNA and dentritic cell-based,
followed (Rezvani et al., 2008, Oka et al., 2004, Van Tendeloo et al., 2010, EC
Morris, 2010). Even though these have only been phase I/II clinical trials,
primarily assessing the safety of each proposed treatment, they have all
shown variable degrees of success in containing WT1-expressing
malignancies correlating to an immunological response in terms of an increase
in WT1-specific CTLs in the patients’ blood.
Despite the somewhat encouraging results from WT1-vaccination trials, their
effectiveness as a tumour immunotherapy is limited when compared to the
triumphant clinical results of vaccines in the prevention of a multitude of
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infections. In part, this is because most trials are limited by recruiting end-stage
cancer patients where the antigen-specific response elicited by the vaccination
is simply not adequate to overcome a substantial tumour load. Another key
issue is that vaccination strategies rely on naturally occurring TAA-specificities
to be present in the immunised patients T cell repertoire. As TAAs are self-
Ags, the TAA-specific T cell repertoire is tolerised and therefore compromised
both in terms of numbers and responsiveness. Previous work done by the
Stauss/Morris group identified naturally occurring, WT1 specific CTLs from
draining LNs of breast cancer patients, using WT1 tetramers. While these cells
exhibited antigen-specific cytokine secretion and cytotoxicity, killing HLA-A2
positive breast cancer cell lines was only possible following treatment of the
tumour cells with IFNγ which increased the HLA A2 expression levels on these
targets (Gillmore et al., 2006). Therefore this study suggested that perhaps the
biggest limitation of WT1 vaccination-strategies for the induction of antitumour
immunity is not the fact that WT1-specific T cells are limited in numbers, but
the fact that higher avidity WT1-specific T cells are required to be effective in
the context of the tumour microenvironment. The schematic diagram in figure
1.7 describes the principle behind WT1 vaccination and the potential
limitations of such a tumour immunotherapy strategy.
Cancer patient
WT1 overexpressed
rare, naturally occuring
WT1-specific T cells
WT1 Ag vaccination
Naïve
T cell
WT126p
WT1 TCR
professional
activated APC
Signal 2 & 3
Signal 1
T cell
Effector and Memory WT1 specific T cells
expanded by vaccination
High affinity T cell specificities
Good T cell expansion
Low affinity T cell specificities
Poor T cell expansion
Recognition of WT1 Ag on tumour
Effective response
Tumour clearance
WT1 T cell memory. NO relapse
No effective interaction with
WT1 Ag on tumour
No response
No tumour clearance
Figure 1.7 WT1 Ag vaccination as a tumour immunotherapy strategy. Patients
with malignancies that overexpress the WT1 TAA can be vaccinated with WT1 Ag to
expand a naturally occuring WT1 specific T cell population already present in the
patient and drive its differentiation into memory T cells. Upon recognising tumour
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Figure 1.7 (continued)
cells the WT1 specific T cells can then mount an effective immune response leading
to tumour clearance. However, the success of vaccination strategies relies on
naturally-occurring high affinity WT1 T cell specificities being present in the patient
prior to vaccination. As WT1 is a self-Ag it is likely that high-affinity WT1 specific T
cells will be deleted in the thymus during T cell development. The thymic fate of
high affinity WT1 specific T cells is examined in this project.
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1.4.2.3.2 Adoptive T cell transfer
Adoptive transfer of a particular number of tumour-specific T cells aiming to
passively provide the patient with tumour-reactive, functional T cells, is an
alternative more interventional approach to vaccination. Clinical trials where
tumour infiltrating lymphocytes (TILs) are adoptively transferred to cancer
patients, have so far provided encouraging results. In 2002 Dudley et al
reported that the adoptive transfer of TILs found in a melanoma metastasis
could result in primary and metastatic partial tumour regression in a
considerable percentage of the patients recruited in the trial. In vitro IL-2
treatment was required to reverse the anergic character of these autologous T
cells that were expanded prior to their return to the patients they were derived
from. Receiving non-myeloablative lymphodepleting chemotherapy prior to
adoptive T cell transfer, proved to contribute to the treatment’s success as the
proliferation of the transferred T cells was in part homeostatic and in these
conditions regulatory T cells were absent to impede their action (Dudley et al.,
2002). Despite its promising outcome, such an approach has a number of
practical limitations. Firstly, tumour-responsive TIL cannot be successfully
harvested from all patients. Even in cases where this proves not to be a
problem, a lengthy in vitro culture period is necessary for the cells’ expansion
to the appropriate numbers and as this procedure is labour intensive and
therefore expensive, making it widely available would be difficult. The
schematic representation in figure 1.8 described the basic principles of
Adoptive T cell Transfer as a Tumour Immunotherapy strategy.
Figure 1.8 Adoptive Transfer of WT1-specific T cells as a tumour
immunotherapy strategy. The autologous transfer of TAA-specific T cells into
cancer patients, involves the isolation of such cells from the patient and the
subsequent in vitro expansion in order to obtain cell numbers that could clear the
tumour once returned to the patient. Therefore this strategy relies on naturally
occuring TAA-specific T cell being present in the patient in the first place. Even
though the isolated TAA-specific T cells can be manipulated in vitro to overcome
any anergic character they might still be susceptible to peripheral tolerance when
they are adoptively transferred into the patient.
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1.4.2.3.3 TCR gene therapy
An alternative approach to obtaining TAA-specific T cells is by employing TCR-
gene transfer into the patients’ primary T cells. Once the genes for the TCR of
a T cell clone that demonstrated TAA-specific function are isolated and cloned
into a viral vector, any given number of a patient’s T cells - of initially varied
specificities - can be easily and rapidly redirected to express that particular
TCR. TCR gene therapy can therefore serve as an almost generic treatment
for many cancer patients. In the case of WT1-TCR gene therapy this could be
applied to patients with most leukaemias, as well as to patients with breast or
colon cancer. Nevertheless, as the specificity of any TCR is defined not only by
its cognate peptide, but also by the HLA molecule on which the antigen is
presented, selecting the patients for which a certain TCR-gene therapy would
be suitable not only depends on their malignancies overexpressing the
targeted TAA, but also on their HLA phenotype.
Clay et al isolated the genes for a MART-1 specific, HLA-A2 restricted TCR
from the TIL culture of a melanoma patient, and were the first to report
successfully transducing primary human T cells with TCRαβ genes and in that
way redirecting their specificity. The genetically modified CD4 and CD8 T cells
exhibited antigen-specific cytokine secretion and about half the transduced
CD8 T cell clones lysed HLA-A2+ melanoma cell lines(Clay et al., 1999a).
Soon after, Kessels et al strengthened the case of TCR gene transfer-based
tumour immunotherapies, by developing an in vivo model where the adoptive
transfer of TCR-gene modified murine splenocytes into syngeneic recipients,
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provided antigen specific protection against both infection and a tumour
expressing the relevant Ag (Kessels et al., 2001).
Although TAA-specific T cells can be easily obtained with TCR gene transfer,
identifying a T cell specificity that can efficiently recognise a TAA and result in
the killing of the tumour cells that express it, remains an essential prerequisite.
In fact, the cell surface expression of the TCR introduced into a primary T cell
is often lower than desired. Given that one of the most well recognised tumour
evasion mechanisms is the downregulation of tumour antigens from the
transformed cell’s surface, lower expression levels of the TCR recognising
such an Ag is problematic in the context of tumour immunotherapy.
A number of techniques are currently being developed to improve the
transduced-TCR lower expression levels, but employing high-affinity TCRs for
TCR gene therapies can also compensate for this considerably as the T cell
avidity for a target cell is a function of both the number of TCRs on the T cell
surface and the individual TCR’s affinity. However, identifying tumour reactive
T cell clones bearing a high affinity TCR for the targeted TAA is a challenging
matter. TAA-specific T cells essentially recognise self-Ags and are therefore
subject to central and peripheral tolerance mechanisms. High-affinity TAA-
specific T cells are unlikely to pass through the thymus unnoticed, so they are
scarce in the periphery. The few that would emerge from the thymus, like any
other autoreactive T cell, will be compromised by the multiple tolerance
mechanisms the periphery has to offer.
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1.4.2.3.3.1 Allo-restricted specificities for TCR gene therapy
The same year that the Nobel prize was awarded to Doherty and Zinkernagel
for their discovery that virus-specific CTL responses are self-MHC restricted
(Zinkernagel and Doherty, 1974), Stauss et al suggested that peptide-specific
recognition in the context of allogeneic, rather than self, MHC molecules could
provide a unique opportunity to bypass this problem and obtain high-avidity
TAA-specific CTLs. In a proof-of-principle murine study, they used a TAP-
deficient cell line to present a TAA-peptide on the Kb MHC class I molecule to
lymphocytes from Balb/c mice. Such co-cultures yielded Balb/c CTL clones
that could lyse a Kb-lymphoma cell line endogenously presenting the particular
peptide (MDM2-derived peptide) in an antigen-specific manner, while they
spared healthy Kb cells expressing MDM2 at lower levels (Sadovnikova and
Stauss, 1996).
Stauss’ group then went on to identify TAA allorestricted specificities in the
human setting. Using a synthetic WT1 peptide - pWT126 - they generated
HLA-A2 allorestricted WT1-specific CTLs. In vitro analysis determined that
these cells were both pWT126-specific and HLA-A2 specific and could
efficiently clear CD34+ HLA-A2 positive leukaemia cell lines and fresh
leukaemia cells from patients whilst sparing healthy CD34+ BM cells that
expressed the antigen at lower levels (Gao et al., 2000). Further experiments,
in an in vivo xenotransplantation model, showed that the allorestricted WT1 T
cells could selectively inhibit the engraftment of human leukaemic, but not
healthy stem cells in the NOD/SCID mouse (Gao et al., 2003). Therefore, early
in the past decade, the idea of generating and adoptively transferring such
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allorestricted CTLs in cancer patients as an immunotherapeutic strategy was
discussed. Nevertheless, the already mentioned limitations of T cell adoptive
transfer coupled with the recognised complication that T cells derived from a
mismatched donor are to be rejected by the recipient, advocated in favour of
utilising such high-avidity TAA-specificities by cloning their TCR genes and
developing TCR gene transfer-based tumour immunotherapies.
1.4.2.3.3.2 WT1-TCR gene therapy: Challenges and Limitations
Indeed Stauss’ group confirmed in an in vivo model that human WT1-TCR
gene modified T cells obtained the specificity and function of the allorestricted
WT1-specific CTL from which the TCRα and TCRβ genes were cloned.
Lymphocytes from a patient with leukaemia were redirected to selectively kill
autologous leukaemic CD34+ cells expressing this Ag, while transduced T
cells from a healthy donor did not attack healthy CD34+ stem cells that also
express WT1 at low levels. For the first time, this study demonstrated that TCR
td human T cells can be functionally active in vivo, since WT1-TCR td but not
mock td T cells showed therapeutic efficacy against a human leukaemia cell
line in the NOD/SCID murine model (Xue et al., 2005). In preparation for a
WT1-TCR gene therapy trial in acute myeloid leukaemia patients, these results
were taken a step further; in a recent paper where Xue et al showed that a
patient’s cells can be genetically engineered in this fashion to eliminate
autologous leukaemia progenitor cells in vivo. In this same study a number of
modifications to the TCR vector construct used were examined for the purpose
of optimising the expression of the WT1-TCR in primary human T cells and
improving the safety of TCR gene therapy (Xue et al., 2010).
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These promising pre-clinical results are in support of the phase I/II clinical trial
of the high avidity HLA A2 allorestricted WT1-TCR gene therapy for the
treatment of leukaemia that is currently underway by the Stauss/Morris group.
The effect that the physiological low-level WT1 expression in some healthy
tissues has on the phenotype and function of genetically redirected WT1-
specific T cells when these are adoptively transferred in patients is not known.
Will such cells be tolerised by the periphery and rendered ineffective in fighting
cancer, or will their high avidity for the WT1-self Ag instruct them to cause
autoimmune damage? Furthermore, given the evidence showing that naturally
occurring WT1-specific T cells can be identified both in healthy individuals and
cancer patients, a number of WT1 vaccination trials are in development.
Nevertheless, eliciting low-avidity WT1-specific T cells by any means of
immunisation is not adequate for tumour immunotherapy purposes. Hence,
even though there is evidence that central tolerance against WT1-specific T
cells is incomplete, the question of how thymic education shapes the high
affinity WT1-specific T cell repertoire, is more pertinent. This is because it is
such a population that could be effectively enhanced following WT1-
immunisation, both in terms of numbers and functional activity to target WT1
expressing malignancies. The schematic diagram in figure 1.9 describes the
identification of the high avidity, HLA-A2 allorestricted WT1 TCR and its use in
a WT1-TCR gene therapy for the treatment of WT1-overexpressing
malignancies.
Figure 1.9 Identification of a high-avidity, HLA-A2 allorestricted WT1-specific T
cell line and using the genes for this WT1 TCR in TCR gene therapy for the
treatment of WT1-TAA overexpressing malignancies. T cells from HLA A2
negative individuals were stimulated with HLA-A2 positive cells to identify HLA A2
specific T cells. HLA-A2 specific, HLA-A2 negative T cells were subsequently
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Figure 1.9 (continued)
stimulated with pWT126 loaded HLA-A2 target cells, to identify WT1 specific, HLA-
A2 allorestricted T cells. Following 3 rounds of stimulation these cells were
transferred into 96-well plates in limiting dilution cultures in order to isolate WT1-
specific T cell lines. A high-avidity WT1-specific, HLA-A2 allorestricted T cell line
was identified and the genes for this TCR were cloned. These genes have now been
placed in a single retroviral vector to be used in a WT1 TCR gene therapy trial for
the treatment of leukaemia. WT1 TCR gene therapy involves harvesting the patient
T cells and transducing them with the genes for the WT1 TCR. Expression of the
WT1 TCR will redirect the patient T cells to recognise and clear leukaemic cells
overexpressing the WT1 Ag, upon their transfer back into the patient. However, as
WT1 is a self-Ag, ithe in vivo function of these high-avidity, WT1 specific T cells
might be compromised by peripheral tolerance mechanisms.
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1.5 Project Aims
This PhD project aimed to examine the thymic development of high-avidity,
HLA-A0201-restricted WT1-specific T cells as well as their phenotype and
function in the periphery, in a clinically relevant murine model. In particular we
were interested in answering the following questions regarding T cells
expressing the WT1-TCR:
1. Are these cells subject to central tolerance during their development?
2. If following thymic development, high avidity WT1-specific T cells emerge
into the periphery, do they then become tolerised in the periphery? Do
they become deleted or anergic due to their self-specificity?
3. How does their specificity for the WT1-TAA define their phenotype and
function?
4. Do these cells cause autoimmune damage in healthy tissues expressing
the WT1-antigen at low levels, in particular in the BM and kidney?
1.6 The experimental model
In order to address the above questions the WT1-TCR genes were transferred
into purified lineage negative (Lin-ve) murine HSCs and subsequently
transplanted into HLA-A0201 Tg, syngeneic recipients. As described in the
schematic representation of the experimental model, in figure 1.10, the
transduced murine T cell progenitors home to the thymus where they express
the HLA-A2 restricted WT1-TCR in a timely fashion with the CD3 molecule, at
the DN stage. Thymic development of the WT1-specific thymocytes in this
Figure 1.10 Schematic diagram of the experimental model. BM was harvested
from donor mice and the cells were taken through a magnetic Lineage negative
selection, facilitating the enrichment of the BM cells in HSCs. Following negative
selection the Lin-ve BM cells were transduced with a lentiviral construct containing
the genes for the WT1 TCR. The next day 0.5x106 transduced HSCs were
transferred in each A2Kb tg, lethally irradiated recipient by intravenous injection into
the tail vein. A2Kb tg mice express a hybrid HLA A2 molecule. Once in vivo, the
transduced T cell progenitors homed from the BM to the thymus, where they
expressed the WT1 TCR. In the thymus WT1-specific developing thymocytes went
through positive and negative selection . It was likely that during thymic development
they would be presented with the WT1 Ag in the context of HLA A2. Therefore, in
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Figure 1.10 (continued)
this system it was possible to ask whether high affinity, WT1 specific T cells can
escape thymic deletion. Subsequently, if they would escape central tolerance,
emerging in the periphery, it was possible to ask whether they were susceptible to
peripheral tolerance mechanisms and if not whether they could cause any
autoimmune damage because of their self-specificity.
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system takes place in the context of HLA-A2 positive thymic epithelial cells. In
both human and mouse, WT1 is expressed at low levels in the periphery - in a
fraction of CD34+ HSCs and kidney podocytes – but is expressed widely and
at high levels during prenatal development (Hohenstein and Hastie, 2006).
Therefore it is expected that WT1 will be one of the many self-antigens
promiscuously expressed in the thymus facilitating the negative selection of
potentially autoreactive T cells. Stauss’ group has previously observed WT1
expression in the mesothelial lining of the thymus, but not in the epithelial
stroma were positive and negative selection take place (unpublished data).
However, at present time no report has been made to ascertain that the WT1
Ag is not promiscuously expressed by mTECs in particular. Such promiscuous
expression in only a small number of mTECs could be enough to shape the
thymic development of WT1-specific T cells.
Therefore, in the absence of this information, the experimental model
presented here addresses the question of whether high-affinity WT1-specific T
cells are subject to central tolerance mechanisms. The phenotype and function
of WT1-specific T cells emerging in the periphery in this system, was studied
extensively to explore the possibility of these cells being either tolerised or
causing autoimmune damage. To confirm that the results obtained related to
the WT1 specificity, rather than being an artefact of the HSC isolation and
lentiviral transduction protocol, a second construct containing the genes for the
high avidity, HLA A2 restricted, LMP2-specific TCR was used in control
experiments. T cells bearing this TCR, are specific for an Ebstein-Barr Virus
epitope derived from the LMP2 protein, a non-self epitope. Finally, the results
produced by our model can also to some extent be extrapolated to inform us
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about the fate of high affinity self-specific T cell in the thymus and the
periphery, especially in view of recent data suggesting that self-antigen can
mediate the differentiation of naive T cells into memory in the context of
homeostatic proliferation (Haluszczak et al., 2009).
Below the important parameters of the experimental model used in this project
are discussed.
1.6.1 WT1 expression in human and mouse.
WT1 expression is highly conserved between human and mouse and the
tissue distribution of this protein is also very similar among these two and other
species (Kent et al., 1995). In 2000, Oka et al, being one of the groups in
support of an oncogenic role for wildtype WT1, especially in the context of
leukaemia pathogenesis, went on to explore whether it could also serve as a
target Ag for antitumour immune responses and potentially in the context of
tumour immunotherapy. Using a peptide library-based method for predicting
MHC class I-binding peptides (Udaka et al., 1995, Stryhn et al., 1996) from the
WT1 protein sequence, they identified and synthesised 4 H-2Db-restricted
WT1 peptides. One of these three peptides, the Db126 peptide, induced
antigen-specific CTLs in response to in vivo immunisation that subsequently
lysed and rejected WT1-expressing tumour cells introduced in the immunised
animals. The authors then confirmed that this is a naturally occurring antigenic
epitope, by testing peptide fractions from WT1-expressing tumour cell lysates
for their sensitising activity to Db126-specific CTLs (Oka et al., 2000b). In the
same year, this group showed that this same epitope could also bind to the
human class I molecule, HLA-A2.1. As with the case of murine leukemic cells,
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HLA-A2.1 positive leukaemic cells endogenously expressing the WT1 protein
were lysed in an HLA-A2 restricted, WT1 antigen-specific fashion by Db126-
specific human CTLs (Oka et al., 2000a). The HLA A2 allorestricted high
avidity WT1-TCR, currently evaluated in a TCR gene therapy clinical trial
conducted by our lab, is specific for the pWT126 that has been shown to be
identical in human and mouse. This and the similar tissue distribution of WT1
in the two species, allowed the generation of the in vivo murine model
presented above to study the effects of physiological WT1 expression in
healthy tissues on the development and functional activity of T cells expressing
this particular WT1-TCR.
1.6.2 The WT1-TCR
The interaction between the WT1-specific TCR with the hybrid HLA A2
molecule used in this study is described in figure 1.11. The variable TCRα and
TCRβ chains are derived from a high-avidity HLA-A2 allorestricted pWT126-
specific CTL clone. The identification and characterisation of this specificity
has been described in detail in section 3.2.3.3.1. The constant regions of the
human WT1-TCR have been murinised for the purposes of the TCR gene
therapy clinical trial, as it has been shown that this modification improves the
dimerization between the introduced TCRα and TCRβ chains (Cohen et al.,
2006). In this way the risk of mispairing between endogenous and exogenous
α and β chains, which has been shown to give rise to autoreactive specificities
in the context of TCR gene transfer in primary T cells (Bendle et al., 2010), is
minimised. Hybrid TCRs appear to enhance the function of transduced T cells
when compared to fully human molecules of the same specificity and affinity
APC
WT126p
a b
Human variable regions
Murine constant regions
ss
murine
CD8
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WT1 specific T cell
Figure 1.11 Schematic representation of the interaction between the
transgenic HLA A2/Kb molecule presenting WT126p and the murine CD8 T cell
expressing the murinised, Cys 1- modified, human WT1 TCR. The hybrid HLA-
A2Kb molecule expressed in HLA-A2Kb (A2Kb) tg mice contains the human alpha1
and alpha2 domains that interact with the human HLA-A2-restricted TCR and are
fused to a murine alpha 3 domain, which facilitates the interaction of this molecule
with the murine CD8 coreceptor.
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and this is thought to be due to a stronger and more stable interaction between
murine constant regions and the human CD3 molecule.
Another modification also made to this TCR molecule to enhance specific
pairing between the introduced TCR chains is the addition of a second
disulphide bond between the two constant chains (Cohen et al., 2007, Kuball
et al., 2007, Thomas et al., 2007). Finally, the genetic sequence for the hybrid
WT1-TCR was codon optimised, which has been shown to improve TCR
expression levels and therefore enhances their in vivo functional activity
(Scholten et al., 2006, Jorritsma et al., 2007).
This set of modifications were performed for the purposes of the recently
commenced WT1-TCR gene therapy clinical trial, as they are documented to
cumulatively improve the surface expression of the introduced TCR and the
antigen-specific function of human transduced T cells in vivo. Nevertheless,
these modifications are likely to have similar effects when the TCR is
expressed in murine T cells and therefore are likely to increase further the
avidity of the WT1 T cells, thus facilitating the study of the thymic selection and
peripheral function of high avidity WT1 TAA-specific T cells. Furthermore,
using the same TCR as in the clinical trial offers clinically relevant information
about the in vivo behaviour of T cells bearing this particular TCR.
1.6.3 The HLA A2 Tg mouse
The HLA A2Kb transgenic mice used in this project were a kind gift from
Mathias Theobald. These animals expressed hybrid HLA-A0201 molecules
consisting of human α1 and α2 domains, while the α3 domain is of murine
origin. An antigenic class I epitope binds in the groove formed by the α1 and α2
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domains, and from this position it is presented to CTLs. Upon TCR-pMHC
complex binding, the interaction between T cell and its target is strengthened
by the CD8 co-receptor present on cytotoxic T cells, binding to the α3 domain
of the MHC class I molecule. In fact this interaction partly defines T cell avidity.
In our model, the human-murinised TCR is expressed on murine CD8 T cells.
It is the use of HLA A2Kb transgenic mice that not only allows the human
variable regions of the WT1-TCR to bind to the pWT126:HLA A2 complex in
the same way they would in human, but also enables optimal binding of the
murine CD8 to the murine α3 domain of the hybrid HLA A2Kb molecule. A
schematic representation of the interaction between the modified pWT126-
specific TCR and the pWT126:HLA A2Kb complex is shown in figure1.11.
1.6.4 TCR gene transfer in HSCs for the in vivo study of T cell selection
and function
TCR transduction of HSC was first reported by Clay, who interestingly back in
1999 suggested that this could be an adoptive immunotherapy strategy and
performed in vivo experiments to prove that it was technically possible to
generate antigen specific cells (Clay et al., 1999b). Later, Baltimore and Yang
revived and further explored this idea by investigating the phenotype and
functional activity of OTI and OTII-specific T cells generated in vivo following
transfer of OTI and OTII TCR-transduced HSC-enriched BM cells into
irradiated recipients. These cells emerged from the thymus exhibiting a naive
phenotype, and following antigenic stimulation they rapidly differentiated into
fully functional effector and memory T cells that were also able to confer
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significant tumour protection against an OVA-expressing tumour (Yang and
Baltimore, 2005).
Essentially mice reconstituted with TCR-td HSC, were comparable to TCR Tg
mice. The main differences between the two are technical; given that the TCR
genes are available, the former only takes a few weeks to generate. However,
unlike TCR Tg mice it is not possible to propagate a mouse line containing the
particular antigen-specific T cells by breeding. Holst et al named these mice
retrogenic mice, in reference to the retroviral vectors used to transduce the
HSCs and to distinguish them from TCR Tg mice. In their 2006 paper these
authors demonstrated that retrogenic mice can serve as models for the in vivo
study of T cell selection and function. In particular they transfered male
antigen-specific TCR-td HSCs into male and female mice and, as predicted,
observed the thymic deletion of such developing thymocytes in male, but not
female mice. In the case of the HY TCR, negative selection was incomplete
with the surviving HY-specific T cells being tolerised in the periphery of male
recipients (Holst et al., 2006), as was the case of HY-TCR Tg equivalents
described many years before (Kisielow et al., 1988). In this work, as in some of
their previous publications (Szymczak et al., 2004, Arnold et al., 2004) the
Vignali group constructed and used 2A peptide-linked TCR vectors. Linking the
TCRα and TCRβ chain genes with the 2A peptide, rather than the commonly
used IRES, allows for the stoichiometric expression of the two genes. When
placed in the same open reading frame the 2A-linked genes are transcribed as
one. Through a ribosomal ‘skip’ mechanism the 2A consensus motif, results in
the co-translational separation of the proteins encoded upstream and
downstream of this typically 18-20aa long peptide. The only remnant of this
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cleavage process is that the C-terminal of the 2A peptide remains attached to
the upstream protein. Despite the theoretical possibility of these virus-derived,
few amino acids to be immunogenic, this has not yet been described.
1.6.5 Lentiviral vectors for TCR gene transfer in HSC
In this project, unlike the first studies performing TCR gene transfer into HSCs,
a lentiviral construct was preferred over a retroviral vector. This made the
choice of a porcine tchechovirus 2A sequence (P2A) even more pertinent, as
there is evidence that the non-stoichiometric expression observed with the use
of an IRES element is consistently a problem with bicistronic lentiviral vectors
with the second transgene always being underexpressed. The main advantage
of lentiviral over retroviral vectors is that they can transduce non-dividing cells
(Sakuma et al., 2012). One of the technical objectives of this project is the
efficient transduction of HSCs rather than more differentiated progenitors, to
achieve the long-term and unlimited in vivo provision of T cell progenitors
destined to express the introduced TCR when in the thymus. Abolishing the
requirement for activation and proliferation of the cells prior to their infection
with the viral vector carrying the genes of interest, secures to a certain extend
the stem cell potential of the transduced HSCs.
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Chapter 2 – Materials and Methods
2.1 Mice
C57Bl/6 mice were purchased from Charles River Laboratories or the
Comparative Biology Unit of University College London, Royal Free Campus.
HLA-A2Kb transgenic (A2Kb Tg) mice of C57/Bl6 background were a kind gift
from Theobald M (University Medical Centre, Utrech, The Netherlands).
C57Bl/6, CD45.1 C57Bl/6, A2Kb mice as well as A2Kb mice crossed to
CD45.1 mice (A2Kbx CD45.1) were bred and maintained in the Comparative
Biology Unit of University College London. All animals were housed in
pathogen-free conditions in individually ventilated cages and were kept in
accordance with the University and United Kingdom Home Office regulations.
All procedures were performed aseptically, and irradiated animals received
2.5% enrofloxacin (baytril, Bayer) in their water for 1 week before irradiation
and for 2 weeks after irradiation, unless otherwise specified in individual
experiments. Donor mice were 7 to 10 weeks old at the time of bone marrow
(BM) harvest. Recipient mice were 12 weeks old at transplantation and
received 9.4Gy irradiation in 2 divided doses at day -2 and day 0. Secondary
adoptive transfer recipients were sublethally irradiated (5Gy) 4 hrs before T cell
transfer.
2.2 Lentiviral vector constructs
2.2.1 PCR & primers
For the purposes of cloning the hybrid WT1-TCR sequence in the pSin
second-generation lentiviral vector containing a spleen focus forming virus LTR
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promoter and the HIV-1 central polypurine tract cis-active element, the human
WT1 Vα and murine Cβ (mCβ) gene segments were PCR amplified from the 
pGA4 cloning plasmid, as described in Chapter 3, section 3.2.1.
The primers used are listed in table 2.1. The mixture used for each PCR
amplification reaction was prepared using the following amounts of reagents:
10ng DNA template, 2.5mM of each of dATP, dTTP, dCTP, dGTP (dNTP
mixture), 50μM of each 5’ and 3’ primers, 1μl Pfu turbo polymerase, 10μl 10x
Buffer. Final volume of the reaction mixture was 100μl made up with distilled
H2O (ddH2O).
Primer sequence Highlighted
sequence
amplify V WT1
TCR chain
GGATCCAGCCACCATGCTGCTG
CTGCTGGTGCCC
BamH1 restriction
site
amplify V WT1
TCR chain
CCGCGGGCTCGGGGTTCTGGA Sac2 restriction site
amplify mC
chain
CTCGAGGACCTGCGGAACGTG
ACCCCCCCC
Xho1 restriction site
to
amplify mC
chain
TGTACAGCGGCCGCGTCGACT
CATCAGCTGTTCTTCTTCTT
Not1 restriction site
Table 2.1 List of primers used for PCR amplification reactions to clone the
hybrid WT1 TCR sequence from the pGA4 cloning plasmid into the pSin
second-generation lentiviral vector.
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2.2.2 Restriction digests
Restriction digests were performed both to confirm that the correct
modifications in a particular construct/DNA sequence have been achieved
(screening digests) and to prepare DNA for ligation/cloning (preparative
digests). Mixtures used for each were the following:
Screening digests: 10μl mini prep DNA, 0.5μl of enzyme(s) required, 2μl
10xBSA, 2μl appropriate 10x NEB buffer. Final volume of the reaction mixture
was 20μl made up with ddH2O and this was incubated at 37oC for 2hrs. 5μl of
Ethidium Bromide was then added to the mixture and the digested DNA bands
were visualised under UV light.
Preparative digests: 6μg DNA, 5μl appropriate NEB buffer, 5μl 10xBSA, 1.5μl
of each enzyme. Final volume of reaction mixture was 50μl made up with
ddH2O. The mixture was incubated at 37oC for 4hrs. This was then mixed with
10μl of Ethidium Bromide and run on 2% agarose gel. The digested DNA
bands were visualised under UV light and the band of interest was removed
from the gel with the use of a scapel. DNA was then purified using Qiagen
DNA purification kit following the manufacturer’s instructions.
2.2.3 Ligation Reactions
PCR amplified gene segments replaced sequences previously present in the
cloning pGA4 and lentiviral backbone vectors. Two different ligation mixtures
were prepared for each reaction; one containing insert and vector at an 1:1
molar ratio and a second one containing insert and vector at a 3:1 molar ratio.
The ligation mixtures were prepared in a final volume of 10μl made up with
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ddH2O. Each ligation and contained 1μl 10x Ligation Buffer, 0.5μl DNA ligase,
100ng of (digested) vector, and the appropriate amount of insert calculated
with the following formula:
ng of vector x size of insert in Kb x insert:vector molar ratio = ng of insert to use
size of vector in Kb
Ligation mixtures were incubated at 4oC overnight and the ligated DNA was
then used to transform DH5 maximum efficiency competent E.coli (Invitrogen).
2.2.4 Transformations
Transformations of DH5 maximum efficiency E.coli were performed as per
manufacturer’s protocol. Following transformations with ligated DNA, up to 10
colonies from each transformation LB-agar plate were harvested and cultured
overnight in LB-medium, at 37oC in a shaker. Both LB-agar plates and LB-
medium contained 100μg ampicillin ng/ml. DNA was then prepared using the
Qiagen DNA Miniprep Kit as per manufacturer’s protocol. The prepared DNA
was screened with a restriction digest using the appropriate restriction
digestion enzymes to confirm the presence of the insert used in the ligation, as
described in section 2.2.2.
2.2.5 Maxipreps
To produce the necessary quantities of DNA to be used for the production of
lentiviral particles the Qiagen DNA Maxiprep kit was used as per
manufacturer’s protocol.
102
2.3 Preparation of lentiviral particles
2.3.1 Preparation of lentiviral particles
For the production of lentiviral particles, 2x106 293T packaging cells were
cultured overnight in IMDM medium containing 10% FCS, 1%
penicillin/streptomycin and 1% L-glutamine, in 175 cm2 flasks for 24hrs at
37oC, 5% CO2 in a humidified atmosphere. 12-18 hours later the flasks were
70% confluent and packaging cells were co-transfected with pMD.G, a plasmid
encoding the vesicular stomatitis virus glycoprotein (VSV-G) envelope and
pTcmVΔ8.91, a plasmid encoding the genes required for the generation of
functional viral particles, together with the pSIN lentiviral vector encoding the
GFP or TCR genes. Medium was replaced with fresh IMDM supplemented as
above 24hrs after transfection, and the viral supernatant was harvested 48hrs
later and concentrated 100x using ultracentrifugation as described below.
2.3.2 Concentrating lentivirus
The lentiviral supernatant was harvested and centrifuged at 1500rpm for 5min
to remove any cellular debris. It was then pipetted slowly onto 5ml of 20%
sucrose solution (20% in water) in Ultra-clear Centrifuge tubes 25x89mm from
Beckman, to prevent any further cellular debris from pelleting during
ultracentrifugation. The lentiviral supernatant was ultracentrifuged at 25000rpm
for 2hrs at 4oC and was then discarded as the lentiviral particles were pelleted
in an invisible pellet. The virus was then resuspended in StemSpan medium
(100x concentrated), aliquoted in 200μl batches and stored at -80oC for future
use. Each aliquot could only be thawed once.
103
2.3.3 Quantification of viral particles
To estimate the number of viral particles per μl of the concentrated virus 5x105
58-/- cells in 1ml of RPMI medium supplemented with 10% FCS 1%Pen/Strep
and 1% L-glutamine were transduced with a serial dilution of concentrated
lentivirus (0.1μl to 12.5μl). This was repeated for each new batch of lentivirus.
Transduction was performed by adding the specified amount of virus into each
well and replacing with fresh medium 24hrs later. The transduced cells were
kept in culture and FACS analysed 48hrs later for transgene expression. The
percentages of GFP, WT1-TCR or LMP2-TCR were each time plotted in a
graph as shown in figure 2.1 and a “standard curve” was drawn. As it is widely
accepted that at low transduction efficiencies each transduced cell receives
one functional virus, the total number of functional viral particles per μl of
concentrated virus was calculated based on the volume of virus required to
reach a transduction efficiency of 20%. For the purposes of our experiments
an MOI (Multiplicity of Infection) 10 was used to transduce the Lin-ve BM cells.
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Figure 2.1 to calculate the number of viral particles per l of
concentrated lentivirus. 5x105 58-/- cells in 1 ml of cell culture medium were
transduced with a serial dilution of concentrated lentivirus (0.1-12.5 l). 24hrs later
fresh medium was added and 48 hours later the cells were analysed by Flow
Cytometry for transgene expression. The percentages of transduced 58-/- cells in
relation to the amount of virus added were plotted in a graph to produce a
. Here the standard for the LMP2 TCR lentivirus is shown. The volume
of virus corresponding to 20% transduction was used to calculate the total number of
functional viral particles per l.
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2.4 HSC isolation, infection and transfer
2.4.1 BM harvesting
Whole BM was harvested from 7- to 10- week old donor mice (C57Bl/6 or
A2Kb Tg as specified in each experiment). Donor animals were sacrificed
using Schedule 1 procedures and sprayed thoroughly with 70% ethanol.
Femurs, tibias and pelvic bones were removed from the donor animals, using a
sterile technique. Bones were kept in ice cold RPMI and the BM was harvested
by cutting each end of every bone and flushing it with ice cold RPMI medium
containing 1% Pen/Strep using a syringe attached to a 25-gauge needle. A
single cell suspension of BM cells was then prepared by mixing the cells using
a syringe attached to a 16-gauge needle.
2.4.2 Lineage negative selection
Uncommitted BM progenitors, highly enriched in HSCs, were negatively
selected using either the lineage cell depletion kit for mouse (Miltenyi Biotec)
or the Haematopoietic Progenitor Enrichment kit (StemCell Technologies)
following the manufacturer’s protocols. Lineage negative BM (Lin-ve BM) cells-
highly enriched in HSCs- were placed in culture at 1x106cells/ml in StemSpan
medium (StemCell Technologies) containing 50U/ml penicillin/streptomycin,
100ng/ml murine Stem Cell Factor, 100ng/ml human Fms-like tyrosine kinase
3, 100ng/ml human IL-11, and 20ng/ml murine IL-3 (all cytokines purchased
from Peprotech). In experiments where the transduction of Lin-ve cells was
required this was performed by adding the necessary volume of the
appropriate lentiviral particles to provide an MOI of 10. 18-24 hrs after
transduction, the transduced Lin-ve BM cells were harvested, washed and
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resuspended in RPMI containing 1% Pen/Strep. Cells were then counted and
resuspended at a concentration that would allow the transfer of the required
number of cells into recipient animals. In preliminary cell number titration
experiments, mock transduced cells were used that had undergone the same
procedures, apart from the addition of virus in the cell culture.
2.4.3 HSC transplant
HSC transplants with mock, GFP td, WT1-TCR or LMP2-TCR td Lin-ve BM
cells were performed in 11-12 wk old A2Kb Tg mouse recipients that were
lethally irradiated with 9.4Gy in two fractions, unless otherwise specified in
individual experiments. In all experiments except the cell number titration
experiments (section 3.3.2), each recipient received 5x105 Lin-ve BM cells by
tail vein injection. Tail bleeds were performed at weeks 5, 7, and 9 after
transplantation. Recipient animals were sacrificed 11 weeks after
transplantation and thymus, spleen, LNs and BM were harvested for
phenotypic analysis and functional characterisation of T cells.
2.4.4 Standardised clinical monitoring
All transplated mice were monitored on a daily basis and scored according to
the standardised clinical monitoring system presented in table 2.2 Mice scoring
4 or higher were sacrificed.
score 0 0.5 1 2
Fur Normal fur angle 90o
Hunch None slight hunch, lost
when mouse moves
Significant hunching,
reduced on
movement
severe
hunching
persistent on
movement
Eyes Normal < 50% closed <50% closed <
100%
Eyes closed
Activity Normal mild to moderate
reduction in
spontaneous
movement, resist
handling
Severe reduction in
spontaneous
movement , do not
resist handling
No
spontaneous
movement
Table 2.2 Standardised clinical monitoring system for HSC transplant
recipients. Mice were assessed on the appearance of their fur and eyes, the
presence of a hunch, and their activity.
107
108
2.4.5 Histology
Samples of bone marrow and kidney from mice receiving WT1-TCR and
LMP2-TCR td HSCs were fixed in 10% neutral buffered formalin, processed
routinely and stained with haematoxylin and eosin (H&E). The blinded
histological analysis of tissue samples from mice looking for evidence of T cell
infiltration and autoimmune damage in these tissues that are known to
physiologically express low levels of the WT1 Ag, was carried out by Dr. Emma
Morris, Dept of Immunology, Royal Free and University College Hospital
Medical School, UCL.
2.4.6 Adoptive T cell transfer into secondary recipients
Lentiviral TCR-transduced C57Bl/6 Lin-ve BM cells were transferred into
lethally irradiated A2KbxCD45.1 Tg recipients as described above (section
2.4.3). Seventeen weeks after transplantation the mice were sacrificed, and
their spleens were harvested. Splenocytes from 5 primary recipients were
pooled and untouched CD3 T cell selection was performed using a mouse
pan-T cell isolation kit (Miltenyi Biotech) as per manufacturer’s protocol. A total
of 3x106 T cells were transferred to secondary A2KbxCD45.1 recipients that
were sublethally irradiated (5Gy) 1 day prior to the transfer. Tail bleeds were
performed at day 9 and 28 after adoptive transfer. On days 69 and 70, in vivo
cytotoxicity assays (see section 2.5.1) were performed and splenocytes from
these secondary recipients were also used in ex-vivo proliferation assays as
described in section 2.5.2, materials and methods.
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2.4.7 Serial HSC transplants
Serial HSC transplants were performed using BM cells from primary WT1-TCR
HSC transplant recipients (A2KbxCD45.1 to A2Kb transplant). BM cells were
pooled together and 5x106 cells were transferred into each lethally irradiated
(9.4Gy administered in two portions) C57Bl/6 secondary recipients. The mice
were monitored on a daily basis and tail bleeds were performed at 3, 5, 8 and
12 weeks after transplantation, to monitor the reconstitution kinetics of all
haematopoietic lineage at these time points by FACS analysis. BM cells from
untreated A2KbxCD45.1 Tg mice were used to reconstitute lethally irradiated
C57Bl/6 mice as a control for donor-derived haematopoietic reconstitution.
2.5 T cell phenotypic analysis and functional assays
2.5.1 In vivo cytotoxicity assays
Splenocytes from female A2Kb Tg mice were peptide loaded with 100μM of
either relevant peptide (WT1-TCR pWT126, LMP2-TCR pCLG) or an irrelevant
HLA-A0201 presented epitope before labelling them with 1.5μM
carboxyfluorescein diacetate succinimidyl ester (CFSE; CFSEhi) or 0.15μΜ
CFSE (CFSElo) respectively, for 5min at 37oC. The cells were then washed
once in ice-cold RPMI with 8% FCS and twice with ice-cold PBS. Labelled cells
were mixed at a 1:1 ratio, relevant:irrelevant targets and a total of 10x106 total
cells were injected per mouse by tail vein injections. 18hrs later, injected
animals were sacrificed and splenocytes were analysed by flow cytometry to
identify CFSE high or CFSE low labelled targets. Control untreated A2Kb Tg
mice were injected with the same mix of labelled target cells. Percentage
antigen-specific in vivo cytotoxicity was determined using the following formula:
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[1-((A:B)/(C:D))], where A= mean number of relevant peptide-loaded
splenocytes at 18hrs in experimental mice; B = mean number of irrelevant
peptide-loaded spelnocytes at 18 hrs in experimental mice; C = mean number
of relevant peptide-loaded splenocytes at 18hrs in control mice and D = mean
number of irrelevant peptide-loaded splenocytes at 18hrs in control mice.
2.5.2 Ex-vivo proliferation assays
Splenocytes from mice that had been transplanted with WT1 or LMP2-TCR td
HSCs, or mice that had received adoptively transferred of T cells from primary
transplant recipients, were labelled with 1.5μM CFSE as described in section
2.5.1 and placed in culture at 1x106 cells/ml. The CFSE labelled cells were
then stimulated with 100μM of relevant (pWT126 or pCLG accordingly) or
irrelevant peptide for 5 days before the CFSE dilution of WT1 or LMP2-specific
T cells were analysed by flow cytometry. WT1 and LMP2-specific T cells were
identified by staining with human Vβ2 and human Vβ13 antibodies
respectively. In the case of A2Kb Tg mice receiving C57Bl/6 TCR td HSCs,
professional antigen presenting cells (APCs) were almost completely replaced
with donor C57Bl/6 BM-derived APCs. Therefore, to ensure adequate antigen
presentation, the assayed labelled splenocytes were stimulated with an equal
number of A2Kb Tg splenocytes loaded with relevant/irrelevant peptides
(100μM), with the final cell concentration being 1x106 cells/ml.
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2.5.3 Antibodies and FACS analysis
2.5.3.1 Antibodies
Optimum concentration of the monoclonal antibodies (MAbs) used was
determined in a titration assay where a mixture of cells consisting of both cells
staining positive and negative for each MAb was stained with increasing
concentrations of the MAb. The staining profile was analysed by flow cytometry
to identify the lowest concentration of the MAb at which a clear separation
between the negative and positive population of cells was obtained. This was
then used in subsequent experiments. The following fluorescently labelled anti-
murine antibodies (BD Bioscience) were used in this project: CD45.1 APC
Cy7, CD3 APC, CD3 FITC, CD4 FITC, CD8 PE Cy5, CD44 APC, CD62L FITC,
B220 PE Cy5, CD11b APC, Lineage cocktail antibody APC, Sca1 PECy7, and
streptavidin APC. Anti-human Vβ2.1 PE, Vβ2.1 biotin and Vβ13 were
purchased from Immunotech. An LSR II cytometer (BD Bioscience) was used
for flow cytometric analysis. Data were analysed using FACS DIVA (BD) and
FlowJo Version 7 (TreeStar) software.
2.5.3.2 Preparing blood samples from tail bleeds for staining
Red blood cells were lysed prior to antibody staining blood samples for FACS
analysis by transferring the sample in 9ml of H2O. 10 seconds later 1ml of
10xPBS was added to restore isotonic conditions. The solution was then
centrifuged at 1500rpm for 5min and stained as described below.
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2.5.3.3 Cell Counting and viability
All cells were counted using a haemocytometer (Immune Systems) under a
light microscope. Cell viability was assessed using 0.1% trypan blue (Sigma,
UK) in PBS as live cells exclude the trypan blue dye.
2.5.3.4 Staining for cell surface molecules
Antibody staining for cell surface molecules for flow cytometric analysis, was
performed in the following way. Cells were harvested, counted and washed in
ice-cold staining buffer (PBS with 1% FCS) and pelleted. The cells were
resuspended in 50μl of staining buffer containing the appropriate dilution of the
relevant monoclonal antibodies, and the samples were incubated for 25
minutes at 4oC in the dark. After the incubation, samples were washed twice in
ice-cold staining buffer and resuspended in 500μl of staining buffer. Samples
were acquired on an LSR II Flow cytometer and analysed using FACS DIVA
(BD) and FlowJo Version 7 (Treestar) software.
2.5.4 ELISA
Supernatants from the ex vivo proliferation assays were harvested on day 5
and stored at -20oC. IL-2 and IFN-γ production after peptide stimulation,
described in section 2.5.2, was determined by performing ELISA on these
supernatants using the BD OptEIA mouse IL-2 and IFNγ ELISA sets, as per
manufacturer’s protocol.
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2.5.5 Peptides
The WT1 and LMP2, HLA A0201 restricted epitopes used in functional assays
to determine the antigen specific T cell activity of WT1 and LMP2-specific T
cells respectively were the following:
WT1 derived epitope, pWT126: RMFPNAPYL
EBV derived epitope, pCLG: CLGGLLTMV
The HLA A0201 restricted epitopes used as irrelevant controls, as specified in
individual experiments were the following:
pWT235: CMTTWNQMNL
pEBV GLC: CLCTLVAML
pCMV NLV: NLVPMVATV
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Chapter 3 – Results 1 - Preparation of the lentiviral constructs used for
TCR gene transfer in HSCs and validation of the experimental in vivo
model.
3.1 Introduction
The fate of high avidity, A2-restricted WT1-specific T cells in the thymus and in
the periphery was studied in an HLA A2 transgenic mouse model. As
discussed in the Introduction (Chapter 1) the cognate epitope for the WT1-TCR
(pWT126), is expressed at low levels and presented in both species. The
experimental model used was also described in the schematic representation
of figure 1.10. Murine HSCs were transduced with the genes for the WT1-TCR
and were subsequently transferred in HLA A2 Tg mice. In vivo, developing
thymocytes expressing the WT1-TCR go through thymic development while in
the thymus peripheral self-Ags are promiscuously presented on HLA A2
molecules. Depending on whether they can escape negative selection, WT1-
specific thymocytes then emerge in the periphery where they are susceptible
to the effects of WT1 Ag expression by rare BM progenitors and renal
podocytes.
In this chapter the molecular work performed to prepare the lentiviral
constructs used for TCR gene transfer in HSCs is described. Even though
TCR gene transfer in HSCs has previously been validated and used to study
the development and function of other T cell specificities (Yang and Baltimore,
2005, Arnold et al., 2004) these studies used retroviral vectors and enriched
for HSCs by treating donor mice with 5-Fluorouracil prior to BM harvest. In this
project, lentiviral vectors were preferred for gene transfer. In addition, BM
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harvest from untreated donor animals was followed by the magnetic separation
of Lin-ve BM cells which are highly enriched in HSCs. Therefore, it was
necessary to optimise the conditions for and validate the experimental model
before proceeding with TCR td HSC transplant experiments to study the fate of
WT1-specific T cells in the context of the low level, physiological expression of
WT1 Ag. The preliminary experiments performed to establish the in vivo model
are presented in this chapter.
3.2 WT1-TCR and LMP2-TCR lentiviral constructs
3.2.1 Generation of pSin-WT1-TCRα-p2A-WT1-TCRβ vector.
Figure 3.1 shows a schematic representation of the cloning strategy used to
generate the pSin-WT1-TCRα-p2Α-WT1-TCRβ lentiviral vector. The genes for
the WT1-TCR-p2A- WT1-TCRβ were present in the pGA4 cloning plasmid
and had to be transferred into the lentiviral vector backbone. To do this the
restriction sites in the WT1-TCR pGA4 construct were modified. The existing
WT1 Vα1.5 chain sequence was amplified by PCR with a 5’ primer containing
the BamH1 restriction site without a Not1 restriction site, thus removing the
Not1 restriction site from the PCR product. Similarly, the murine Cβ chain was
amplified with a 3’primer containing an additional Not1 restriction site after the
stop codon and before the BsrG1 site. The original Vα and Cβ chains were
removed from the WT1-TCR-pGA4 plasmid by BamH1/Sac2 and Xho1/BsrG1
double digestions respectively, to be replaced with the corresponding, mutated
PCR-amplified sequences. Figure 3.2A shows the gel electrophoresis following
screening restriction digestions of the modified hybrid WT1-TCR – pGA4
plasmid with XhO1/Not1. BamH1/Not1 restriction digests were then used to
Figure 3.1 Schematic representation of cloning strategy to obtain WT1 TCR in
lentiviral vector.
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release the complete WT1-TCR sequence from the pGA4 cloning vector, and
to remove the insert from the lentiviral vector backbone before the two were
ligated together. The list of primer sequences used is found in chapter 2,
Materials and Methods. A screening digestion with BamH1/Not1 was
performed on the final hybrid WT1-TCR lentiviral construct to confirm that the
required plasmid was produced. The relevant gel electrophoresis of the
digested DNA is shown in figure 3.2B.
400bp
1500bp
2000bp
Figure 3.2 Screening restriction digests to confirm modifications performed in
DNA constructs. A. screening restriction digestion of modified WT1 TCR in pGA4
with XhO1/Not1. The smaller band (around 400 bp) confirms that the original Not1
restriction site has been removed and a new Not1 restriction site has been inserted
as indicated. B BamH1/Not1 restriction digestion on final construct (WT1 TCR in
lentiviral vector) to confirm that the hybrid WT1 TCR has been successfully
transferred into the lentiviral vector.
A
B
XhO1+Not1
screening digestion
BamH1+Not1
screening digestion
B
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3.2.2 Cloning of the LMP2-TCR genes into the lentiviral vector
The hybrid LMP2-TCR was cloned from the pMP71 retroviral vector, into an
empty lentiviral backbone as described in figure 3.3. The LMP2-TCRα-p2A-
LMP2-TCRβ genes in the retroviral construct were preceded by a Not1
restriction site and followed by a BsrG1 restriction site. These sites were used
to release the LMP2-TCR sequence fragment from the pMP71 backbone.
Figure 3.3 describes the cloning strategy and shows the gel electrophoresis of
the digested empty .lentiviral vector and hybrid LMP2-TCR in pMP71 vector
digested with Not1/BsrG1. However, the lentiviral construct in which this
sequence was to be cloned, originally contained two BsrG1 restriction sites.
Site directed mutagenesis was used to remove the second BsrG1 site
(BsrG1(B)) as described in the schematic diagram in figure 3.4. Primers which
introduced a point mutation within the BsrG1(B) site were used to PCR amplify
the entire lentiviral vector. The PCR product was then digested with Dpn1 to
discard the original plasmid. XL10-Gold competent cells were then transformed
with the PCR product containing the mutated lentiviral construct and colonies
were screened by BsrG1 digestions. The appearance of a linearised DNA
sequence, as shown in figure 3.4, confirmed that a single BsrG1 restriction site
was present following site directed mutagenesis.
Figure 3.3 Schematic representation of cloning strategy for the transfer of the
hybrid LMP2 TCR sequence from the pMP71 retroviral vector, into an empty
lentiviral vector. Agarose gel electrophoresis of preparative digestions as
indicated.
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Figure 3.4 Schematic representation of site-directed mutagenesis.
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(no insert)
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Dpn1 digestion of original plasmid
(methylated DNA)
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3.2.3 Cell surface expression of WT1 and LMP2-TCRs following lentiviral
vector transduction of 58-/- cells
To confirm that the two new lentiviral constructs generated could mediate the
surface expression of the WT1 and LMP2-TCRs, the 293T cell line was
transfected with each construct to produce the corresponding viral particles
and the 58-/- murine thymoma cell line was transduced with the produced
recombinant lentiviral particles. The same protocol was later used throughout
the study for the lentiviral transduction of HSCs and is described in detail in
Materials and Methods, chapter 2. The FACS analysis plots in figure 3.5
demonstrate that 3 days post-transduction levels of WT1 and LMP2-TCR
surface expression were as expected, dependent on the MOI of the
concentrated lentivirus added to the cell culture. TCR expression was
determined by FACS analysis on gated viable 58-/- cells, using anti-Vβ2 and
Vβ13 antibodies respectively.
FSC
V 2
MOI 0 MOI 0.01 MOI 0.02 MOI 0.04
MOI 0.09 MOI 0.18 MOI 0.36 MOI 0.71
FSC
MOI 0 MOI 0.01 MOI 0.02 MOI 0.04
MOI 0.08 MOI 0.16 MOI 0.32 MOI 0.64
V 13
WT1 TCR transduced 58-/- cells
LMP2 TCR transduced 58-/- cells
Figure 3.5 Lentiviral constructs containing hybrid TCR sequences effectively
transduce the 58-/- cell line resulting in the expression of the introduced
TCRs. A. 0.5x106 58-/- cells are transduced with increasing amounts of
concentrated lentiviral particles (increasing MOI) containing the sequence for the
hybrid WT1 TCR. B.0.5x106 58-/- cells are transduced with increasing amounts of
concentrated lentiviral particles containing the sequence for the hybrid LMP2 TCR.
A&B 72hrs post-transduction the cells were stained with human V 2 and V 13
antibodies respectively and TCR expression was measured by FACS.
35.1
0.1 3.4 5.8 10.7
16.7 25.6 40.3 52.0
0.4 2.0 3.6 5.2
8.2 14.6 22.1
A
B
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3.3 Establishment of the in vivo murine model to study the development,
phenotype and function of WT1-specific T cells
3.3.1 Enrichment and lentiviral transduction of Lineage Negative BM
cells.
Uncommitted BM progenitors, highly enriched in HSCs were negatively
selected using either the Miltenyi Biotech Lineage cell depletion kit for mouse,
or the Haematopoietic Progenitor Enrichment kit from StemCell Technologies
following the manufacturers’ protocols. A negative selection kit was preferred
to ensure that the HSCs were unaffected from the magnetic separation
process. Purity and cell surface phenotype of Lin-ve BM cells before and after
Lin-ve selection were assessed by FACS analysis following staining with
Lineage cocktail and Sca-1 antibodies. The yield after the Lin –ve BM stem cell
separation was around 1% and the purity ranged between 87-94%
(representative FACS plots before and after Lin-ve selection, shown in figure
3.6). The Lin-ve Sca-1+ve compartment of BM cells has been shown to
contain pluripotent HSCs (Uchida and Weissman, 1992, Spangrude et al.,
1988).
Prior to in vivo experiments it was important to confirm that lentiviral
transduction of Lin-ve BM cells efficiently mediates the expression of the
introduced transgene in this cell population. This was not possible to test in
vitro using the TCR lentiviral constructs, as TCR surface expression requires
the similteneous expression of the CD3 molecule, an event taking place after
progenitor BM cells have entered the thymus and committed to the T cell
lineage. For this reason, a GFP lentiviral construct was used. Lin-ve BM cells
were transduced with lentiviral GFP particles (MOI 20) and kept in culture.
Figure 3.6 Enrichment of Lineage negative HSCs and lentiviral
transduction. BM cells were harvested from 7-10 wk old donor mice and
enriched in HSCs by means of Lineage Negative Selection prior to being
transduced with a lentiviral vector. Biotin-streptavidin APC conjugated Murine
haematopoietic Lineage cocktail (CD5, CD11b, CD45R, anti-Ly6g, 7-4, Ter-
119) and PECy7 Sca1 antibodies were used to stain BM cells prior and after
magnetic separation.
SS
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C
y7
FSC Lineage cocktail APC
Total BM (pre-selection)
Lin-ve BM cells (after selection)
Total BM (pre-selection)
Lin-ve BM cells (after selection)
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After 3 days 95% of the Lin-ve BM cells expressed GFP, as determined by
FACS analysis. The presence of two GFP positive cell populations suggested
that integration of more than one GFP gene occurred in a proportion of
transduced cells (figure 3.7) when an MOI of 20 was used. Therefore, an MOI
of 10 was used for all subsequent experiments. Achieving lower transduction
efficiencies with this MOI was in fact desirable to allow WT1-specific T cells to
develop in a polyclonal environment of endogenous T cell specificities.
Lentiviral GFP transduction of Lin-ve BM cells
mock transduced
Lin-ve BM cells
GFP transduced
Lin-ve BM cells
G
FP
FI
TC
FSC
Gated on
live Lin-ve
BM cells
Fig.3.7 Lin-ve BM cells are efficiently transduced with a lentiviral GFP vector.
GFP-lentiviral supernatant was added to 0.5x106 Lin-ve BM cells, at an MOI of 20. In
mock transductions no lentivirus was added. 24 hrs later the cell culture medium and
virus were replaced with fresh StemSpan medium. 72 hrs later the cells were
analysed by Flow Cytometry for the expression of the GFP transgene. The presence
of two distinct GFP positive populations suggests that integration of more than one
GFP genes occured in a proportion of the transduced cells.
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3.3.2 Optimisation of HSC transplant experiments
All experiments utilised 5x105 cells and an irradiation dose of 9.4Gy
administered in 2 fractions. Transplant recipients were also kept on antibiotics
(Baytril) for 1 week prior to the transplant and 2 weeks after. With these
experimental conditions no transplant-related mortality was observed.
3.3.3 Donor-derived haematopoietic reconstitution in recipients of
lentivirally td HSCs.
To test the engraftment potential of genetically modified BM stem cells,
congenic transplants were performed in C57Bl/6 mice. Donor CD45.1 positive
C57Bl/6 Lin-ve BM cells were transduced with lentiviral GFP control vector
(MOI 10) prior to transfer into lethally irradiated (9.4Gy) wild-type (WT) C57Bl/6
animals. Tail bleeds were performed at 5, 6 and 9 weeks and at 6.5 months
post-transplant. Peripheral blood samples were stained with anti- CD45.1, anti-
CD3, anti-CD8 and anti-B220 antibodies to determine donor chimerism in the T
and B cell lineages. Figure 3.8A shows representative FACS plots of
peripheral blood samples stained for CD8 T cells (CD3, CD8 positive
lymphocytes) and B cells (B220 positive lymphocytes) and the congenic
marker CD45.1 used to identify donor-derived cells. The graph in figure 3.8B
showing the percentage donor chimerism in the T and B cell lineage at the
various time points, illustrates that donor B cell engraftment occurred more
rapidly than T cell engraftment. In recipients receiving 5x105 cells, 30.8%
(median) of T cells were donor-derived 5 weeks post-transplant, increasing to
80% (median) 9 weeks post-transplant. At 6.5 months post-transplant the
levels of donor T cell chimerism were > 90%. Therefore, in subsequent
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experiments, recipients of TCR td HSC transplants were allowed to
reconstitute for longer than 9 weeks (11 wks) post-transplant, prior to
performing the phenotypic analysis and functional assays of the in vivo
generated WT1-specific T cells.
Figure 3.8 Donor-derived haematopoietic reconstitution at different time points
in recipients of lentivirally transduced HSCs.
C57Bl/6 Lin-ve BM cells were transduced with a lentiviral construct containing a GFP
transgene, prior to their transfer into lethally irradiated congeneic recipients. tail
bleeds were performed at 5, 6, 9 and 28 weeks post-transplant to monitor donor T
and B cell reconstitution by FACS analysis. Peripheral blood samples were stained
with murine anti- CD45.1, CD3, CD8 and B220 antibodies. (A) Representative FACS
plots of peripheral blood samples, 5 and 9 weeks post-transplant as indicated. The
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Figure 3.8 (continued)
CD45.1 congeneic marker identified donor-derived, T cells, CD8 T cells and B cells.
Percentages shown are on gated viable lymphocytes and gated viable CD3 positive
lymphocytes as indicated. (B) Graphs show percentage donor (CD45.1 positive) T or
B cells in total T or B cells at the indicated time points, in individual transplant
recipients. n=4 (3 mice received 5x105 td Lin-ve BM cells and 1 mouse received
2.5x105 cells).
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3.3.4 Long term gene expression following transplantation of lentivirally
transduced HSCs.
The C57Bl/6 mice receiving GFP-td HSC transplant were used to assess not
only whether lentivirally transduced HSC transplant can result in the
haematopoietic reconstitution of myeloablated recipients but also to confirm
that they can give rise to a differentiated progeny expressing the introduced
gene. As illustrated in figure 3.9A and B, GFP was expressed in both T and B
cells at all recorded time points. Therefore, donor HSCs were successfully
transduced with the lentiviral GFP construct and the transduced uncommitted
progenitor cells were able to differentiate into T and B cells expressing the
transgene.
Figure 3.9 Lentiviral transduction of HSCs results in the long term expression
of the introduced gene in differentiated donor-derived lymphocytes. C57Bl/6
Lin-ve BM cells were transduced with a lentiviral construct containing a GFP
transgene, prior to their transfer into lethally irradiated congeneic recipients. Tail
bleeds were performed at 5, 6, 9 and 28 weeks post-transplant to monitor GFP
expression in the T and B cell lineage. A .Representative FACS plots of peripheral
blood samples taken 9 weeks post transplant and stained with anti-CD45.1, anti-
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Figure 3.9 (continued)
anti-CD8 and anti-B220 antibodies. Top right quadrant in each FACS plot shows the
percentage of GFP transduced cells in gated viable T cells, CD8 T cells and B cells
respectively. B.% GFP expression in peripheral blood donor-derived T and B cells,
at 5, 6, 9 weeks and at 6.5 months.
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3.3.5 Donor derived haematopoietic reconstitution in recipients of TCR td
HSC transplants
The in vivo experimental model to study the development and function of WT1-
specific T cells in the context of physiological WT1 Ag expression, involved
TCR td HSC transplants. In these experiments the introduced TCR would only
be expressed on T cells, because TCR surface expression is linked to CD3
expression. It was therefore important to establish that TCR transgene
expression solely on T cells did not affect donor T cell reconstitution. C57Bl/6
Lin-ve BM cells were transduced with the WT1-TCR lentiviral construct, prior to
their transfer into 9.4Gy irradiated A2Kb recipients. Tail bleeds were performed
at 6 and 8 weeks post transplant and the peripheral blood samples were
stained with anti-CD45.1, anti-CD3, anti-CD8 antibodies to monitor donor-
derived T cell reconstitution. Recipient mice were sacrificed at 11 weeks post-
transplant and single cell suspensions were prepared from the spleen, Lymph
Nodes (LNs) and BM of each animal and stained with the same antibodies
prior to FACS analysis. Figure 3.10 demonstrates that 6 weeks post-transplant
the mean percentage of donor derived, CD45.1 positive T cells in 9 recipients
was 49.5% and 43% among donor CD8 T cells (range 41.4%-58% and 29.5%-
60.9% respectively) increasing to >90% (range 88.3-95.2% and 92-96.3% for
total and CD8 T cells respectively) at 11 weeks in the spleen and LNs and
84% and 87.8% in the BM. Therefore, donor T cell chimerism was similar to
that observed in GFP-td HSC transplant recipients.
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Figure 3.10 Donor-derived T reconstitution following transplantation of WT1
TCR transduced C57Bl/6 HSCs into A2Kb tg recipients. Lin-ve BM cells from
C57Bl/6 recipients were lentivirally transduced with the genes for the hybrid WT1
TCR, prior to their transfer into 9.4Gy irradiated A2Kb recipients. Each recipient
animal received 5x105 cells. Peripheral blood samples taken at 6 and 8 weeks post-
transplant, as well as splenocytes, LN and BM single cell suspensions harvested at
11 weeks post-transplant were stained with anti-CD45.1, anti-CD3 and anti-CD8
antibodies to monitor donor-derived T cell reconstitution. The chart summarises the
results in 9 recipients, showing the mean percentage of donor derived to total T cells
and CD8 T cells.
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3.3.6 The class I restricted WT1-TCR is expressed in a proportion of
donor derived CD8 T lymphocytes following transplant with WT1-TCR
transduced HSCs
TCR gene transfer into HSCs allows the study of both thymic development and
peripheral function of T cells expressing the particular TCR of interest, in an
otherwise polyclonal T cell environment as only a small proportion of T cells
will be expressing the introduced TCR. In this way this system is more
physiologically relevant than a TCR transgenic mouse model. Nevertheless, as
it was possible that WT1-specific T cells would undergo thymic deletion due to
their specificity, it was important to first establish whether any WT1-specific T
cells survived negative selection in the thymus and emerged in the periphery,
prior to proceeding with further experiments. Furthermore, it was important to
confirm that T cells expressing the HLA A2 restricted WT1-TCR, obeyed the
long established rule that T cells expressing a class I restricted TCR commit to
the CD8 T cell lineage during thymic development (Teh et al., 1988, Singer et
al., 2008).
To answer these questions, TCR expression in splenocytes from A2Kb Tg
mice receiving 5x105 WT1-TCR transduced A2KbxCD45.1 HSCs, were
assessed 11 weeks post-transplant. WT1-specific T cells were indeed detected
in the periphery, suggesting that at least some of these T cells escape thymic
deletion. As expected, the introduced TCR was only expressed in donor
derived T cells and this is illustrated in the representative FACS histogram in
figure 3.11A. The percentage of WT1-specific T cells in donor lymphocytes,
donor T cells and donor CD8 T cells in the spleens of the same group of
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transplant recipients, is shown in figure 3.11B. The mean value of WT1-
specific T cells in the spleens of transplant recipients were 0.9% of donor
lymphocytes, 3.3% of donor T cells and 9.6% of donor CD8 T cells, 11 weeks
post transplant. For this analysis, splenocytes were stained with anti CD45.1,
anti-CD3, anti CD8 murine antibodies, and human anti Vβ2 antibody was used
to identify cells expressing the WT1-TCR. Analysis of the WT1 specific T cell
development, phenotype and function in this group of mice was performed and
is described in detail in Chapters 4 and 5.
Verifying that WT1-specific T cells were committed to the CD8 T cell lineage
was done by staining splenocytes from the WT1-TCR td HSC transplant
recipients with anti- human Vβ2, murine anti-CD4 and anti- CD8 antibodies. 
Representative FACS histograms showing CD4 and CD8 expression in Vβ2 
positive and negative T cells are shown in figure 3.11C. It is obvious from the
right panel histogram in this figure that CD8 expression in V2 positive T cells
is different from that of the whole CD8 T cell population. This phenotype was
investigated in detail and is discussed in the following chapters.
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Figure 3.11 WT1 TCR is expressed in a proportion of donor derived CD8 T
cells following transplant with WT1 TCR transduced HSCs. Recipient A2Kb tg
mice were irradiated with 9.4Gy prior to receiving 5x105 WT1 TCR transduced
A2KbxCD45.1 HSCs. 11 weeks post-transplant the mice were sacrificed to study
the in vivo generated WT1 specific T cells. n=9. (A) FACS histogram comparing V 2
expression in CD3 positive and CD3 negative lymphocytes in splenocytes from a
representative transplant recipient. (B) Mean percentage of V 2 positive T cells in
donor derived lymphocytes, T cells and CD8 T cells in transplant recipients. (C) CD4
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Figure 3.11 (continued)
and CD8 expression profiles of V 2 positive and total donor derived T cells in a
representative transplant recipient. Splenocytes were stained with murine anti
CD45.1, anti CD3, anti CD4, anti CD8 and anti human V 2 antibodies prior to FACS
analysis.
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3.4 Discussion
In order to study the in vivo thymic and peripheral fate of high avidity, HLA A2-
restricted WT1-specific T cells, an in vivo model of TCR td HSC transplants in
A2Kb Tg mice recipients was utilised. The genes for the WT1 and LMP2
specific HLA A2 restricted TCRs were inserted in lentiviral vector plasmids and
the constructs were validated in the 58-/- cell line. HSCs were enriched by the
magnetic separation of Lin-ve murine BM cells. HSC transplant conditions
were optimised to an irradiation dose of 9.4 Gy in two fractions prior to the
transplant, and a cell dose of 5x105 Lin-ve BM cells. Phenotypic and functional
analysis of WT1/LMP2-specific T cells was performed at least 11 weeks post-
transplant when donor reconstitution on all haematopoietic lineages was
consistently over 90%. The appearance of WT1 specific CD8 T cells, in the
periphery of WT1-TCR td HSC transplant A2Kb recipients not only confirmed
that the experimental system is working, but also suggested that at least a
proportion of WT1-specific T cells survive negative selection in the thymus and
therefore emerge in the periphery. The development and function of WT1-
specific T cells were subsequently studied in detail and these results are
presented in the next chapters.
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Chapter 4 – Results 2 - Thymic development of WT1 specific T
cells and phenotypic analysis.
4.1 Introduction
Having confirmed that WT1 specific, CD8 T cells can be generated in vivo in
our experimental system, this model was then used for the further study of the
development, phenotype and function of these cells in the context of
physiological WT1 Ag expression. It was already shown in the previous
chapter that WT1-specific T cells emerged in the periphery and that while they
were commited to the CD8 T cell lineage, the expression of the CD8 co-
receptor on these cells differed from that of T cells expressing endogenous
murine class-I restricted TCRs. This chapter is concerned with the phenotypic
analysis of the WT1-specific T cells in the thymus and the periphery.
4.2 Results
4.2.1 WT1-specific T cells emerge in the periphery and exhibit CD3
downregulation
Purified lineage negative BM stem cells from A2Kb transgenic mice were
transduced with the lentiviral WT1-TCR vector and transferred into A2Kb Tg
mice that had received 9.4Gy irradiation. Recipient mice were tail bled 6 and 8
weeks post-transplant and blood samples were stained with CD45.1, CD3,
CD4, CD8 and Vb2 antibodies and analysed by FACS. 11 weeks post-
transplant the mice were sacrificed and their thymuses, spleens, LNs and BM
were harvested for further phenotypic analysis and functional assays.
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WT1-specific T cells were readily detected in tail bleed samples as well as in
the spleen, LNs and BM of all A2Kb Tg mice that had received WT1-TCR td
HSCs, but not in control A2Kb mice. Interestingly, as shown in the
representative FACS plots in figure 4.1.A the level of CD3 expression in the
Vβ2 positive T cell population appeared reduced in comparison to that of 
donor-derived T cells expressing endogenous murine TCRs. The CD3
molecule can be a marker of the level of TCR expression, as the cell surface
expression of the two molecules is coupled. One possibility for the observed
CD3/TCR downregulation in WT1-specific T cells was that this was due to low
promoter activity of the lentiviral vector used to drive TCR expression. To
exclude this, further experiments were performed. The genes for the WT1-TCR
in the lentiviral construct were replaced with the genes for a hybrid, HLA-
A0201-restricted TCR specific for a non-self peptide derived from the Latent
Membrane Protein 2 (LMP2) of Epstein Barr virus (Hart et al., 2008). This TCR
was also codon optimised and had an additional disulphide bond and was
cloned into an identical vector backbone to the WT1-TCR. As in the WT1-TCR
transplant, LMP2-specific T cells identified by staining with the human anti-
Vβ13 antibody were readily detectable in the periphery of recipient mice that 
had received LMP2-TCR td HSCs and this is shown in the bottom row of figure
4.1A. However, in this case the levels of TCR/CD3 expression were similar to
that of donor-derived T cells expressing endogenous TCRs. The bar chart in
figure 4.1B summarises the CD3 MFI of WT1 and LMP2-specific T cells
compared to that of the corresponding endogenous donor derived T cells in
each experiment (Vβ2 –ve and Vβ13 –ve respectively). These results
confirmed a statistically significant downregulation of TCR/CD3 expression in
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WT1-specific T cells which appeared to be a feature of this self-reactive WT1-
TCR but not of the non-self reactive LMP2-TCR that was used as a control.
Figure 4.1 WT1 specific T cells emerge and persist in the periphery. (A) FACS
analysis of peripheral T cells in spleen, LNs and BM of A2Kb Tg mice killed 11 weeks
after transplantation with TCR transduced Lin-ve A2Kb BM stem cells. Mice received
untransduced stem cells (top row), WT1 TCR transduced stem cells (middle row,
n=8, or LMP2-TCR transduced stem cells (bottom row, n=5). Viable lymphocytes
were stained with anti-CD3, and anti-human V 2.1 (WT1 TCR) and anti-human V 13
(LMP2 TCR) antibodies before FACS analysis. Percentages of V 2.1+ and V 13+
cells in total lymphocytes. (B) Cell surface CD3/TCR expression levels of the WT1
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Figure 4.1 (continued)
TCR (self-reactive) and the LMP2 TCR (non-self-reactive) were compared with
endogenous polyclonal T cells derived from transplanted stem cells (V 2.1 -ve and
V 13-ve respectively). Data are mean SD of CD3 mean fluorescent intensity (MFI;
n=8 mice for WT1 TCR and n=5 mice for LMP2 TCR).* p-value <0.05, **p-
value<0.01, ns non significant, all based on 1-way ANOVA).
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4.2.2 WT1-specific T cells escape negative selection, but CD3
downregulation takes place in the thymus
The presence of WT1-specific T cells in the periphery of A2Kb Tg mice that
had received WT1-TCR td HSCs suggested that developing WT1-specific T
cells can escape thymic deletion. The possibility that mature T cells along with
HSCs were transduced with the introduced TCR genes is remote for two
reasons. The transferred BM cells were enriched in HSCs by immunomagnetic
lineage negative selection prior to their transduction removing most if not all T
cells along with any other cells committed to other haematopoietic lineages.
More importantly though, lentiviral transduction of murine T cells is known to
be very difficult to achieve (Baumann et al., 2004, Tsurutani et al., 2007,
Kerkar et al., 2011). Nevertheless, to confirm that WT1-specific T cells were
generated through thymic development and to study this further, 11 weeks
post-transplant thymic tissue was harvested from the A2Kb Tg mice that had
received WT1-TCR td A2Kb HSC, stained with anti- CD3, CD4, CD8 and
human Vβ2 antibodies and analysed by FACS.  
CD4/CD8 thymocyte phenotyping as shown in representative FACS plots in
figure 4.2A, was used to study WT1-TCR expression at the different stages of
thymic T cell development. The WT1-TCR was expressed early on and
throughout T cell development, first in immature double-negative (DN)
thymocytes, then in the more mature double-positive (DP) population and
consequently in the CD8 single positive (SP) T cells. As expected, only very
few T cells expressing this HLA class I-restricted TCR went on to mature into
CD4 SP T cells. This was consistent with the absence of such cells in the
periphery of transplanted A2Kb Tg mice as discussed in chapter 4.
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Figure 4.2 WT1 TCR are selected in the thymus. A. FACS analysis of thymocytes
isolated from A2Kb mice transplanted with Lin-ve A2Kb stem cells transduced with the
lentiviral WT1-TCR vector. Thymocytes were stained with antimurine CD3, CD4 and
CD8 antibodies together with anti-human V 2.1 to detect the WT1 TCR chain. SP
indicates single positive; DP, double positive; and DN, double negative.
Representative plots from a total of 8 mice are shown. B. Percentage of CD3 positive
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Figure 4.2 (continued)
thymocytes expressing the WT1 TCR at each stage of thymic development. Column
bars represent mean percentage SEM. n=8.. ns indicates non-significant.
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A summary of the frequencies of WT1-TCR-expressing thymocytes in the 8
recipients, at each stage of T cell development is shown in figure 4.2B. Similar
frequencies of WT1-TCR expressing T cells in the DP and CD8 SP cells were
noted, indicating that as CD4+CD8+ WT1-specific T cells progressed through
thymic development to become CD8+ cells, they were not deleted by central
tolerance mechanisms. Endogenous TCRαβ complexes are not normally
expressed before thymocytes reach the DP stage of T cell development. The
presence of WT1-TCR expressing thymocytes in the DN stage and their
relative high frequency compared to later stages of T cell development is most
likely explained by the non-physiological early expression of the lentiviral TCR
construct, a similar phenomenon to what is observed in TCR transgenic mice.
In order to delineate whether the noted TCR/CD3 downregulation in WT1-
specific T cells (figure 4.1) takes place in the thymus or following the cells’ exit
in the periphery, the levels of TCR/CD3 expression in the spleen were
compared to those in the thymus at the different stages in T cell development.
This analysis, summarised in the bar chart in figure 4.3, showed that WT1-
TCR/CD3 expression levels in the periphery were similar to those in the
thymus and always lower than that of endogenous TCRs on other donor
derived T cells. TCR/CD3 downregulation was evident as early as the DN
stage, and was consequently thought to be a thymic event. Therefore, even
though WT1-specific T cells are not deleted in the thymus, the observed
TCR/CD3 downregulation taking place during thymic development may be the
result of central tolerance. On the other hand, it is possible that WT1-specific T
cells only manage to evade negative selection by downregulating their TCR
early in their development. The prediction then would be that following their
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thymic education, this self-specific T cell population will be poorly functional in
the periphery. The phenotype and function of WT1-specific T cells in the
periphery was studied in detail and these results are presented below.
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Figure 4.3 CD3/ WT1 TCR downregulation in WT1 specific T cells takes place in
the thymus. Mean CD3/TCR expression levels of WT1 (V 2 positive) and endogenous
polyclonal T cells SEM, at different stages of T cell development and in the periphery of
transplant recipients (WT1 TCR td HSCs A2Kb A2Kb, n=8). Single cell suspensions of
thymocytes and splenocytes were stained with anti-CD45.1, anti-CD3, anti-CD4, anti-
CD8 and human anti-V 2.1 antibodies to identify WT1 specific T cells and the donor-
derived endogenous polyclonal T cell population at progressive stages of thymic T cell
development and in the periphery. *** p=value < 0.001.
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4.3 WT1-specific T cells differentiate into memory phenotype cells in the
absence of vaccination
4.3.1 WT1-TCRhi and TCRlo subsets identified in the periphery
TCR and CD8 downregulation in the context of self-antigen are thought to be
mechanisms of peripheral tolerance (Morahan et al., 1991, Rocha and von
Boehmer, 1991, Schönrich et al., 1991). With CD3 being a surrogate marker
for TCR expression levels, TCR downregulation was observed in WT1-specific
T cells. Therefore, the levels of the CD8 co-receptor in these cells were also
examined. A2Kb Tg mice receiving either WT1 or LMP2-TCR td HSC
transplants were sacrificed at 11 weeks post-transplant and single cell
splenocyte suspensions were stained with anti-CD45.1, anti-CD3, anti-CD8
and anti- human Vβ2.1 antibodies respectively, prior to FACS analysis. Figure
4.4A shows that the mean CD8 expression levels on Vβ2 positive cells
detected in the spleen of WT1-TCR td HSC transplant recipients, were
significantly lower than that of polyclonal donor derived CD8 T cells expressing
endogenous murine TCRs.
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Figure 4.4 TCR down-modulation in WT1 specific T cells is associated with a
relative CD8 upregulation. 5x105 WT1 or LMP2 TCR td A2Kb Lin-ve BM cells were
transferred into 8 and 5 lethally irradiated A2Kb tg mice recipients respectively. 11
weeks post-transplant, transplant recipients were sacrificed and spleens, LNs and
BM were harvested. Single cell suspensions from individual spleens were stained
with anti-CD45.1, anti-CD3, anti-CD8 and anti-human V 2 or anti-human V 13
antibodies accordingly prior to FACS analysis. A. Column graph of the mean CD8
MFI in V 2 positive and V 2 negative donor-derived CD8 T cells and V 13 positive
and V 13 negative donor-derived CD8 T cells in WT1 and LMP2 TCR HSC
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Figure 4.4 (continued)
transplant recipients respectively. Error bars= SD. ** p-value< 0.01. B.
Representative FACS plots of peripheral T cells in spleen, LNs and BM to examine
TCR and CD8 modulation in WT1 and LMP2 specific T cells compared to
endogenous polyclonal donor derived T cells. After gating on viable donor-derived
CD3+ cells, percentages of TCRhi and TCRlo populations are indicated.
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4.3.2 WT1-TCR downregulation is associated with a relative upregulation
of the CD8 coreceptor
As LMP2-specific T cells also exhibited lower expression levels of the CD8 co-
receptor than other donor derived T cells, it was thought that this phenomenon
was related to the experimental system rather than to the WT1 self-antigen
specificity. Surprisingly though, the representative FACS plots in figure 4.4B
reveal that further TCR down-modulation in WT1-specific T cells was coupled
with a relative upregulation of the CD8 molecule, giving rise to two WT1-
specific T cell subsets. A TCRlo CD8hi (TCRlo) population and a TCRhi CD8lo
(TCRhi) population of WT1-specific T cells were present in spleen, LNs and
BM. On the other hand in LMP2-specific T cells a single TCRhi population was
observed, suggesting that TCR downregulation and CD8 upregulation were
likely to be related to the WT1 self-antigen specificity. These results are
summarised in the column graph of figure 4.5A, where the mean CD8 MFI
among the different Vβ2 and Vβ13 T cell populations is documented. The
presence of a TCRlo population among WT1-specific T cells could potentially
explain the observed CD3 downregulation among the total Vβ2 positive T cell
population. However, comparing the mean CD3 MFI among TCRlo and hi
WT1-specific T cells with that of endogenous CD8 T cells, as well as with
LMP2-specific T cells confirms that instead both WT1 specific populations
exhibit a marked CD3 downregulation that becomes more pronounced in WT1-
TCRlo cells (figure 4.5B).
Figure 4.5 TCR down-modulation is observed in TCRhi and TCRlo WT1
specific T cell subsets. 5x105 WT1 or LMP2 TCR td A2Kb Lin-ve BM cells were
transferred into 8 and 5 lethally irradiated A2Kb tg mice recipients respectively. 11
weeks post-transplant, transplant recipients were sacrificed and spleens, LNs and
BM were harvested. Single cell suspensions from individual spleens were stained
with anti-CD45.1, anti-CD3, anti-CD8 and anti-human V 2 or anti-human V 13
antibodies accordingly prior to FACS analysis. A. Column graph of mean CD8 MFI
in WT1 TCRlo, WT1 TCR hi and V 2 negative donor CD8 T cells in the spleens of
WT1 TCR HSC transplant recipients (n=8) and mean CD8 MFI in V 13 positive
(TCRhi) and V 13 negative donor derived CD8 T cells in the spleens of LMP2 TCR
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Figure 4.5 (continued)
HSC transplant recipients (n=5). B. Column graph of mean CD3 MFI in WT1 TCRlo,
WT1 TCRhi and V 2 negative donor derived CD8 T cells in the spleens of WT1
TCR td HSC transplant recipients, and mean CD3 MFI in V 13 positive (TCR hi)
and V 13 negative CD8 donor derived T cells in the spleens of LMP2 TCR td HSC
transplant recipients. All mean MFIs are shown as mean SD. *** = p-value <
0.001, ns indicates non-significant.
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4.3.3 WT1-specific T cells exhibit a memory phenotype in the absence of
vaccination
Changes in TCR and CD8 levels have been associated with responses to
antigen encounter, and subsequent activation or tolerance induction
(Schönrich et al., 1991). For this reason the activation phenotype of WT1 and
LMP2-specific T cells was examined by FACS analysis. As shown in figure 4.6,
a large proportion of the WT1-specific T cells expressed high levels of CD44
and CD62L (range 28-69% of Vβ2 positive T cells, median 55.2% in LNs,
A2Kb to A2Kb transplant), a phenotype normally associated with central
memory T cells, while the activation phenotype of LMP2-specific T cells was
similar to that of donor derived T cells expressing endogenous TCRs (control
endogenous T cells) and consistent with a naive-like phenotype (CD44 low
CD62L positive). Therefore, specificity against the WT1 self-antigen, but not
against a foreign antigen was shown to drive the generation of memory
phenotype T cells in the absence of vaccination.
4.3.4 WT1 specific T cell differentiation to central memory T cells is not
dependent on WT1 Ag presentation by professional APCs
The survival of naive T cells is known to require tonic TCR stimulation by MHC
molecules expressed on haematopoietic cells, whereas memory T cells are
thought to be able to survive in the absence of this tonic triggering. However,
the role of haematopoietic cells in the generation and maintenance of memory
T cells in the absence of vaccination is not known and experiments were
designed to study this. Lin-ve BM cells were isolated from C57Bl/6 donor mice
and transduced with the genes for the WT1-TCR. These cells were then
160
transferred into myeloablated A2Kb recipients and allowed to reconstitute the
haematopoietic system of the recipient animals with C57Bl6 derived cells, so
that cross-presentation by professional APCs was not possible in this setting
as donor BM derived cells did not express the hybrid A2Kb molecule. The
cognate Ag of the WT1-TCR could only be presented directly by the few
peripheral tissues expressing it at low levels. However, as C57Bl/6 BM
progenitors, which are one of the few cell types physiologically expressing the
WT1 Ag, lack the HLA A2 molecule, they were unable to present the pWT126
on the appropriate class I molecule for TCR recognition. The mice were
allowed to reconstitute for 15-17 weeks and were then sacrificed and spleens,
LNs and BM were harvested for phenotypic and functional analysis of WT1-
specific T cells. The FACS plots in figure 4.6 demonstrate that CD44hi
CD62Lhi WT1-specific T cells were still generated in the absence of A2Kb
professional APCs (B6 to A2Kb transplant), implying that the development of
Tcm WT1-specific T cells (CD44hi CD62Lhi) was not dependent on antigen
presentation on haematopoietic cells.
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Figure 4.6 Peripheral WT1 specific T cells differentiate into memory
phenotype, in the absence of vaccination. A2Kb lethally irradiated recipients
received 5x105 WT1 or LMP2 TCR td HSCs, as specified. 1st, 3rd and 4th columns
A2Kb donor Lin-ve BM cells . 2nd column C57Bl/6 donor Lin-ve BM cells. A2Kb
and C57Bl/6 transplant recipients were sacrificed 11 and 15-17weeks post
transplant respectively. Spleens, LNs and BM were harvested and single cell
suspensions were prepared and stained with hV 2/ hV 13, and murine CD8, CD44
and CD62L antibodies. Representative FACS plots of CD44 and CD62L expression
on gated hV 2+ve and hV 13+ve T cells as well as gated endogenous donor
derived peripheral T cells are shown. Percentages stated refer to the percentage of
each indicated subset in hV 2+ve, hV 13+ve and endogenous donor derived T
cells.
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The results of the detailed analysis of the naive (CD44lo CD62Lhi), Tcm
(CD44hi CD62Lhi) and Tem (CD44hi CD62Llo) T cell frequencies in the spleen
of mice expressing the WT1-TCR or LMP2-TCR are shown in figure 4.7. While
the majority of LMP2-specific T cells as expected were naive, significantly less
WT1-specific T cells exhibited this phenotype (p<0.001). The opposite was
true for Tcm T cells, as these were significantly more frequent in WT1-specific
T cells than in LMP2-specific T cells (p<0.001). Interestingly, higher
frequencies of Tem T cells were only noted in WT1-specific T cells generated
in mice reconstituted with WT1-TCR td A2Kb stem cells, (p<0.01) but not in
those reconstituted with WT1-TCR td B6 stem cells (ns, non-significant),
alluding to the idea that antigen presentation by haematopoietic cells promoted
the differentiation of WT1-specific T cells into Tem phenotype.
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Figure 4.7 Antigen presentation by professional APCs promotes the
differentiation of WT1 specific T cells into the EM phenotype. Summary data of
naive (CD44lo, CD62Lhi), CM (CD44hi, CD62Lhi), and EM (CD44hi, CD62Llo) WT1-
and LMP2-specific T cell frequencies in transplanted mice expressing the WT1-TCR
or the LMP2 TCR. ***p <0.001, **p<0.01, ns non-significant. A2Kb A2Kb or B6
A2Kb as indicated in the figure. Data correspond to LN FACS plots.
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Percentage donor chimerism in recipients receiving WT1-TCR td C57Bl/6 HSC
transplants, at the time of this phenotypic analysis ranged between 92%-97%.
Representative FACS plots, of single cell suspensions from spleen, LNs and
BM of recipient animals stained with anti-CD3 and anti-CD45.1 antibodies,
demonstrate that CD3 negative lymphocytes, including professional APCS, are
in their great majority donor derived (figure 4.8A). The pooled data from all
recipient animals (n=8) are summarised in the column graph in figure 4.8B.
Nevertheless, the fact that complete donor reconstitution was never reached in
the B6 to A2Kb transplants makes it possible that the very small number of
residual A2Kb+ APCs contributed to, or was sufficient for, the development of
central memory and effector memory phenotype cells in the mice transplanted
with B6 stem cells. This would imply that such minimal cross-presentation of
the pWT126 to WT1-specific T cells is enough to cause a major shift in the
activation phenotype of the WT1 specific T cell population.
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Figure 4.8 Donor Chimerism in C57Bl6, WT1 TCR HSC transplant recipients.
Lethally irradiated A2KbxCD45.1 mice received 5x105 C57Bl/6 WT1 TCR td Lin-ve
BM cells (n=8). 15-17 weeks post-transplant recipient mice were sacrificed and
spleen, LNs and BM were harvested and single cell suspensions were prepared.
Cells from individual organs were stained with murine anti-CD45.1 and anti-CD3
antibodies. A. Representative FACS plots of splenocytes, LNs and BM cells stained
with above antibodies. Cells were gated on viable lymphocytes. Donor derived cells
were CD45.1 negative. B. Donor chimerism in CD3 negative lymphocytes. Bars
show mean donor chimerism SD.
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4.3.5 WT1-TCRhi and TCRlo T cells exhibit different activation
phenotypes
Since the TCRhi WT1-specific T cell subset exhibited a similar TCR/CD8
phenotype to that of LMP2-specific T cells, the idea that this subset would also
have a similar activation phenotype to LMP2-specific T cells was also
attractive. In this scenario, the TCRlo WT1-specific T cell subset would
exclusively contribute to the Tcm WT1-specific population. To examine this,
the activation phenotype of the TCRhi and TCRlo WT1-specific T cells was
analysed and representative FACS plots of splenocytes are shown in figure
4.9A. Both in the presence and absence of professional antigen presentation
(A2Kb to A2Kb and B6 to A2Kb transplants respectively) TCRlo cells were
predominantly of Tcm phenotype (mean 67% and 84% respectively). In the
case of TCRhi WT1-specific T cells in the presence of professional Ag
presentation, a shift towards the memory phenotype was still observed with
most cells being either Tcm (mean 34%) or Tem (mean 37%). In contrast, in
the B6 to A2Kb setting the activation phenotype of TCRhi WT1-specific T cells
follow a population distribution more similar to that of endogenous T cells, with
most cells being naive (mean 53%).
These results suggested that while professional Ag presentation was not
required to drive a proportion of WT1-specific T cells towards a Tcm
phenotype, it did have an effect on further activating all WT1-specific T cells.
Noting naive, Tem and Tcm cells within the TCRhi WT1-specific T cells in the
A2Kb to A2Kb setting, while most TCRlo cells are Tcm, supports the
hypothesis that chronic low level WT1 Ag encounter, results in WT1-TCR
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triggering. T cell activation allows the WT1-specific T cells to progress from
naive to memory as they downregulate their TCR and convert from TCRhi to
TCRlo. Therefore, the TCRhi subset contains all 3 activation phenotypes
(naive, Tem and Tcm) whereas the TCRlo subset being the most differentiated
is mainly enriched in CM T cells.
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Figure 4.9 TCRlo WT1 specific T cells exhibit a CM activation phenotype,
TCRhi WT1 specific T cells consist of naive, effector and CM T cells. A. CD44,
CD62L phenotypic FACS analysis of gated WT1 TCRhi and WT1 TCRlo peripheral
T cell populations, following antibody staining of splenocytes from transplant
recipients receiving either A2Kb (top panel) or C57Bl/6 (bottom panel) WT1 TCR td
HSCs. Single cell splenocyte suspension from individual recipients were stained with
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Figure 4.9 (continued)
murine anti-CD45.1, anti-CD3, anti-CD8, anti CD-44, anti-CD62L and human anti-
V 2. Representative FACS plots shown. B. Column graph summarising %of CM, EM
and naive V 2 positive T cells in the TCRlo and TCRhi WT1 specific T cell subsets
in transplant recipients receiving either C57Bl/6 or A2Kb WT1 TCR td HSC
transplants. Data shown are mean SEM. A2Kb A2Kb transplant n=8, B6 A2Kb
transplant n=8. *** p-values < 0.001, ** p-values <0.05, ns indicates non-significant.
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4.3.6 WT1-specific T cells preferentially accumulate in the BM
The BM resident progenitor cells are one of the few cell types expressing low
levels of the WT1 Ag in healthy subjects. In view of this, the frequency of WT1-
specific T cells within the donor T cell compartment in the BM was compared
to their frequency in spleen and LNs. The graph in figure 4.10A summarises
the percentage frequency of WT1 and LMP2-specific T cells in these three
organs and demonstrates the preferential accumulation of WT1-specific T cells
in the BM compared to spleen and BM. As expected no enrichment of LMP2-
specific T cells was observed in the BM.
The accumulation of WT1-specific T cells in the BM could also potentially be
explained by the fact that the majority of these cells exhibited a memory
phenotype. Being memory T cells it was possible that they were selectively
recruited and proliferated at this site which is thought to be the niche of Tcm T
cells. This scenario was further investigated in the A2Kb Tg mice reconstituted
with WT1-TCR td C57Bl/6 HSCs, where direct and cross- presentation of the
WT1 Ag could not contribute to the preferential accumulation of WT1-specific T
cells in the BM. Indeed, despite the lack of Ag presentation, the BM was
enriched in WT1-specific T cells in the B6 to A2Kb transplant recipients,
suggesting that the BM environment plays a part in this phenomenon. The
column graph in figure 4.10B shows the mean fold-enrichment of WT1-specific
T cells in the BM compared to spleen and LNs in transplant recipients
receiving A2Kb or C57Bl/6 HSCs, as indicated. In the presence of effective Ag
presentation (A2Kb to A2Kb transplant) this enrichment is higher, but it only
becomes statistically significant when the frequency of WT1-specific T cells in
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the BM is compared to that in the LNs. Therefore, it was thought that the BM
environment and WT1 Ag presentation were likely to have a cumulative effect
on the preferential accumulation of WT1-specific T cells in the BM donor T cell
compartment.
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Figure 4.10 WT1 specific T cells preferrentially accumulate in the BM. A Column
graph showing the mean frequency of WT1/LMP2 specific T cells in donor derived T
cells in the spleens, LNs and BM of A2Kb and B6 HSC transplant recipients, as
indicated. B. Column graph indicating the ratio %V 2 positive T cells in BM to %V 2
positive T cells in spleen and BM to LNs, in A2Kb to A2Kb and B6 to A2Kb WT1 TCR td
HSC transplant recipients, as indicated. C. Column graph showing the % of TCRlo WT1
specific T cells among total WT1 specific T cells (TCRlo+TCRhi), in spleen, LNs and BM
in A2Kb to A2Kb and B6 to A2Kb WT1 TCR td HSC transplant recipients, as indicated.
For all A, B and C values shown are mean SEM. . ***p-value < .001, **p-value < .01,
*p-value<0.05, ns indicates not significant. WT1 TCR A2Kb to A2Kb HSC
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Figure 4.10 (continued)
transplant 5x105 Lin-ve BM cells, n=8. B6 to A2Kb HSC transplant 5x105 Linv-ve BM
cells, n=8. LMP2 TCR A2Kb to A2Kb HSC transplant, 5x105, n=5. Spleens, LNs and
BM were harvested from tranplant recipients 11 or 15-17 weeks post-transplant (A2Kb
to A2Kb and B6 to A2Kb respectively) and single cell suspensions from individual
organs were stained with murine anti-CD45.1, anti-CD3, anti-CD8, anti-CD44, anti-
CD62L and human anti-V 2.1 and anti-V 13 identifying WT1 and LMP2 specific TCRs
respectively. The stained samples were then analysed by FACS analysis.
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4.3.7 WT1 Ag expression in BM progenitors and BM environment both
contribute to the preferential accumulation of WT1-specific T cells in the
BM
WT1-specific T cells exhibiting a Tcm phenotype, were mainly found in the
TCRlo subset (figure 4.9). It was therefore expected that if the observed BM
enrichment was to be mainly driven by the memory phenotype of WT1-specific
T cells, then higher frequencies of TCRlo WT1-specific T cells would be noted
in the BM rather than in the other organs. While this was indeed the case in
the B6 to A2Kb setting, where WT1 Ag presentation cannot contribute to the
phenomenon, the difference in the A2Kb to A2Kb transplant was minimal
(figure 4.10c).
Even though TCRlo WT1-specific T cells which had a Tcm phenotype in their
majority, were not significantly enriched in the BM compared to the periphery,
what remained possible was that the TCRhi WT1-specific T cell subset in the
BM shifted towards a Tcm phenotype. The FACS plots in figure 4.11A, show
the activation phenotype of WT1-specific TCRhi T cells (left 3 plots) in spleen,
LNs and BM of a representative A2Kb to A2Kb WT1-TCR td HSC transplant
recipient. While a marked shift towards a memory profile is observed in WT1
specific TCRhi cells present in the BM, to a certain extent this is also the case
for the donor derived endogenous polyclonal CD8 T cell population (far right
plot). This was examined in more detail and the relative frequencies of Tcm
WT1-specific T cells among total Vβ2 positive, TCRlo and TCRhi WT1-specific
T cells was calculated based on the same FACS analysis as for figure 4.11A.
These data, shown in the column graph of figure 4.11B illustrate that the
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percentage of Tcm-phenotype WT1-TCRhi cells is significantly increased in the
BM compared to spleen and LNs. Nevertheless, the increase in the proportion
of Tcm T cells in the BM among WT1 specific TCRhi T cells is similar if not
less than that observed among donor derived polyclonal CD8 T cells
expressing an endogenous TCR repertoire. Therefore, as TCRhi WT1-specific
T cells are enriched in Tcm phenotype T cells in keeping with a baseline
increase of memory T cells present in the BM compared to the periphery, it can
be concluded that this is unrelated to the WT1 specificity. On the other hand, it
is possible to consider that among the endogenous T cell repertoire a certain
percentage of T cell specificities will have encountered Ag (including self-Ag),
been activated and eventually differentiated to Tcm T cells which then
preferentially home to the BM. In a similar fashion, TCRhi, WT1-specific T cells
also encounter their cognate Ag, resulting in a similar increase in the
percentage of Tcm T cells among TCRhi and endogenous CD8 T cells being
noticed in the BM.
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Figure 4.11 WT1 specific, TCRhi T cells in the BM exhibit increased
frequencies of CM phenotype cells A. FACS analysis of the CD44, CD62L
activation phenotype of gated WT1 specific TCR hi T cells, found in the spleen, LNs
and BM of A2Kb to A2Kb WT1 TCR td HSC transplant recipients (left 3 plots) and
donor derived CD8 T cells expressing endogenous TCRs (far right plot).
Representative FACS plots shown.B. Column graph summarising the percentages
of CM T cells (CD44, CD62L positive) in total V 2 specific T cells, as well as TCRlo
and TCRhi WT1 specific T cells, in spleens, LNs and BM of A2Kb to A2Kb and B6
to A2Kb HSC transplant recipients, as indicated. The percentage of CM T cells
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Figure 4.11 (continued)
population in A2Kb to A2Kb transplant recipients is also shown (far right group).
Values shown are mean SEM. ***p-value < .001, **p-value < .01, *p-value<0.05,
ns indicates not significant. FACS analysis was performed following antibody
staining of single cell suspensions from individual spleens, LNs and BM of
transplant recipients sacrificed at 11 and 15-17 weeks post transplant (A2Kb to
A2Kb and B6 to A2Kb respectively), with murine anti-CD45.1, anti CD3, anti-CD8,
anti-CD44, anti-CD62L and human anti-V 2.1 antibodies.
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4.4 Discussion
In this chapter we present data showing that WT1-specific T cells escape
negative selection, in mice expressing the WT1 Ag in physiological levels and
tissue distribution. Instead of being deleted, WT1-specific T cells appeared to
downregulate CD3 in the thymus. This event persisted in the periphery and
was considered a surrogate marker for TCR downregulation. Interestingly,
despite the expectation that the CD3/TCR downregulation would compromise
the function of WT1-specific T cells in the periphery, our results suggest this
not to be the case. The phenotypic analysis of WT1-specific T cells provided
surprising evidence that these cells’ specificity for the WT1 self-Ag mediated
their activation and differentiation into Tem and Tcm-phenotype T cells. WT1-
specific T cells were found to preferentially accumulate in the BM, and our data
suggested that both Ag presentation at this site and the BM environment which
is known to serve as a niche for Tcm T cells contributed to this enrichment.
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Chapter 5 - Results 3 - Functional analysis of WT1-specific T
cells
5.1 Introduction
The phenotypic analysis of WT1-specific T cells, presented in Chapter 4,
showed that specificity for this TAA not only did not prohibit their development
from thymocytes to mature T cells emerging in their periphery, but also drove
their differentiation into Tem and Tcm cells. On the contrary, LMP2-specific T
cells exhibited a phenotype similar to that of the endogenous polyclonal T cell
repertoire, consisting mainly of naive T cells. Memory T cells, unlike naive T
cells, are expected to exhibit rapid effector function upon antigenic stimulation.
As both functional activity and phenotype are necessary to define a cellular
subset, such analysis of the in vivo generated WT1-specific T cells in our
experimental model was essential. This was also important to confirm that
WT1-specific T cells were not tolerised, as even though this would disagree
with their observed phenotype it was what was originally predicted due to their
self-specificity.
5.2 Results
5.2.1 WT1-specific T cells display antigen specific in vivo cytotoxicity
activity in the absence of vaccination
The killing activity of WT1-specific T cells was assessed by in vivo cytotoxicity
assays. These were described in detail in Materials and Methods, Chapter 2.
Briefly, A2Kb splenocytes were loaded with pWT126 or an irrelevant peptide,
labelled with different concentrations of CFSE (CFSEhi and CFSElo
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respectively) and mixed at an 1:1 ratio prior to being injected into mice that had
been reconstituted with WT1-TCR td HSCs. 18hrs later, splenocytes of
injected animals were harvested and analysed by FACS to identify CFSE-
labelled cells. Figure 5.1A shows representative FACS histograms of CFSE
labelled target cells persisting in the spleens of control and WT1-TCR td HSC
recipients. Strong antigen-specific killing activity was observed both in mice
that were transplanted with A2Kb or B6 WT1-TCR transduced HSCs and this
is consistent with the presence of memory phenotype WT1-specific T cells
identified in both experimental systems. The in vivo killing antigen specific
activity of LMP2-specific T cells was also assessed using the LMP2 cognate
antigen epitope (pCLG) in the same assay. Unlike WT1-specific T cells, LMP2-
specific T cells did not exhibit any antigen-specific cytotoxicity. As LMP2-
specific T cells had a naive phenotype, the fact that they did not exhibit
antigen-specific cytotoxicity was justified and expected in the absence of any
previous priming antigenic encounter. Primary human T cells transduced with
the LMP2-TCR have previously been demonstrated to effectively kill and
proliferate in an antigen specific manner (Hart et al., 2008) when activated
rather than naive, and this further supports the notion that the in vivo antigen-
specific killing activity of WT1-specific T cells relates to their memory
phenotype. Figure 5.1B summarises the in vivo cytotoxicity assay data from
all subjects in the WT1 and LMP2-TCR transplants.
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Figure 5.1 WT1 specific T cells exhibit antigen specific in vivo cytotoxicity in
the absence of vaccination. In vivo cytotoxicity of CFSE labelled, peptide-loaded
target cells. A2Kb Tg mice, 11 weeks after transfer of BM stem cells transduced with
the WT1-TCR (top panel, n = 7 A2Kb A2Kb, n = 5 B6 A2Kb) or LMP2-TCR
(bottom panel, n = 4 A2Kb A2Kb) were intravenously injected with a 1:1 mix of
relevant: irrelevant peptide-loaded A2Kb Tg splenocytes, differentially labeled with
CFSE (WT1-TCR is specific for WT126 peptide, and LMP2-TCR is specific for CLG
peptide). Control untreated A2Kb Tg mice were injected with CFSE-labeled peptide-
loaded target cells. Eighteen hours later, splenocytes of injected animals were
harvested and analyzed by FACS to identify CFSE-labeled cells. A. Representative
plots showning gated CFSE labelled target cells, 18hrs post- injection.
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Figure 5.1 (continued)
Top row shows target cells in control and WT1 TCR td HSC transplant recipients.
Bottom row shows target cells in control and LMP2 TCR td HSC transplant
recipients. WT126p loaded targets are cleared in mice containing WT1 specific T
cells. No antigen specific killing is observed in LMP2 TCR td HSC transplant
recipients. B Summary data of in vivo cytotoxicity assays are shown on the right.
Percentage antigen-specific cytototoxicity was calculated as described in vivo
cytotoxicity assays, materials and ***p < 0.001.
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5.2.2 WT1-specific T cells exhibit antigen specific ex-vivo proliferation in
the absence of prior in vivo vaccination
The function of WT1-specific T cells was studied further with ex-vivo
proliferation assays. A detailed description of these assays is given in Chapter
2, Materials and Methods. Briefly, splenocytes from TCR td HSC transplant
recipients (A2Kb to A2Kb) were harvested 11 weeks post-transplant, labelled
with CFSE and placed in culture. Relevant or irrelevant peptide was added to
the wells and the cells were kept in culture, in the dark for 5 days. On day 5,
the cells were stained with human anti-Vβ2/Vβ13 as appropriate and FACS
analysed for CFSE dilution in Vβ positive and Vβ negative lymphocyte
populations indicating proliferation.
The left panel in figure 5.2A shows a representative FACS histogram
comparing the CFSE dilution in gated Vβ2 positive and Vβ2 negative
lymphocytes in splenocytes of transplant recipients receiving WT1-TCR td
HSCs. In all subjects, consistently more than 80% of the WT1-specific T cells
present in the ex-vivo culture on day 5 had proliferated (figure 5.2B). This was
an antigen-specific response as no proliferation was noted among the Vβ2
negative lymphocytes. In contrast to WT1-specific T cells, LMP2-specific T
cells did not proliferate upon stimulation with their cognate antigen and this is
illustrated in the right panel histogram of figure 5.2A. The dot plot in figure 5.2B
summarises the results of these two experiments. Figure 5.2C shows
representative CFSE dilution FACS plots of gated lymphocytes from the CFSE
labelled splenocyte cultures of A2Kb WT1-TCR transplant recipients stimulated
either with the pWT126 or an irrelevant peptide, confirming that no proliferation
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was noticed in the presence of the latter. Interestingly, it appears that WT1-
specific T cells expressing either high or low levels of the WT1-TCR, as
identified by the human anti-Vβ2 antibody, proliferate. It is tempting to assume
that these two populations correspond to the TCRlo and TCRhi WT1-specific T
cells noted on FACS analysis directly ex-vivo and which exhibited different
activation phenotypes (memory and naive respectively). While this remains a
possibility, the fact that the two WT1 specific T cell subsets were stimulated ex-
vivo with their cognate antigen together, in the same culture, makes it
impossible to trace any subsequent phenotypic changes in each of the two
WT1 specific T cell populations. What is reasonable to deduce from these data
is that both TCRlo and TCRhi cells are able to proliferate in an antigen specific
manner.
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Figure 5.2 WT1 specific T cells exhibit antigen-specific ex-vivo proliferation. Ex
vivo proliferation of splenocytes from mice previously transplanted with WT1-TCR
and LMP2-TCR-transduced A2Kb or B6 BM stem cells. Splenocytes were stimulated
for 5 days with 100 M relevant or irrelevant peptide. CFSE-labeled splenocytes were
analyzed by FACS for CFSE dilution after anti human V 2.1 or V 13 antibody
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Figure 5.2 (continued)
staining. A. Representative FACS proliferation histograms of gated V 2 positive and
negative lymphocytes (left) and V 13 positive and negative lymphocytes (right). Both
A2Kb BM stem cell recipients. B. Summary data of ex-vivo proliferation assays using
splenocytes harvested from mice transplanted with WT1-TCR (n=8 A2Kb A2Kb, n
= 3 B6 A2Kb) and LMP2-TCR (n = 5 A2Kb A2Kb) transduced BM stem cells
**p-value < .01, ***p-value < .001. C. Representative FACS plots of gated, CFSE
labelled lymphocytes from splenocytes of A2Kb WT1 TCR td HSC transplant
recipients, on day 5 of ex-vivo proliferation assay. Left panel, cells stimulated with
pWT126. Right panel, cells stimulated with irrelevant peptide.
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5.2.5 WT1-specific T cells produce IL-2 and IFN-γ in an antigen specific 
manner
Antigen specific cytokine secretion was examined in WT1 and LMP2-specific T
cells generated in mice that received WT1 or LMP2-TCR td A2Kb HSCs
respectively. As described in chapter 2, materials and methods, IL-2 and IFN-γ
production following the ex-vivo relevant and irrelevant peptide stimulation of
splenocytes from WT1 and LMP2-TCR td HSC recipients, was measured by
ELISA. The IL-2 and IFNγ ELISAs were performed on cell culture supernatant
from each condition set up for the ex-vivo proliferation assays (section 5.2.2).
As for the ex-vivo proliferation assay, cytokine secretion was measured on day
5 and the results were in agreement with the results of the killing and
proliferation assays, figure 5.3A and 5.3B demonstrate that antigen specific IL2
and IFNγ production was only noted in the case of WT1-specific T cells being
stimulated with their cognate peptide. LMP2-specific T cells did not however
produce IL-2 or IFN-γ after stimulation with their cognate antigen, consistent
with non-primed, naive T cells.
Figure 5.3 WT1 specific T cells show antigen-specific cytokine secretion.
Splenocytes harvested from A2Kb mice transplanted with WT1-TCR-transduced
(n=8) and LMP2-TCR-transduced (n=8) A2Kb BM stem cells were stimulated ex vivo
with 100 M relevant or irrelevant peptide for 5 days. ELISAs were performed to
detect antigen-specific IFN- and IL-2 secretion. ***p-value < .001, **p-value < .01,
ns indicates not significant.
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5.2.6 WT1 specific T cell memory-phenotype subset exhibits functional
activity without prior vaccination
The data described above demonstrate that the phenotypic differences
between WT1 and LMP2-specific T cells described in chapter 5 were
associated with equally dramatic differences in the functional activity of these
two specificities in the absence of prior vaccination. Among WT1-specific T
cells two phenotypically different subsets were observed, a TCRhi and a TCRlo
subgroup. Interestingly, only TCRhi LMP2-specific T cells were noted and their
activation phenotype was similar to the WT1-TCRhi T cells which were
predominantly of naive phenotype. Due to this similarity, it was hypothesised
that the function of WT1-TCRhi cells would be similar to that of LMP2-specific
T cells, leaving the WT1-TCRlo subset responsible of the functional activity
demonstrated by WT1-specific T cells (sections 5.2.1-5.2.5).
Ideally, the two WT1 specific T cell subsets would have been FACS sorted
prior to ex-vivo proliferation and cytokine secretion assays in order to delineate
their functional activity. However, due to the small cell numbers FACS sorting
was technically difficult at the time the experiments were performed and an
alternative approach was employed.
To further investigate the in vivo function of WT1 specific memory phenotype T
cells, adoptive T cell transfer experiments were performed to generate mice
lacking naive phenotype cells. T cells were purified from mice that were
previously transplanted with WT1-TCR HSCs and then adoptively transferred
(AT) into irradiated secondary A2Kb Tg recipients. The secondary recipients
did not contain any WT1-TCR td HSCs, and were therefore unable to generate
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“new”, WT1-specific T cells in the thymus. It was therefore expected that the
naive phenotype WT1-specific T cells would eventually be lost whilst the
memory phenotype WT1 specific T cells would persist. A schematic diagram of
the experimental set up is shown in figure 5.4.
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Figure 5.4 Schematic representation of WT1 specific T cell Adoptive Transfer
Experiment. WT1 specific T cells were generated in vivo in primary HSC transplant
recipients receiving WT1 TCR td , B6 BM stem cells. 11 weeks post-transplant the
primary recipients were sacrificed and spleens were harvested. Single cell
splenocyte suspensions from 3 primary recipients were pooled together and T cells
were isolated by magnetic separation ( pan-T cell isolation kit, Miltenyi Biotech). 4
secondary recipients received 5Gy of irradiation one day prior to the transfer. Each
recipient received 3x106 cells,. Tail bleeds were performed on day 9, and 28 post AT
and on day 69 and 70 in vivo cytotoxicity assays were performed as described in
materials and methods. Splenocytes from the secondary recipients were used in ex-
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Figure 5.4 (continued)
vivo proliferation assays and phenotypic analysis of WT1 specific T cells. LNs and
BM were also harvested for phenotypic analysis.
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Tail bleeds were performed at day 9 and day 28 post-AT to monitor donor T cell
and in particular WT1 specific T cell engraftment over time. The column graph
in figure 5.5 shows that the mean percentage of WT1-specific T cells in the
donor CD8 T cell compartment increased over time. While only 13.2% percent
of the CD8 T cells transferred into secondary recipients were Vβ2 positive (day
0, cells were FACS analysed prior to AT), by day 9 their percentage among
donor CD8 T cells increased to 28.4% and then to 37.9% on day 28 in
peripheral blood samples. These percentages remained similar 10 weeks post-
AT, in both spleens and LNs of secondary recipients. While the lymphopaenia-
driven proliferation of transferred cells unquestionably contributes to the initial
expansion of WT1-specific T cells along with all other donor T cell specificities,
WT1-specific T cells exhibited improved engraftment. This may have been
because WT1-specific T cells proliferated more in response to cognate
antigen, in addition to surviving better due to their memory phenotype and
function. As in the primary recipients some enrichment for WT1-specific T cells
in the donor CD8 T cell compartment was observed in the BM compared to
spleen and LNs (Chapter 4, section 4.2.6).
Figure 5.5 WT1 specific T cells display preferential engraftment in the A2Kb
Adoptive Transfer recipients. Column graph summarising the percentage of WT1
specific T cells in the donor T cell compartment in secondary AT recipients (tail
bleeds n=4, spleen, LNs and BM n=3). First column shows the percentage of WT1
specific T cells in the T cells used for AT, as these were FACS analysed prior to
their transfer in the secondary recipients. Second and third columns show the
percentage of WT1 specific T cells in donor T cells in peripheral blood samples
taken on day 9 and day 28 post-transfer. Last 3 columns show the same
percentages in the spleen, LNs and BM 70 days post-AT. Results shown are mean
SEM.
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The FACS plots in figure 5.6A look at the TCR/CD8 phenotype of the
adoptively transferred cells, at the time of the transfer and 10 weeks later,
confirming that whilst both TCRhi and TCRlo WT1-specific T cells were
transferred into the secondary A2Kb recipients, only the latter were present at
the time the functional assays were performed. The TCR/CD8 phenotype
“switch” of the adoptively transferred WT1-specific T cells, was justified as the
secondary recipients were unable to generate new naive WT1-specific T cells.
It is likely that this was in part driven by the lymphopenic environment in which
the Vβ2 positive and negative T cells were transferred. However, comparing
the activation phenotype of WT1-specific T cells and Vβ2 negative, polyclonal
donor T cells, revealed that the former converted to the memory phenotype
more efficiently. The relevant representative FACS plots, illustrating the
CD62L, CD44 phenotype of Vβ2 positive and negative cells in LNs, spleen and
BM are shown in figure 5.6B. Consequently it was concluded that the WT1-self
specificity contributed to the shift of WT1-TCRhi to TCRlo cells and naive to
central memory phenotype, over and above the effects of homeostatic
proliferation in a lymphopenic environment.
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Figure 5.6 WT1-specific memory phenotype T cells display antigen specific
effector function. T cells were purified from A2Kb, mice transplanted with WT1
TCR td B6 BM stem cells and used for adoptive transfer into irradiated secondary
A2Kb Tg recipient mice. A. At 10 week post-AT, splenocytes, LNs and BM were
harvested and stained with anti-human V 2 and anti-murine CD8 antibodies and
FACS analysed to examine the TCR/CD8 phenotype of the adoptively transferred
WT1 specific T cells. Far left plot shows the TCR/CD8 phenotype of the T cell, after
magnetic separation and prior to AT. Remaining 3 plots show the TCR/CD8
phenotype of gated donor T cells in LNs, spleen and BM..B. 10 weeks post-AT cells
the harvested splenocytes, LNs and BM were stained with anti-human V 2 and
anti-murine CD8, CD44 and CD62L and FACS analysed to study the activation
phenotype of V 2 positive and negative donor T cells at these sites. FACS plots
show the CD44 CD62L phenotype of gated donor V 2 positive and negative T cells
as indicated. Representative FACS plots are shown.
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The phenotypic analysis of the WT1-specific T cells adoptively transferred into
secondary recipients, confirmed that these mice were suitable to assess the
functional activity of the TCRlo WT1 specific T cell subset. Therefore, in vivo
cytotoxicity and ex-vivo proliferation assays were performed 10 weeks post-AT,
using the same methods as in the primary recipients. The graph in figure 5.7A
shows the results of in vivo cytotoxicity assay, which were comparable to the
corresponding data obtained from the primary WT1 HSC transplant recipients.
WT1 specific memory T cells, also exhibited antigen-specific ex-vivo
proliferation as demonstrated by the representative histogram in figure 5.7B
comparing CFSE dilution in gated Vβ2 positive and negative lymphocytes. The 
representative FACS plots in figure 5.7C. demonstrate marked CFSE dilution
among the Vβ2 positive lymphocytes in the presence of the WT126 but not
after stimulation with an irrelevant peptide.
These results clearly show that the CD44hi CD62Lhi memory phenotype T cell
population was capable of displaying antigen-specific effector function without
prior vaccination. When considered in the context of an observed lack of
functional activity of LMP2-specific T cells which exhibited a TCRhi, CD44lo
CD62Lneg naive phenotype, these results suggest that the TCRhi, naive
phenotype WT1-specific T cells would not exhibit the rapid antigen specific
functional activity shown by the TCRlo subset.
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Figure 5.7 WT1 specific memory T cells exhibit antigen specific function. A.
WT1 specific T cells show antigen specific in vivo cytotoxicity activity. On day 69
post-AT transfer, secondary A2Kb recipients (n=3) were injected with CFSE labelled
peptide loaded target cells, using the same procedure as for primary recipients
(section 6.1). Graph shows percentage antigen specific cytotoxicity calculated as
described in materials and methods. B. Ex-vivo proliferation assay. On day 70 post-
AT splenocytes were harvested from secondary recipients, CFSE labelled and
placed in culture with 100 M of WT126 or an irrelevant peptide. 5 days later these
cells were stained with human anti-V 2 antibodies to identify WT1 specific T cells.
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Figure 5.7 (continued)
Representative FACS histogram showing CFSE dilution in gated V 2 positive and
negative lymphocytes on day 5. C. Ex-vivo proliferation assay. Representative
FACS plots show gated lymphocytes from splenocyte cell cultures from AT
recipients, containing either the pWT126 (left panel) or an irrelevant peptide (right
panel).
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5.2.7 WT1-specific T cells do not cause any autoimmune damage in
tissues physiologically expressing low levels of the WT1 antigen
Since WT1 specificity did not correlate with thymic deletion or peripheral T cell
tolerance, and in fact a subset of WT1 specific T cells was driven to
differentiate towards a fully functional, memory phenotype population,
investigating whether these cells were able to cause autoimmune damage was
relevant. Two sites of WT1 Ag expression in healthy tissues are the BM
progenitor cells and the renal podocytes of kidneys. Bone Marrow and kidney
from A2Kb recipient mice that received WT1-TCR td HSCs were harvested and
analysed by histopathology to detect autoimmune damage relating to T cell
tissue infiltration. The same organs were harvested from mice that received
LMP2-TCR td HSCs and stained in the same way to control for any tissue
damage caused by the experimental conditions. Histological analysis
performed by Dr. Emma Morris revealed no autoimmune damage or T cell
infiltration in the tissues examined, irrespective of whether these were
harvested from WT1- or LMP2-TCR td HSC transplant recipients (data not
shown).
In view of the preferential enrichment of WT1-specific T cells in the BM of
transplanted animals, it was important to further investigate any potential
damage on the stem/progenitor BM cells known to be expressing the WT1 Ag,
To do this BM was harvested from WT1-TCR transplanted and control animals
and transferred into myeloablated secondary recipients in order to monitor
their long-term haematopoietic reconstitution. Tail bleeds were performed at 3,
5, 8 and 12 weeks post-transplant and the blood samples obtained were
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stained with murine anti-CD11c, anti-B220 and anti-CD3 antibodies to identify
cells of the granulocyte, B cell and T cell lineages respectively and murine anti-
CD45.1 to distinguish between donor and recipient derived cells. The results
obtained are summarised in the column graph in figure 5.8. This graph shows
the percentage of donor derived cells in gated granulocytes, B cells and T cells
at the indicated time points. The dark blue columns represent the percentage
donor reconstitution in the secondary recipients receiving a BM transplant from
control, untreated animals (n=5), whereas the light blue columns represent the
same data obtained from secondary recipients receiving BM cells from the
primary recipients of the WT1-TCR td A2Kb HSC transplants. The graph
demonstrates that the presence of WT1-specific T cells in the BM did not
impair the ability of BM stem/progenitor cells for haematopoietic reconstitution.
However, unlike donor derived B cell and granulocyte reconstitution, T cell
engraftment was significantly slower in the experimental mice compared to the
control. It is possible that the altered T cell reconstitution kinetics was a
consequence of the lentiviral vector-driven WT1-TCR expression in developing
thymocytes. The best control for this would have been a serial BM transplant
from primary recipients of LMP2-TCR td HSC transplant.
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Figure 5.8 WT1 specific T cells accumulating in the BM do not impair stem cell
function. Hematopoietic engraftment in secondary C57Bl/6 recipients (CD45.2)
after transplantation of BM cells from A2Kb Tg mice that were previously
transplanted with A2Kb BM stem cells (CD45.1) transduced with the WT1-TCR (n =
10). Peripheral blood of secondary recipients was stained with antimurine CD45.1,
CD3, B220, and CD11b to identify donor hematopoietic cells, donor T cells, donor B
cells and donor granulocytes, respectively. The peripheral blood analysis was done
at weeks 3, 4, 8, and 12 after second transplantation. Control C57Bl/6 recipients
received BM stem cells from untreated A2Kb (CD45.1) Tg mice (n = 5). Percentage
of donor-derived cells are shown after gating on total granulocytes, B cells, and T
cells, respectively. *p-value < .05, **p-value < .01, ***p-value < .001. ns indicates not
significant.
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5.3 Discussion
In this chapter, the functional activity of WT1-specific T cells was analysed. In
agreement with their phenotype, these cells exhibited antigen-specific in vivo
killing and ex-vivo proliferation and cytokine secretion. This was clearly related
to their activation phenotype rather than simply their specificity, as LMP2-
specific T cells which in another study were shown to have antigen-specific
functional activity when activated (Hart et al., 2008), had a naive phenotype in
our system and did not respond to their cognate Ag in the absence of prior Ag
exposure.
The use of AT experiments from the primary WT1-TCR td HSC transplant
recipients, to secondary A2Kb recipients allowed us to study the functional
activity of Tcm, TCRlo WT1-specific T cells in particular. The results obtained
confirmed that this population indeed had antigen-specific functional capacity.
However, in the absence of any data from functional assays on TCRhi WT1-
specific T cells we can only speculate that this population did not contribute to
the functional activity of the WT1-specific T cells in the primary transplant
recipients.
Finally, despite their surprising phenotype and function, WT1-specific T cells
did not appear to cause any autoimmune damage at sites of low level
physiological WT1 Ag expression.
This work and its implications are discussed in detail in the following chapter.
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Chapter 6 - Discussion
In this project, TCR gene transfer into HSCs was employed to investigate the
thymic development and peripheral function of T cells specific for the TAA
WT1. WT1 has been the target of many T cell based immunotherapies,
including vaccination approaches, WT1-specific T cell AT and TCR gene
transfer and is regarded a very attractive target for such therapies for a number
of reasons. WT1 is overexpressed in many tumours and haematological
malignancies but only expressed at low levels in a few healthy tissues. Thus,
WT1-specific immunotherapies can be applied to the treatment of a variety of
cancers. Furthermore, studies have shown that WT1 expression in
transformed cells is not only involved in oncogenesis (Yamagami et al., 1996,
Algar et al., 1996), but also in tumour metastasis (Barbolina et al., 2008). This
makes it unlikely that WT1 expression will be switched off as a tumour evasion
mechanism.
While many of the WT1-specific T cell therapies are already being tested in
clinical trials, the very fact that WT1 is a self-Ag raises questions around the
issues of T cell tolerance and autoimmunity. In order to study these two
opposing phenomena, an in vivo humanised murine model was developed.
Murine BM cells were enriched for HSCs and transduced with the genes for
the high avidity, HLA-A2 allorestricted WT1-TCR. Transferring these cells into
myeloablated HLA A2 Tg recipients provided T cell progenitors that expressed
the introduced TCR on the cell surface when in the thymus, following assembly
with the CD3 molecule. The WT1 Ag expression pattern in mouse is similar to
that seen in humans and the cognate Ag for this particular WT1-TCR, the
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pWT126, is identical in the two species. Therefore in the HLA A2 Tg recipients,
high-avidity WT1-specific T cells would be expected to go through thymic
development - possibly be susceptible to central tolerance mechanisms - and
subsequently circulate in the periphery of a mouse exhibiting a WT1 Ag
expression pattern similar to that seen in humans.
6.1 TCR td HSC transplants preferred over TCR Tg mice for the in vivo
study of WT1-specific T cells
Utilising TCR td HSC transplants recipients instead of TCR Tg mice was
preferred as in this setting, the introduced gene inserts at different, distinct
sites in each cell. While there is still a bias towards certain sites, the fact that
the transgene does not insert at a single genomic site prevents founder effects
that cannot be excluded in transgenic mice (Bettini et al., 2012). Another
important advantage of this model was that the WT1-TCR expressing T cells
were expected to represent only a proportion of the whole T cell repertoire. As
the focus of this study was to elucidate the effect of physiological self-Ag
expression on the phenotype and function of high avidity WT1-specific T cells,
it was important that this was not the only T cell specificity generated. It was
therefore possible to compare the development and differentiation of the WT1-
specific T cells to that of the endogenous polyclonal T cell repertoire.
Furthermore, Leitao et al have shown that inter- as well as intra-clonal T cell
competition for p:MHC complexes shapes both the naive and
activated/memory T cell pool as it affects the relative expansion of one
specificity over another (Leitão et al., 2009). Therefore in order to strengthen
the argument that any effects observed among WT1-specific T cells were
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driven by specificity for their cognate self-Ag rather than by homeostatic
expansion, it was desirable to study the fate of these cells in the presence of a
polyclonal T cell population competing for self p:MHC complexes possibly
including the pWT126:MHC complex. Indeed, in our experimental model both
WT1 and LMP2-specific T cells formed less than 10% of total CD8 T cells.
Importantly, this experimental system also provided us with the means to study
the effect of WT1 Ag expression on WT1-specific T cells in the absence of BM-
derived, professional APCs. Experiments addressing this issue were carried
out by transducing B6 HSCs with the genes for the WT1-TCR and
subsequently transferring them into lethally irradiated A2Kb Tg mice. In this
way, the haematopoietic system, including professional APCs, was
reconstituted with B6 cells unable to present the pWT126 on HLA A2. At the
same time the A2Kb thymic epithelial cells of the recipient animals, being
radio-resistant could still mediate the thymic development of the HLA-A2
restricted WT1-specific T cells.
Haematopoietic stem cells can rescue lethally irradiated recipients by fully
reconstituting haematopoietic function (Rekers et al., 1950, Lorenz et al.,
1951). As they also have the ability to self-renew, they can provide long-term
haematopoietic reconstitution. In mice these cells are found in the Lin-ve
Sca1+ve BM compartment (Uchida and Weissman, 1992). Therefore, BM cells
were enriched for HSCs by magnetic separation. Lin-ve BM cells, found in the
untouched negatively selected fraction of the magnetic separation, were used
in all experiments. Long-term donor derived haematopoietic reconstitution was
achieved both in the primary HSC transplants, as well as in serial BM
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transplant experiments where lethally irradiated syngeneic recipients received
BM from the primary HSC transplant recipients. This verified that HSCs were
present in the small number of Lin-ve, lentivirally transduced Lin-ve BM cells.
Donor haematopoietic reconstitution in transplant recipients receiving WT1-
TCR td HSCs was confirmed and the final steps in setting up the experimental
model involved demonstrating WT1-TCR cell surface expression to be
exclusively found on T cells. Despite lacking a regulatory element dictating
transgene expression to the CD8 T cell lineage, this was expected because
TCR surface expression is dependent on the correct assembly of the TCR-
CD3 multimeric complex. Since CD3 gene expression is only switched on in
developing thymocytes, the introduced TCR can only appear on the surface of
T cells. Indeed FACS analysis of CD3 positive and negative lymphocytes in
WT1-TCR HSC transplant recipients showed that human Vβ2 expression -
used to identify WT1-TCR expression - was only present in CD3 positive
lymphocytes. Since the WT1-TCR is a class I restricted TCR, WT1-specific T
cells generated in this experimental system committed to the CD8 T cell
lineage. LMP2-specific T cells, generated in the same way using the class I
restricted, LMP2 specific TCR genes, followed the same pattern.
6.2 WT1-specific T cells escape thymic deletion
The emergence of WT1-specific T cells into the periphery of WT1-TCR td HSC
transplant recipients indicated that physiologic low level WT1 Ag expression in
a few tissues was not linked to complete thymic deletion of developing
thymocytes bearing this specificity. Analysis of developing thymocytes, showed
similar frequencies of CD3 positive cells expressing the WT1-TCR at the DP
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and CD8 SP stages of T cell development, excluding the possibility that a
percentage of WT1 specific developing T cells could be the subject of negative
selection.
Thymic expression of the WT1 Ag has been reported in some studies. In our
lab high levels of WT1 expression have previously been observed only in the
mesothelial lining but not in the epithelial stroma of the thymus. Therefore, if
this self-Ag is not expressed in the epithelial thymic compartments mediating
negative selection, WT1 specific thymocytes would be expected to go through
thymic development unaffected by central tolerance. However, while the WT1
expression pattern in adult life is limited to renal podocytes, testicular Sertoli
cells, ovarian granulosa cells and a small subset of haematopoietic
progenitors, it is still possible that WT1 may be expressed in the thymus. More
than a decade ago, Klein et al using the inducible inflammatory protein CRP
which is only expressed in the presence of inflammation, demonstrated that
the thymic expression of peripheral self-Ags was independent of the time at
which they are expressed in the periphery (Klein et al., 1998). With this in mind
and the fact that WT1 is extensively expressed in embryonic life, it would be
reasonable to expect that WT1 will be one of the many peripheral Ags
expressed in the thymus with the purpose of shaping a non-autoreactive T cell
repertoire. Furthermore, in a detailed and definitive study looking at PGE in the
different cell subsets of the thymus, Derbinski et al showed that this was a
property of mTECs and any particular peripheral Ag was only expressed in
100-1000 mTECs per thymus while not all mTECs exhibited PGE (Derbinski et
al., 2001, Derbinski et al., 2008). Therefore, it is possible that WT1 is only
expressed in the thymus at low levels in a few mTECs but is not readily
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detectable. Nevertheless, such a low-level expression profile in the thymus
may still be adequate to induce central tolerance against WT1 specific
thymocytes.
Interestingly, even though WT1-specific T cells were not susceptible to thymic
deletion, CD3 downregulation was observed in this cell population in
comparison to endogenous donor-derived T cells. Since LMP2-specific T cells,
generated in control LMP2-TCR td HSCs transplant experiments displayed
CD3 expression levels similar to the endogenous T cells, this was not an
experimental artefact related to the lentiviral transduction. As TCR surface
expression is coupled to that of the CD3 molecule, the CD3 MFI was
considered to be a surrogate marker for TCR expression levels. Back in the
early 1990s when it was still thought that the expression of self-Ags in the
thymus was only derived from either thymic proteins or Ags circulating in the
bloodstream carried by professional APCs, Schonrich et al described TCR
downregulation as a mechanism of peripheral T cell tolerance. So it was
perhaps somewhat surprising that the CD3/TCR downregulation observed in
WT1-specific T cells in our project proved to be a thymic event persisting in the
periphery rather than only a peripheral event. In their study, Schonrich et al
used a double Tg model where the Tg TCR was specific for an experimental-
Ag expressed under a brain-restricted promoter. While they confirmed that this
Ag was not expressed in the thymus by PCR and Southern Blotting on cDNA
from whole thymus, it remains possible that low level Ag expression in only a
small number of mTECs was present but not detected (Schönrich et al., 1991).
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Regardless of whether TCR downregulation takes place in the periphery or the
thymus, it is a well accepted tolerance mechanism. For this reason, the
observed CD3/TCR downregulation in WT1-specific T cells in our experiments
was likely to be either a central tolerance process alternative to clonal deletion,
or the mechanism by which these cells managed to evade negative selection
in the thymus. With these two possibilities essentially being flip sides of the
same coin, it was predicted that following their thymic education, WT1-specific
T cells would be poorly functional in the periphery.
6.3 WT1-specific T cells spontaneously differentiate to memory T cells in
the absence of vaccination
On this basis, demonstrating that WT1-specific T cells were not anergic but
instead differentiated spontaneously into fully functional memory phenotype T
cells was not anticipated. Some indirect evidence has been provided by a
number of publications that central, as well as peripheral tolerance to WT1-
specific T cells is incomplete. Firstly WT1-specific T cells have been detected
in both healthy volunteers and leukaemia patients (Rezvani et al., 2003,
Scheibenbogen et al., 2002, Rezvani et al., 2005), as well as breast cancer
patients (Gillmore et al., 2006). WT1-specific T cells identified in leukaemia
patients showed an activated phenotype and antigen-specific IFNγ secretion in
response to peptide stimulation and were of greater frequency and magnitude
than in healthy controls suggesting that the WT1 TAA is immunogenic rather
than tolerogenic. Consistent with the presence of naturally occurring WT1-
specific T cells in the human T cell repertoire, WT1 peptide and DNA
vaccination trials have resulted in both an immunological WT1 T cell response
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and a transient clinical response in a proportion of vaccinated patients (Oka et
al., 2004, Keilholz et al., 2009, Rezvani et al., 2008).
The classical paradigm of memory T cell development dictates that naive T
cells respond to their cognate Ag and co-stimulation, expanding to form a large
Ag-specific effector population, which following antigen clearance contracts.
The small number of memory T cells surviving is able to mount an immune
response effectively and faster upon a subsequent antigen exposure.
Nevertheless, it is now well accepted that memory T cells can also be
generated in lymphopenic conditions, driven by homeostatic proliferation (Cho
et al., 2000, Goldrath et al., 2000). The current understanding of this
phenomenon is that TCR interactions with self p:MHC complexes together with
exposure to IL-7 under steady-state conditions provide survival signals to
naive T cells. In lymphopenia these signals become mitogenic and promote
naive T cell proliferation and differentiation into memory T cells, in the absence
of exposure to cognate Ag (Boyman et al., 2009). The development of WT1
specific memory T cells in our system could clearly not be justified by the
classic mechanism of memory T cell development, as apart from some limited
WT1 self-Ag availability, signals 2 and 3 necessary for T cell activation were
absent. On the contrary, LIP-driven memory T cell development does require
p:MHC- TCR interaction but not co-stimulation, therefore making this process
worth considering as an explanation for the appearance of WT1-specific
memory T cells in our model.
In our system WT1-specific T cells were initially generated in a lymphopenic
environment, as the WT1-TCR td HSC transplant recipients were lethally
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irradiated prior to the transplant. However, the phenotype and function of WT1-
specific T cells was studied after haematopoietic reconstitution was achieved
in the transplant recipients. At that time around 20% of the endogenous T cell
specificities exhibited a memory, CD44hi CD62Lhi phenotype and a similar
percentage of LMP2-specific memory T cells were noted in control, LMP2-TCR
td, HSC transplant recipients. These results were in agreement with other
studies reporting that 15-20% of total CD8 T cells in unimmunised, steady-
state mice are comprised of memory phenotype cells, present even in mice
housed under germ-free conditions (Haluszczak et al., 2009, Huang et al.,
2005). In fact, Haluszczak et al isolated foreign-antigen specific CD8 T cells
from unprimed mice and showed that 10-30% of these very rare T cell
specificities exhibited a memory phenotype. Having controlled for and
excluded the possibility that this was the result of exposure to their
corresponding foreign antigens they also showed that these so called “Virtual
Memory”, antigen-specific T cells had the phenotypic signature of CD8 T cells
undergoing homeostatic proliferation. Similar to this study, a proportion of WT1
and LMP2-specific T cells as well as endogenous CD8 T cells exhibit a
memory phenotype in non-lymphopenic hosts. However, the percentage of
central memory cells in WT1-specific T cells was much higher (mean of 8
recipients= 50% in A2Kb to A2Kb transplant, mean of 8 recipients=70% in B6
to A2Kb transplant), suggesting that even if the initial lymphopenic conditions
contributed to the formation of this memory population the self-Ag specificity
had an effect over and above that of LIP-driven memory development. Staining
the WT1-specific T cells with an antibody against α4 integrin, a molecule
Haluszczak et al elegantly showed, can be used to discriminate memory T
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cells generated by antigen priming (α4 integrin high) from those developed in
response to homeostatic proliferation (α4 integrin low), can in the future be
utilised to provide more information on the stimulus driving development of the
memory WT1 specific T cell subset.
Kieper et al have shown that a higher TCR affinity for self p:MHC complexes
gives naive T cells a competitive advantage for homeostatic proliferation both
in lymphopenic and T cell-sufficient conditions (Kieper et al., 2004). The affinity
of this interaction is a separate parameter from the TCR affinity for its cognate
Ag, and it was determined by the expression levels of the CD5 molecule
(Azzam et al., 1998) on the different transgenic specificities used. Relating
these findings to our model in which high-affinity WT1-specific T cells
developed and circulated in subjects expressing their cognate Ag, can perhaps
explain our findings. The hypothesis would be that in our system specificity for
the self-Ag WT1 resulted in the preferential homeostatic proliferation of WT1-
specific T cells which consequently drove their differentiation into memory T
cells. On adoptively transferring WT1 specific and endogenous polyclonal T
cells from the primary WT1-TCR td HSC transplant recipients to secondary
lymphodepleted A2Kb recipients, the percentage of WT1-specific T cells
among total donor T cells increased 3-fold in the first 4 weeks post-AT. In this
lymphopenic environment, WT1-specific T cells also converted more efficiently
to a memory phenotype than the endogenous specificities undergoing LIP-
driven memory differentiation, suggesting again that this self antigen-specificity
contributed to the observed memory phenotype differentiation. Labelling the
WT1 and endogenous polyclonal T cells with CFSE prior to their transfer into
secondary recipients would have allowed us to directly assess the hypothesis
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that the WT1 specificity conferred a proliferative advantage in lymphopenic
conditions similar to that observed by Kieper et al. Without such direct
evidence, it is not possible to distinguish between a proliferative or a survival
advantage of WT1-specific T cells, mediating the cells’ improved engraftment.
The initial period of lymphopenia, induced by irradiation prior to the TCR td
HSC transplants performed in this study can be considered to have an impact
similar to that of neonatal lymphopenia. Min et al demonstrated that around
20% of adoptively transferred T cells in newborn mice undergo LIP-driven
memory phenotype development (Min et al., 2003). These findings are in
agreement with our observations in LMP2 and endogenous polyclonal
specificities, but also with the results described by Haluzsczak et al, mentioned
above.
The observed WT1-specific memory development in the absence of
immunisation is similar to the previously described memory T cell development
driven by homeostatic proliferation in the context of irradiation, neonatal
lymphopenia, or even steady-state homeostasis in adult subjects. However,
the similarity is more evident in the phenotypic profile of LMP2-specific and
endogenous polyclonal T cells, rather than with that of WT1-specific T cells.
Our data indicate that the spontaneous differentiation and persistence of WT1
specific memory T cells, is over and above any background memory T cell
development driven by homeostatic processes. Our hypothesis, illustrated in
figure 6.1 is that the chronic stimulation by self-Ag triggers WT1 T cell memory
development.
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Figure 6.1 Schematic diagram illustrating the TCR triggering hypothesis. WT1
specific T cells escape negative selection but demonstrate a relative CD3
downregulation compared to endogenous developing thymocytes. In the periphery
the chronic, low level WT1 Ag presentation results in the activation of a proportion of
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Ag-specific function
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Figure 6.1 (continued)
WT1-specific T cells which downmodulate their TCR further. TCR triggering in
response to chronic Ag encounter seems to be driving the WT1 specific T cells to
differentiate into fully functional memory T cells. As the thymus continuously feeds
the periphery with new, naive TCRhi WT1 specific T cells , TCRhi and TCRlo WT1
specific T cell subsets co-exist in the periphery.
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To unequivocally test this hypothesis, ideally we would allow the development
of WT1-specific T cells in A2Kb mice, as already described in this thesis, and
subsequently FACS sort naive WT1-specific T cells to transfer them in 4
different groups of mice. Two of these groups of mice would consist of A2Kb,
WT1 knockout animals and the other two groups would consist of A2Kb, as
those used throughout most experiments presented in this thesis. The other
two groups would also be standard A2Kb, or WT1 knockout A2Kb, but they
would also be lymphodepleted with 6Gy of irradiation prior to the AT. With this
experimental setup we will be able to ask whether naive WT1-specific T cells
are driven to functional memory cells by the interaction with their cognate Ag,
both in a lymphopenic and in a T-cell sufficient, steady-state environment.
Additional control experiments where polyclonal endogenous, or LMP2 specific
naive T cells are adoptively transferred would be useful to assess the
hypothesised proliferative and differentiation advantage that naive WT1-
specific T cells have in the presence of WT1 Ag. Unfortunately, performing
these experiment is not possible as WT1 knockout mice as well as inducible
tissue-specific WT1 knockout animals are not viable beyond term (Martinez-
Estrada et al., 2010).
A less optimal experiment could be to follow the above setup replacing WT1
knockout A2Kb Tg mice with WT B6 animals. These mice express WT1 and
can process and present the pWT126 for which WT1-specific T cells are
specific. However, regardless of this antigenic epitope being available in B6
mice, pWT126 will not be presented on the appropriate class I molecule in
order to be recognised by T cells expressing the human HLA A2 restricted,
WT1-TCR. In this way, the effect that the WT1 Ag has on naive WT1-specific T
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cells can be obliterated simply because these T cells will not be able to
recognise the Ag. However, the limitation of this experiment, is that unlike
using WT1 knockout A2Kb Tg mice, this system cannot be used to exclude the
possibility that cross-reactivity with other epitopes presented by the A2Kb
molecules drives WT1-specific T cell differentiation into memory T cells rather
than encounters with WT1 Ag.
6.4 Memory WT1-specific T cells are produced in the absence of
professional antigen presentation
Interestingly, a memory population was present in the periphery of A2Kb
recipients receiving WT1-TCR td HSC from B6 donors. In this setting the
pWT126 presentation on the HLA A2 molecule is limited to the few non-
professional APCs, mainly renal podocytes, which express the antigen at low
levels. It is therefore possible that chronic, direct presentation by these cells is
enough to mediate T cell memory differentiation. Even in the presence of A2Kb
APCs, these cells are able to present the pWT126 epitope but they do so in
the absence of co-stimulatory signals. Consequently, whether the WT1 Ag is
cross-presented by professional APCs or directly-presented by peripheral
tissue cells might not make a difference to the T cell differentiation profile
instructed by the high avidity WT1-TCR interaction with its cognate Ag. Of
course, this scenario requires that WT1-specific T cells reach the sites were
tissue cells express the WT1 Ag when they circulate in the periphery.
Another explanation for observing memory T cells in the periphery of B6 to
A2Kb transplant recipients may be that WT1 memory differentiation takes
place in the thymus prior to their emergence in the periphery. In the B6 to
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A2Kb WT1-TCR td HSC transplants the haematopoietic system is
reconstituted with B6 cells unable to present pWT126 on HLA A2, but the
recipients’ HLA A2 thymic epithelial cells are radioresistant and persist.
Therefore they can still mediate the thymic development of the A2-restricted
WT1-specific T cells and can also potentially mediate presentation of the WT1
Ag through promiscuous gene expression. All WT1-specific T cells showed
marked TCR downregulation compared to both the endogenous polyclonal
population and LMP2-specific T cells, as measured by CD3 surface expression
levels, and this was shown to be a thymic event persisting in the periphery.
However, in the periphery phenotypic analysis of the WT1-TCR and CD8 co-
receptor expression revealed 2 distinct subsets of WT1-specific T cells.
Memory phenotype WT1-specific T cells mainly belonged to the subset
exhibiting the lowest levels of WT1-TCR, named TCR lo. The other subset
exhibited relatively higher levels of the WT1-TCR, was named TCRhi, and
looked similar to the endogenous polyclonal population. This further TCR
downregulation in the WT1-TCRlo T cells was accompanied by a relative
upregulation of the CD8 co-receptor in comparison to the WT1-TCRhi T cells.
Our hypothesis, as illustrated in figure 6.1, is that WT1-specific T cells
encounter the WT1 in the context of HLA A2 in the thymus and this leads to a
certain level of TCR/CD3 downregulation. However, WT1-specific T cells
escape thymic deletion and emerge from the thymus as naive, TCRhi cells.
Further, chronic, low-level WT1 Ag encounter in the periphery subsequently
causes further TCR downregulation and mediates their differentiation into fully
functional, memory T cells. An experimental limitation remains that it was not
possible to distinguish the two WT1 specific populations (TCRhiCD8lo and
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TCRloCD8hi) among developing thymocytes in the same way they were
identified in the periphery, as the CD8 expression varies at different stages of
thymocyte development. Therefore we were unable to answer the question
whether the thymus only produced naive, TCRhi CD8 low WT1-specific T cells
as expected.
The only reports of memory phenotype CD8 T cells being generated in the
thymus concern the so-called bystander memory CD8 T cells which arise in
response to IL-4 (Weinreich et al., 2010). This phenomenon is prominent in
wild type Balb/c mice, shown to contain increased frequencies of IL-4 secreting
NKT cells, but not in B6 mice (Lai et al., 2011). It is therefore relevant that all
mice used in our experiments were on a B6 background. The group that
reported the existence of Virtual Memory T cells - mentioned above - also
studied bystander memory T cells. “Virtual Memory” T cells, like memory WT1-
specific T cells in our study, formed only a proportion of each specificity
examined. Their site of production, as in our model, was also uncertain until
this year, when Akue et al were able to clarify that these cells, were not
produced in the thymus, but in the periphery during the neonatal period (Akue
et al., 2012). These authors noticed a peak with a subsequent drop and a
plateau in “Virtual Memory” T cell frequencies before mice were 4 weeks old.
Therefore, in order to more directly address the possibility that WT1 specific T
cell memory differentiation was triggered by irradiation-induced LIP, CD44 –
CD62L phenotypic analysis of WT1-specific T cells in the periphery as well as
in the thymus at 1, 2, 3 and 4 weeks post-transplant in addition to those
already performed at 11 weeks when haematopoietic reconstitution was
achieved, would have been very relevant.
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A third explanation about the appearance of WT1 specific memory T cells in
B6 to A2Kb transplant recipients can simply be that since donor chimerism was
only nearly complete in these animals, professional WT1 Ag presentation is
provided by the few remaining A2Kb APCs. Although possible, such a scenario
implies that within this 2-8% of A2Kb APCs persisting in the B6 to A2Kb
transplant recipients, enough cells would cross-present the pWT126 to induce
the differentiation of similar percentages of WT1-specific T cells to a memory
phenotype, as observed when all APCs express HLA A2 (A2Kb to A2Kb
transplant). Even though memory WT1-specific T cells were detected in both
A2Kb to A2Kb and B6 to A2Kb HSC transplants, the proportions of Tcm and
Tem subgroups was not identical. Lower percentages of Tem WT1-specific T
cells were noted in B6 to A2Kb transplant suggesting that WT1 Ag
presentation by professional APCs was needed to observe the Tem
population. It seems unlikely that the difference in the activation phenotype of
WT1-specific T cells in the two settings can be explained by different numbers
of APCs able to present the pWT126 on HLA A2 rather than an all or nothing
effect.
6.5 WT 1 specific T cells accumulate in the BM
Intriguingly, WT1-specific T cells appeared to accumulate in the BM both in
A2Kb to A2Kb and B6 to A2Kb transplant recipients. The BM is one of the few
sites were the WT1 Ag is expressed at low levels, under physiological
circumstances. While in the former setting this phenomenon could be driven by
both direct Ag presentation on BM progenitor cells expressing WT1 and cross-
presentation by professional A2Kb APCs, neither of these cell types could
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mediate Ag presentation in the latter setting. This initially suggested that the
BM enrichment of WT1-specific T cells had to be driven by an antigen-
independent mechanism.
In 2005 Mazo et al showed that Tcm T cells home preferentially to and are
retained in the murine BM and consequently are the predominant subset
among CD8 T cells at this site (Mazo et al., 2005). In the same year, another
two groups showed that memory T cell, known to proliferate in response to
homeostatic cues and independently of antigenic encounter, do so more
efficiently in the BM (Parretta et al., 2005, Becker et al., 2005). It was therefore
hypothesised that preferential homing and proliferation of the Tcm WT1-
specific T cells in the BM could be a reason for the increased frequencies of
WT1-specific T cells in this organ in comparison to the periphery. However, our
results did not offer a straightforward answer. WT1-specific TCRlo cells, shown
to mainly consist of Tcm, were not enriched in the BM compared to the
periphery. Neither did, WT1-specific Tcm cells among either TCRhi or TCRlo
WT1-specific T cells, in the A2Kb to A2Kb transplant setting. However, in B6 to
A2Kb transplant recipients a small difference was observed both in the
percentages of WT1-TCRlo cells and Tcm WT1 T cells in general, perhaps
suggesting that in the absence of professional WT1 Ag presentation, Tcm WT1
T cells are more likely to remain in their homeostatic niche rather than circulate
in the periphery. On the other hand, in the A2Kb to A2Kb transplants effective
direct-presentation and cross-presentation of the WT1 Ag in the BM transforms
what is generally an environment of preferential accumulation of Tcm T cells to
one that is simply another site of Ag presentation. Consequently as Ag is
presented in BM and periphery, the percentage distribution of WT1-specific T
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cells into naive, Tcm and Tem phenotypes becomes broadly similar among the
two sites.
Our data could not provide a conclusive explanation for the preferential
accumulation of WT1-specific T cells in the BM. Additional experiments will be
needed to clarify this and these are described in section 6.8, Future Work.
6.6 TCRlo WT1-specific T cells exhibit antigen-specific function in the
absence of vaccination
WT1-specific T cells not only spontaneously differentiated to memory
phenotype T cells, but also exhibited antigen specific proliferation, cytokine
secretion and killing activity. As WT1-TCRlo cells in their majority had a Tcm
phenotype, whereas WT1-TCRhi cells composed of naive, Tem and Tcm
phenotype cells, it was expected that the functional activity of these two WT1
specific T cell subsets would prove to be different in terms of magnitude and
timing with TCR lo cells responding better and faster.
AT of T cells, containing WT1-TCRhi, WT1-TCR lo and endogenous T cells,
into lymphodepleted secondary recipients, allowed us to study the function of
the TCR low, Tcm phenotype WT1-specific T cells, as at 10 weeks post-AT all
WT1-specific T cells converted to this phenotype. There was evidence that
their subsequent differentiation was driven by their Ag-specificity over and
above the effects of the lymphopenic environment in the irradiated secondary
recipients. The cells showed strong antigen specific in vivo cytotoxicity activity
and ex-vivo proliferation, clearly suggesting that TCR lo, Tcm WT1-specific T
cells were capable of antigen specific function. However, demonstrating the
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same functional activity in sorted TCR lo, Tcm WT1-specific T cells transferred
to non-irradiated A2Kb recipients would indisputably confirm this hypothesis.
6.7 WT1-specific T cells are fully functional but do not cause any
autoimmune damage
Despite the functional activity of WT1-specific T cells, these cells did not
appear to cause any autoimmune damage in tissues expressing the WT1 Ag
at low levels. Earlier work by our group demonstrated that the human T cell
clones from which the genes for this particular WT1-TCR were cloned and
subsequently used for WT1-TCR gene transfer in this and other projects,
effectively killed leukaemic stem cells but did not damage healthy, human
CD34+ stem cells also expressing the WT1 Ag. Furthermore, numerous WT1
vaccination trials showing a range of WT1 specific T cell responses have been
performed, but so far no report of autoimmune damage caused by WT1-
specific T cells has been made. Unlike the WT1-specific T cells in our model,
the WT1-specific T cells expanded by vaccination are likely to be of low avidity
and their frequencies even lower than those achieved here by the WT1-TCR,
lentiviral transduction of HSCs prior to the HSC transplants.
In a recent study, Falkenburg et al isolated WT1-specific T cells that were
either self-HLA A2- restricted or allo-HLA A2 restricted (from HLA A2 positive
and negative individuals respectively) and were able to show that only the
allorestricted specificities recognised the WT1 epitope used in a high avidity
interaction. In contrast, all self-restricted WT1 specificities were of low avidity
supporting the theory that high avidity self-restricted WT1 specificities are
generally deleted in the thymus (Falkenburg et al., 2011). In our case, even
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though the WT1-TCR used was generated from the allorestricted repertoire,
developing thymocytes expressing it went through thymic development before
emerging in the periphery as WT1-specific T cells. Therefore, in this
experimental system the allorestricted TCR was used to model self-restricted,
high avidity T cells liable to central and peripheral tolerance. Demonstrating
that a particular high-avidity WT1 specific T cell specificity, can escape
negative selection without its function being compromised by peripheral
tolerance mechanisms, even when as shown by Falkenburg et al this is not a
common event, is encouraging for vaccination trials targeting TAAs.
Once experiments are performed to clarify the hypothesised differences in the
antigen-specific functional activity of TCRhi and TCRlo WT1-specific T cells,
our model can be used to optimise vaccination protocols in order to
preferentially expand the WT1 specific subset that will be most useful in the
clinical setting. One limitation of our model is the non-physiological frequency
of high avidity WT1-specific T cells. It may therefore be possible to use primary
WT1-TCR td HSC transplant recipients to generate naturally occurring-like
WT1-specific T cells that develop in the thymus and do not undergo any in vitro
manipulation as mature T cells and subsequently adoptively transfer the
required numbers and cell subsets into secondary non-irradiated A2Kb
recipients, in order to setup more physiologically-relevant experimental
conditions.
The results produced in this study are also relevant to the WT1-TCR gene
therapy clinical trial which has recently opened to recruitment. In this trial the
genes for the same WT1-TCR used in this project will be transferred to
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autologous T cells harvested from patients with poor prognosis Acute Myeloid
Leukaemia. The TCR gene-modified T cells will then be returned to the
patients after lymphodepletion and immunological and clinical responses will
be monitored. As discussed already, our results provide additional
reassurance that such high avidity WT1-specific T cells are unlikely to cause
autoimmune toxicity in the clinical trial patients. This is particularly important
since targeting healthy CD34+ HSCs and renal podocytes, that express this
Ag, can potentially result in myelosuppresion and renal failure respectively.
Ex-vivo proliferation and cytokine secretion assays were performed by
stimulating splenocytes from WT1-TCR td HSC transplant recipients containing
WT1-specific T cells with A2Kb splenocytes loaded either with the pWT126 or
an irrelevant HLA-A2 presented peptide as a negative control. A simple way to
test for cross-reactivity of WT1-specific T cells would be to add an additional
control condition where no exogenous peptide would be loaded on A2Kb target
splenocytes. These cells will then be able to present endogenously processed
epitopes to WT1-specific T cells. A proliferative, or cytokine secretion response
under these conditions would indicate that the WT1-specific T cells are able to
also recognise other epitopes on HLA A2. Despite the lack of direct evidence,
the very fact that WT1-specific T cells in our model, expressing an
allorestricted, high avidity TCR on their cell surface, did escape central
tolerance in an HLA A2 thymic environment allows us to speculate that they
should not exhibit any promiscuous off-target recognition. Of course the
limitation of this idea then becomes that while no cross-reactivity might be
exhibited by WT1-specific T cells present in A2Kb transgenic mice this remains
a possibility in the human system.
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6.8 Future work
Demonstrating that high avidity, WT1-specific T cells going through thymic
development in subjects expressing physiological, low levels of the WT1 TAA,
emerge from the thymus, differentiate into memory T cells and are fully
functional in an Ag-specific manner, was unexpected. Having confirmed that
these high avidity WT1-specific T cells were not susceptible to central or
peripheral tolerance mechanisms we attempted to characterise their
phenotype and function in detail and gain an understanding into what drives
their differentiation into fully functional memory T cells.
Currently 3 main questions remain unanswered and can be addressed in
future experiments, as described below.
6.8.1 Delineating the function of TCRhi and TCRlo WT1-specific T cells
TCRhi and lo, WT1-specific T cells together were shown to kill, proliferate and
secrete cytokines in an antigen-specific manner. The AT experiments
described in section 5.2.6, suggested that TCRlo, Tcm phenotype WT1-
specific T cells are capable of this functional activity. However, to
unequivocally test if there are any differences in the functional capacity of the
two WT1 specific T cell subsets it is necessary to isolate each group from the
spleens of WT1-TCR td HSC A2Kb to A2Kb transplant recipients by FACS
sorting.
The two cell populations can then be used in ex-vivo proliferation and cytokine
secretion assays as they have been performed with non-sorted WT1-specific T
cells. To test the in vivo cytotoxicity activity of the two subsets, it would be
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necessary to adoptively transfer each FACS-sorted subset in non-irradiated
A2Kb recipients and then proceed with the same assay as the one performed
in primary WT1-TCR td HSC transplant recipients. It is likely that in the AT
recipients the WT1-TCRhi cells will respond to the physiological low level WT1
Ag presentation, downregulate their TCR and differentiated into Tcm T cells
giving rise to a TCRlo population as the one seen in primary transplant
recipients. To avoid this, the in vivo cytotoxicity assay should be performed the
same day the T cells are transferred into secondary recipients. While
conceptually this is a simple experiment, the technical details of T cell numbers
to be transferred into each secondary recipient, in order to see a response to
this assay, would have to be optimised. Acquiring enough cells from each WT1
specific T cell subset to obtain statistically significant results, most likely would
require large numbers of primary WT1-TCR td HSC transplant recipients.
6.8.2 Are TCR lo, memory WT1-specific T cells derived from TCRhi WT1-
specific T cells in the periphery
The AT experiments, in which bulk WT1-specific T cells were transferred in
lymphodepleted secondary recipients, indicated that TCRhi T cells, consisting
mainly of naive T cells, differentiate to memory T cells and downregulate their
TCR to become WT1-TCRlo cells. Nevertheless, this does not necessarily
reflect the events that lead to the generation of the TCRlo, memory T cell
population in the primary WT1-TCR td HSC transplant recipients. It was
mentioned earlier that FACS analysing thymocytes for the presence of TCRhi
and lo WT1-specific T cells was not possible due to the differential expression
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of the CD8 coreceptor, which is used to identify the two populations, at
different stages in T cell development.
An alternative experiment that could provide us with valuable information,
would involve the AT of FACS sorted TCRhi WT1-specific T cells into non-
irradiated A2Kb secondary recipients. Observing the conversion of naive,
TCRhi WT1-specific T cells into memory T cells and their simultaneous
conversion to a TCRlo population in the steady-state would provide more
direct evidence supporting the hypothesis that the chronic antigenic stimulation
of naive TCRhi, WT1-specific T cells triggers their differentiation into memory T
cells in the absence of vaccination (figure 6.1).
6.8.3 What drives the accumulation of WT1-specific T cells in the BM?
Antigen presentation, the BM environment being a niche for Tcm, or a
combination of both?
Both in the presence and absence of professional APCs (A2Kb to A2Kb and
B6 to A2Kb transplant recipients respectively) WT1-specific T cells
preferentially accumulate in the BM over the spleen and LNs. Even though the
phenotype of the WT1-specific T cells in these 3 different sites was analysed
extensively, our results did not provide us with a conclusive answer as to what
drives this phenomenon and further experiments are required.
To clarify whether the accumulation of WT1-specific T cells in the BM is the
result of increased proliferation in the BM, homing to this organ, or a
combination of both, it is necessary to assess cell division at this site and in the
periphery. Employing the techniques used by Becker et al, active cell division
can be assessed by combining surface staining to identify naive and memory
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WT1-specific T cells with intracellular staining with PI to obtain a snapshot of
DNA synthesis in the 3 different organs studied(Becker et al., 2005).
Combining these results with in vivo BrdU incorporation assays as another
measure of proliferation in spleen, LNs and BM over a fixed amount of time
can offer an accurate description of the site at which most proliferation is taking
place at the time of the assay (PI staining) and which site contains the cells
that have proliferated the most, irrespective of where this proliferation has
taken place (BrdU assays).
In addition AT experiments with FACS-sorted, naive, Tcm and Tem WT1-
specific T cells that would be CFSE labelled prior to their transfer into non-
irradiated A2Kb transgenic recipients could inform us on whether naive WT1-
specific T cells divide and differentiate in the periphery and subsequently
migrate in the BM as Tcm T cells, or whether this differentiation happens
locally in the BM. To confidently distinguish whether this accumulation relates
to antigen presentation in the BM or to the memory character of WT1-specific
T cells these experiments, CFSE labelled, sorted WT1-specific naive and
memory cells should be adoptively transferred into non-irradiated A2Kb and B6
recipients so that their rate and site of proliferation, as well as migration profile
from the periphery to the BM in the presence and absence of WT1 Ag
presentation on HLA A2 can be compared. Of course, ideally we would use
WT1 knockout A2Kb Tg mice rather than B6 mice as secondary recipients. In
WT1 knockouts the WT1 Ag would be truly absent instead of simply not
presented on the appropriate class I molecule for recognition by the hybrid
WT1-TCR. Unfortunately WT1 knockout mice are embryonic lethal.
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6.8.4 The role of WT1-specific T cells in tumour protection and clearance
In this PhD project, high avidity WT1-specific T cells developing in the context
of physiological WT1 Ag expression were shown to have a full armoury of
functional properties. Testing these T cells in tumour challenge experiments,
will allow us to ask whether they can also integrate their killing, proliferation
and cytokine secretion activities to successfully eradicate or contain a tumour.
This will clearly be a much more difficult task, as tumour cells are able to
proliferate, organise themselves in vivo and in most cases establish an
immunosuppressive environment within the tumour site. Therefore, the
recruitment of WT1-specific T cells to the tumour, the rate at which they can kill
transformed, multiplying cells and their ability to maintain effector function
within the tumour microenvironment will be assessed in tumour challenge
experiments. In such experiments, it would be interesting to delineate the
contribution of TCRlo and TCRhi cells in controlling tumour growth. It would be
even more interesting to investigate whether the presence of an establishing
tumour causes any changes in the activation profile of circulating and tumour-
homing WT1-specific T cells and assessing whether ways to encourage or
avoid such changes to suit a therapeutic scenario can be devised.
Nevertheless, establishing an appropriate WT1 expressing-tumour challenge
model in relation to the project presented here will be complicated. The first
requirement would be to establish a murine tumour cell line that expresses the
WT1 Ag, can endogenously process it and subsequently present the pWT126
on the HLA A2 molecule. Preliminary work has been performed towards
establishing such a cell line, however time limitations did not permit the
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completion of this work during this PhD. Following the generation of an
appropriate tumour cell line the second requirement would be to optimise the
tumour cell numbers required to establish a tumour burden that would allow a
difference to be observed among untreated control mice, and mice containing
WT1-specific T cells. Once these requirements are met, the simplest
experimental setup would be to harvest splenocytes from primary WT1-TCR td
HSC transplant recipients and FACS sort WT1-specific T cells from these
samples, to adoptively transfer in tumour bearing, A2Kb Tg mice.
Once the experimental conditions are optimised, the TCRhi and low WT1-
specific T cells can be sorted and transferred separately into tumour bearing
mice. This will allow us to assess their function separately but also track any
phenotypic changes among each subset. WT1 specific T cell subsets could
also be CFSE labelled and their tumour-specific proliferation and migration
profiles studied.
The above tumour challenge experiments would answer questions around the
function of WT1 specific TCRlo and TCRhi subsets individually and together,
within the tumour microenvironment. In addition, tumour challenge experiments
could also be performed to establish a clinically relevant WT1 vaccination
model. In such a model, the tumour cell line would be injected in primary WT1-
TCR td HSC transplant recipients that will already contain fully functional
memory WT1-specific T cells as well as naive WT1 specific T cells. These
conditions will mimic the hypothetical, clinical scenario of high-affinity,
functional WT1 specific T cells being present in a patient. Different WT1
vaccination strategies can subsequently be tested, to identify the protocols that
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would be most successful in enhancing tumour protection and tumour
clearance. Of course protection from a not yet established tumour is a very
different scenario, from tumour clearance. This model can allow the study of
both situations in relation to a WT1-specific antitumour response. It can be
used to ask what breaks tumour protection; is it just a matter of WT1-specific
cell numbers or is it mediated by a phenotypic and functional change among
WT1-specific T cells. It can also be used to ask whether the “naturally
occurring” WT1-specific T cells that failed to prevent the establishment of the
experimental tumour can be made effective to clear the tumour by vaccination.
In order for such experiments to be clinically relevant, the initial frequencies of
WT1-specific T cells in the WT1 TCR td HSC transplant recipients will have to
be reduced substantially. Reducing the MOI of the lentivirus with which the
HSC are transduced prior to the transplant would reduce the percentage of
WT1 specific T cells present in the periphery, but it might also change the
expression levels of the WT1 TCR on individual T cells. To avoid this
complication, HSCs would be transduced with the same MOI as the one used
in this project (MOI 10), but the HSCs transferred into the transplant recipients
will consist on untreated, untransduced HSCs to which a small number of
transduced HSCs will be added. In this way it will be possible to control the
frequency of WT1-specific T cells without affecting the WT1-TCR expression
levels.
6.9 Conclusions
The unexpected finding that high avidity WT1-specific T cells can escape
central and peripheral tolerance in the context of physiological WT1-Ag
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expression and spontaneously differentiate into fully functional, memory T
cells, can be used to optimise WT1 T cell-based tumour immunotherapies.
Dissecting the role of each WT1 specific T cell subset in tumour protection and
clearance will be critical before using this model as a platform to test different
strategies to promote the development and persistence of the most desirable
WT1-specific populations.
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Specificity for the tumor-associated self-antigen WT1 drives the development of
fully functional memory T cells in the absence of vaccination
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Recently, vaccines against the Wilms
Tumor antigen 1 (WT1) have been tested
in cancer patients. However, it is cur-
rently not known whether physiologic lev-
els of WT1 expression in stem and pro-
genitor cells of normal tissue result in the
deletion or tolerance induction of WT1-
specific T cells. Here, we used an human
leukocyte antigen-transgenic murine
model to study the fate of human leuko-
cyte antigen class-I restricted, WT1-
specific T cells in the thymus and in the
periphery. Thymocytes expressing a WT1-
specific T-cell receptor derived from high
avidity human CD8 T cells were positively
selected into the single-positive CD8
population. In the periphery, T cells spe-
cific for the WT1 antigen differentiated
into CD44-high memory phenotype cells,
whereas T cells specific for a non–
self-viral antigen retained a CD44low naive
phenotype. Only the WT1-specific T cells,
but not the virus-specific T cells, dis-
played rapid antigen-specific effector
function without prior vaccination. De-
spite long-term persistence of WT1-
specific memory T cells, the animals did
not develop autoimmunity, and the func-
tion of hematopoietic stem and progeni-
tor cells was unimpaired. This is the first
demonstration that specificity for a tumor-
associated self-antigen may drive differ-
entiation of functionally competent
memory T cells. (Blood. 2011;117(25):
6813-6824)
Introduction
The Wilms Tumor antigen 1 (WT1) is an attractive target for
immunotherapy of leukemia and solid tumors as it is expressed at
high levels in many malignancies, whereas progenitor and stem cell
populations express only low levels of the WT1 transcription
factor.1-5 In acute myeloid leukemia (AML), high WT1 levels are
associated with poor prognosis, and the quantitative measurement
of WT1 RNA transcripts is now widely accepted as a sensitive
molecular marker for monitoring minimal residual disease in
patients undergoing chemotherapy or transplantation.6
In the past few years, vaccination with WT1 peptides has been
tested as a treatment option for various malignancies, including
myelodysplasia and leukemia.7,8 In these studies clinical responses
were observed in 60% to 74% of evaluable patients (including
stable disease and reduced expression of tumor markers), but
correlation with the detection of immunologic responses in periph-
eral blood was variable. Studies in breast cancer patients showed
that WT1-specific T cells were undetectable in peripheral blood,
although present in tumor-draining lymph nodes (LNs).9 There-
fore, failure to detect WT1-sepcific T cells in the blood of cancer
patients might be the result of selective migration to the site of
tumor growth.
It is possible that low-level WT1 expression in normal progeni-
tor cells may result in the central deletion of high avidity
WT1-specific T cells or induce unresponsiveness by peripheral
tolerance mechanisms. However, there is good evidence indicating
that central and peripheral tolerance to WT1 is incomplete. First,
vaccination in humans can induce self-restricted WT1-specific
T-cell responses in some patients, although their frequency is
generally low.10 In addition, WT1-specific T cells were detectable
in leukemia patients after allogeneic stem cell transplantation and
their detection correlated with low risk of leukemia relapse.11
Finally, WT1-specific T cells can be detected in the peripheral
blood of healthy persons.12-17
It is currently unclear to what extent self-antigen expression in
normal tissue shapes the phenotype and functional activity of
WT1-specific T cells. For example, recent studies examining the in
vivo generation of “natural” memory phenotype T cells have
suggested that self-antigen might trigger naive T cells to differenti-
ate into memory phenotype cells.18-20 In this study, we designed
murine model experiments to analyze the thymic development of
HLA-A0201–restricted, WT1-specific T cells and to determine the
phenotype and function of these cells in the periphery.
Previously, we have used the allo-restricted strategy to isolate
HLA-A0201–restricted, pWT126-specific T cells from healthy
persons.21,22 High avidity T-cell lines were established and used
to isolate the genes encoding the - and -chains of a
pWT126-specific TCR. Retroviral TCR gene transfer readily
converted human peripheral blood T cells into high avidity,
pWT126-specific CTL,23 which were able to recognize and kill
CD34 cells of leukemia patients but not normal CD34
hematopoietic progenitor/stem cells. Furthermore, adoptive
therapy with TCR-gene transduced T cells resulted in the
elimination of autologous leukemia cells in the xenogenic
NOD/SCID model.24
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In this study, we transferred the WT1-TCR gene into purified
murine lineage-negative hematopoietic stem cell (HSCs). Transplan-
tation of the gene-modified stem cells into HLA-A0201 transgenic
recipients allowed us to study the phenotype and function of
TCR-expressing cells in the thymus and periphery. Surprisingly,
WT1-specific T cells were not impaired by central or peripheral
tolerance but differentiated instead into memory phenotype T cells
able to display antigen-specific effector function. Thus, self-
specificity for a tumor-associated antigen can contribute to the
establishment of natural memory phenotype T cells.18,19 The
implications of these findings for WT1-based vaccination strategies
are discussed.
Methods
Mice
C57BL/6 mice were purchased from Charles River Laboratories or the
Comparative Biology Unit of University College London, Royal Free
Campus. HLA-A2Kb transgenic (A2Kb Tg) mice on a C57Bl/6 background
were a kind gift from Theobald M (University Medical Center, Utrecht, The
Netherlands). C57Bl/6 CD45.1 and A2KbxCD45.1 Tg mice were bred and
maintained in the Comparative Biology Unit of University College London.
All animals were housed in pathogen-free conditions in individually
ventilated cages and were kept in accordance with the University and
United Kingdom Home Office regulations. All procedures were performed
aseptically, and irradiated animals received 2.5% enrofloxacin (Baytril,
Bayer) in their water 1 week before irradiation and for 2 weeks after
irradiation. Donor mice were 7 to 10 weeks old at the time of bone marrow
(BM) harvest. Recipient mice were 12 weeks old at transplantation and
received 9.4 Gy irradiation in 2 divided doses at day 2 and day 0.
Secondary adoptive transfer recipients were sublethally irradiated (5 Gy) 4
hours before T-cell transfer.
Lentiviral vector constructs
A pSIN second-generation lentiviral vector, containing a spleen focus
forming virus LTR promoter and the HIV-1 central polypurine tract
cis-active element, was modified for this study. Both the codon-optimized
hybrid HLA-A*0201-restricted WT1-specific TCR and the latent mem-
brane protein 2 (LMP2)–specific TCR genes have been described be-
fore.24,25 The WT1-TCR uses the V2.1 and V1.5 TCR chains and is
specific for the WT126 peptide, RMFPNAPYL. The LMP2-TCR uses the
V13.1 and V3.1 TCR chains and is specific for the CLG peptide,
CLGGLLTMV. The hybrid TCR sequences contain murine constant and
human variable region sequences. An additional disulphide bond between
the - and -chains was created by the introduction of 2 additional cysteine
residues in the - and -chain constant regions. The genes for the TCR -
and -chains cloned into the lentiviral vector were separated by a porcine
tsechovirus self-cleaving 2A sequence to optimize expression of both TCR
- and -chain genes. The leader sequence was derived from the pMP71
retroviral vector, and the full-length woodchuck hepatitis virus post-
transcriptional regulatory element was truncated to prevent encoding of the
oncogenic protein X.26
Lentivirus preparation
Human embryonic kidney 293T cells were used to produce WT1-TCR and
LMP2-TCR lentiviral particles. A total of 2  106 293T packaging cells
were cultured in T150cm tissue-culture flasks in Iscove modified Dulbecco
medium supplemented with 10% heat-inactivated FCS (Sigma-Aldrich),
1% penicillin and streptomycin (Pen/Strep), and 1% L-glutamine, for 24 hours
at 37°C, 5% CO2. To produce the appropriate lentiviral particles, the 293T
cells were cotransfected with a plasmid encoding either WT1-TCR or
LMP2-TCR genes, the pMD.G plasmid encoding the vesicular stomatitis
virus glycoprotein envelope, and the pCMV8.91 plasmid that encodes
genes necessary for the production of functional viral particles. The
Fugene6 transfection kit (Roche Diagnostics) was used for packaging cell
transfection as per the manufacturer’s protocol. Twenty-four hours later, the
transfection medium was replaced with fresh IMDM. The lentiviral
supernatant was harvested 48 hours later, concentrated 100 times by
ultracentrifugation, before resuspension in StemSpam medium (StemCell
Technologies) and stored at 80°C until required for transduction. Before
storage, serial dilutions of each lentiviral supernatant were added to 1 mL of
5  105 58/ cells, which were cultured in RPMI medium supplemented
with 10% FCS, 1% Pen/Strep and 1% L-glutamine, to titrate the multiplicity
of infection (MOI). An MOI 10 was used to transduce Lin BM cells in
all experiments.
HSC isolation, infection, and transfer
Whole BM was harvested from 7- to 10-week-old donor mice (C57BL/6 or
A2Kb Tg as specified in each experiment). Briefly, femurs, tibias, and
pelvic bones were removed and the BM was harvested by flushing it with
cold RPMI medium containing 1% Pen/Strep with a syringe equipped with
a 25-gauge needle. Uncommitted BM progenitors, highly enriched in
HSCs, were negatively selected using either the lineage cell depletion kit
for mouse (Miltenyi Biotec) or the Hematopoietic Progenitor Enrichment
kit (StemCell Technologies) following the manufacturer’s protocols.
The lineage selected cells (Lin BM cells) were placed in culture at
1  106 cells/mL in StemSpan medium (StemCell Technologies) contain-
ing 1% Pen/Strep, 100 ng/mL murine stem cell factor, 100 ng/mL human
Fms-like tyrosine kinase 3, 100 ng/mL human IL-11, and 20 ng/mL murine
IL-3. All cytokines were purchased from PeproTech. The Lin BM cells
were transduced with the appropriate lentiviral particles at an MOI of
10. At 18 to 24 hours after transduction, the transduced Lin
BM cells were harvested, washed, and resuspended in RPMI medium
containing 1% Pen/Strep at 2.5  106 cells/mL. Lethally irradiated
recipients received 5  105 Lin BM cells/each by tail vein injections.
Tail bleeds were performed at weeks 5, 7, and 9 after transplantation.
Recipient mice were killed 11 weeks after transplantation, and thymus,
spleen, LNs, and BM were harvested for phenotypic analysis and functional
characterization of T cells.
Adoptive T-cell transfer into secondary recipients
Lentiviral TCR-transduced C57BL/6 Lin BM cells were transferred into
lethally irradiated A2KbxCD45.1 Tg recipients as described in “HSC
isolation, infection and transfer.” Seventeen weeks after transplantation the
mice were killed, and their spleens were harvested. Untouched CD3 T-cell
selection was performed on splenocytes pooled from 5 primary recipients,
using a mouse pan-T cell isolation kit (Miltenyi Biotec). A total of 3  106
T cells were transferred to secondary A2KbxCD45.1 recipients that were
sublethally irradiated (5 Gy) 1 day before the transfer. Tail bleeds were
performed at day 9 and day 28 after adoptive transfer. On days 69 and 70, in
vivo cytotoxicity assays (See “In vivo cytotoxicity assays”) were per-
formed. Splenocytes from the secondary recipients were used in ex-vivo
proliferation assays (See “Ex vivo proliferation assays”).
Serial HSC transplants
BM cells from primary WT1-TCR HSC transplant recipients (A2KbxCD45.1
to A2Kb transplant) were pooled together and then transferred into lethally
irradiated (9.4 Gy) C57BL/6 mice (5  106 cells/recipient). Tail bleeds
were performed at 3, 5, 8, and 12 weeks after transplantation. Peripheral
blood was stained with anti-CD45.1 allophycocyanin-Cy7 (APC-Cy7),
CD3 fluorescein isothiocyanate (FITC), B220 phycoerythrin-Cy5 (PE-
Cy5), and CD11b APC antibodies to monitor the reconstitution kinetics of
all hematopoietic lineages. BM cells from untreated A2KbxCD45.1 Tg
mice were used to reconstitute lethally irradiated C57BL/6 mice as a control
for donor-derived hematopoietic reconstitution.
Antibodies and FACS analysis
The following fluorescently labeled anti–murine antibodies (BD Biosci-
ence) were used in the study: CD45.1 APC Cy7, CD3 APC, CD3 FITC,
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CD4 FITC, CD8a PE Cy5, CD44 APC, CD62L FITC, B220 PE Cy5,
CD11b APC, and streptavidin APC. Anti–human V2.1 PE, V2.1 biotin,
and V13 were purchased from Immunotech. An LSR II cytometer (BD
Bioscience) was used for flow cytometric analysis, and data were analyzed
using FlowJo Version 7 software (TreeStar).
In vivo cytotoxicity assays
Splenocytes from female A2Kb Tg mice were peptide loaded with 100M
of either relevant peptide (WT1-TCR WT126p, LMP2-TCR CLGp) or an
irrelevant HLA-A0201 presented peptide before labeling with 1.5M
carboxyfluorescein diacetate succinimidyl ester (CFSE; CFSEhigh) or 0.15M
CFSE (CFSElow), respectively, for 5 minutes at 37°C. The cells were then
washed once in ice-cold RPMI with 8% FCS and twice with ice-cold PBS.
Labeled cells were mixed at a 1:1 ratio, relevant: irrelevant targets and a
total of 10  106 mixed cells were injected per mouse. Eighteen hours later,
splenocytes of injected animals were analyzed by flow cytometry to identify
CFSE-labeled cells. Control untreated A2Kb Tg mice were injected with
labeled target cells, and in vivo cytotoxicity was calculated as previously
described. Percentage antigen-specific cytotoxicity was determined using
the following formula: [1  ((AB)/(CD))]  100, where A 	 mean
number of relevant peptide-loaded splenocytes at 18 hours in experimental
mice; B	mean number of irrelevant peptide-loaded splenocytes at 18 hours
in experimental mice; C 	 mean number of relevant peptide-loaded
splenocytes at 18 hours in control mice; and D 	 mean number of
irrelevant peptide-loaded splenocytes at 18 hours in control mice.
Ex vivo proliferation assays
Splenocytes from mice that had been transplanted with WT1 or LMP2-TCR-
transduced HSCs, or mice that had received an adoptive transfer of T cells
from primary transplant recipients, were labeled with 1.5M CFSE as in
“In vivo cytotoxicity assays” and placed in culture at 1  106 cells/mL.
CFSE-labeled splenocytes were stimulated with 100M of relevant
(WT126p/CLGp) or irrelevant peptide for 5 days before FACS analysis for
CFSE dilution after anti–human V2 or V13 antibody staining. In the case
of A2Kb Tg mice that received C57BL/6 TCR-transduced HSC cells,
professional antigen-presenting cells were almost completely replaced with
donor C57BL/6 BM-derived antigen-presenting cells. Therefore, to ensure
adequate antigen presentation, splenocytes were harvested from A2Kb Tg
mice, peptide loaded with relevant/irrelevant peptides (100M), and added
to the cell cultures at a 1:1 ratio to the splenocytes from the experimental
mice. The final cell concentration was 1  106 cells/mL.
ELISA
Supernatants from the ex vivo proliferation assays were harvested on day
5 and stored at20°C. IL-2 and IFN-
 production after peptide stimulation
was determined by performing ELISA on these supernatants using the BD
OptEIA mouse IL-2 and IFN-
 ELISA sets, as per the manufacturer’s
protocol.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software Version
5.0, and Microsoft Excel.
Results
TCR gene transfer into stem cells to study the development of
HLA-restricted, WT1-specific T cells
Previous studies have shown that retroviral TCR gene transfer into
HSCs can serve to analyze the development and function of
antigen-specific T cells in the thymus and periphery.27,28 In these
studies, retroviral vectors were used to infect bulk BM cells
followed by transfer into myeloablated recipients. We found that
lentiviral vectors efficiently transduced purified, lineage-negative
stem cells that efficiently reconstituted conditioned recipients and
developed into mature T cells. Hence, we assembled a lentiviral
vector containing the HLA-A0201-restricted TCR specific for the
WT1-derived peptide pWT126 (Figure 1A). The human constant
regions of the TCR- and - genes were replaced with murine
sequences to facilitate expression in murine cells.29 The constant
regions were further modified to encode a cysteine residue to
improve the pairing of the introduced TCR- and - chains (Figure
1B).30 HSCs were transduced with the WT1-TCR lentiviral con-
struct before transplantation into myeloablated transgenic A2Kb
mice (Figure 1D). The transgenic mice expressed hybrid HLA-
A0201 molecules consisting of human 1 and 2 domains, which
together form the peptide binding groove required for antigen
presentation (Figure 1C). The 3 domain was of murine origin to
facilitate appropriate interaction between murine CD8 coreceptors
and the hybrid HLA molecule. Importantly, both human and murine
WT1 proteins are highly conserved, and the HLA-A0201 presented
pWT126 peptide is identical between the 2 species. It has been
demonstrated that murine cells expressing murine WT1 can
generate the pWT126 for major histocompatibility complex (MHC)
presentation and T-cell recognition.31 Further, the endogenous WT1
expression pattern in normal tissues is very similar in humans and
mice.32 Thus, the HLA transgenic host provides an in vivo model to
investigate how physiologic WT1 expression affects the develop-
ment and function of HLA-restricted, WT1-specific T cells.
WT1-specific T cells are selected in the thymus
Purified Lin BM stem cells from A2Kb transgenic mice were
transduced with the lentiviral WT1-TCR vector. Using CD4/CD8
phenotyping and staining with antihuman V antibodies, we found
expression of the WT1-TCR in immature double-negative thymo-
cytes and also in the more mature double-positive population
(Figure 2A) in A2Kb transplant recipients. As expected, the HLA
class I-restricted TCR was selected into the CD8 single-positive
thymocyte population, with little TCR expression in CD4 single-
positive cells. We observed similar frequencies of TCR-expressing
cells in the CD4CD8 population and CD8 cells (Figure 2B),
suggesting no preferential loss of WT1-specific T cells at the
double-positive to single-positive stage of thymic selection. The
relative high frequency of WT1-TCR-expressing thymocytes in the
double-negative population is most probably the result of nonphysi-
ologic early expression of the lentiviral TCR construct, before the
expression of endogenous TCR-/ heterodimers. Together, the
thymus data were compatible with positive selection of WT1-
specific T cells at the double-positive to single-positive stage.
WT1-specific T cells persist in the periphery and differentiate
into memory phenotype cells without vaccination
Next, we explored whether TCR-expressing cells were detectable
in the periphery of transplanted mice (A2Kb3 A2Kb). Mature
T cells expressing the WT1-TCR were readily detectable in the
spleen, LNs, and BM (Figure 3A). As expected, the WT1-TCR was
expressed in peripheral CD8 T cells and not in CD4 cells (Figure
3B). Anti-CD3 antibodies were used to measure the level of
TCR/CD3 complex expression in all T cells derived from the
transplanted stem cell population. There was a substantial reduc-
tion in the level of CD3 expression in the WT1-TCR T cells
compared with the WT1-TCR T cells (Figure 3C). Low expres-
sion of the WT1-TCR could be the result of the self-specificity of
this TCR, or alternatively it could be the result of low promoter
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activity of the lentiviral vector driving TCR expression. We
therefore replaced the WT1-TCR variable gene segments in the
lentiviral vector with the variable region gene segments of an
HLA-A0201–restricted TCR specific for a non–self-peptide de-
rived from the LMP2 of Epstein Barr virus.25 Transplantation
experiments with transduced stem cells indicated that mature T
cells expressing the LMP2-TCR were readily detectable in the
spleen, LNs, and BM of transplanted mice (Figure 3A). As
expected, LMP2-TCR expression was limited to CD8 T cells and
not seen in CD4 T cells (Figure 3B). Importantly, the level of CD3
expression in the LMP2-TCR T cells was similar to that seen in
control T cells expressing endogenous TCR (Figure 3C). This
indicated that the reduced level of TCR/CD3 expression was not
caused by poor expression from the lentiviral vector but was a
feature of the self-reactive WT1-TCR and not of the non–self-
reactive LMP2-TCR.
In previous transgenic models, the down-modulation of TCR
and CD8 was described as an important mechanism of peripheral
tolerance induction.33 Unexpectedly, TCR down-modulation in
WT1-specific T cells was associated with an up-regulation of
CD8 coreceptor expression (Figure 3D). The down-modulation of
TCR and up-regulation of CD8 coreceptors were only seen in
WT1-specific T cells and not in T cells specific for the non–
self-LMP2 antigen (Figure 3D).
Differences in TCR and CD8 expression between WT1 and
LMP2-specific T cells correlated with differences in their activa-
tion status. The expression of the CD44 activation marker in
LMP2-specific (TCR) T cells was similar to that seen in endoge-
nous control (TCR) T cells (Figure 4A). In contrast, a large
proportion of the WT1-specific T cells expressed high levels of
CD44 and CD62L, a phenotype normally associated with central
memory T cells (Figure 4A).
Previous studies indicated that survival of naive T cells required
tonic TCR stimulation by MHC molecules expressed on hematopoi-
etic cells, whereas memory T-cell survival did not require tonic
triggering by hematopoietic cells.34 However, the role of hematopoi-
etic cells in the generation of memory phenotype T cells in the
absence of vaccination has not yet been explored. Hence, we
analyzed whether the generation and maintenance of WT1-specific
memory phenotype T cells was dependent on antigen-presentation
by hematopoietic cells. Stem cells from normal B6 mice were
transduced with the WT1-TCR lentiviral vector and transplanted
into HLA-A2Kb transgenic B6 recipients. In the transplanted mice,
hematopoietic cells, including professional antigen-presenting cells,
were unable to present antigen to the HLA-A0201–restricted
WT1-TCR. Analysis of WT1-specific T cells in these mice showed
that the development of CD44highCD62Lhigh memory phenotype
cells was not dependent on antigen presentation by hematopoietic
cells (Figure 4A bottom row).
A more detailed analysis of the naive (CD44lowCD62Lhigh),
central memory (CD44highCD62Lhigh), and effector memory
(CD44highCD62Low) T-cell frequencies in mice expressing
WT1-TCR or LMP2-TCR showed that the WT1-TCR–expressing
population contained significantly less naive phenotype T cells
Figure 1. Schematic representations. (A) Schematic representation of the pSIN second-generation lentiviral vector encoding the codon-optimized, murinized hybrid
HLA-A0201–restricted pWT126-specific Cys-1 modified TCR - and -chain genes (or the HLA-A0201–restricted LMP2-specific Cys1 modified TCR chains) separated by a
self-cleaving porcine tsechovirus 2A sequence. SFFV indicates spleen-forming focus virus; LTR, long terminal repeat; and WPRE, woodchuck hepatitis virus
posttranscriptional regulatory element. (B) Schematic representation of the Cys-1 modified, codon-optimized hybrid TCR containing murine constant regions (black outline)
and human variable regions. (C) Schematic representation of the hybrid HLA-A2Kb molecule expressed in HLA-A2Kb (A2Kb) transgenic mice. The hybrid MHC class
I molecules in A2Kb mice contain human alpha1 and alpha2 domains that interact with the human HLA-A2–restricted TCR, fused to a murine alpha3 domain, which facilitates
interaction with the murine CD8 coreceptor. (D) Schematic representation of TCR-transduced HSC transplantation. Lineage BM stem cells (HSCs) were transduced with
lentivirus at an MOI of 10. Each lethally irradiated recipient received 5  105 bulk transduced HSCs.
6816 POSPORI et al BLOOD, 23 JUNE 2011  VOLUME 117, NUMBER 25
 For personal use only. by guest on October 1, 2012. bloodjournal.hematologylibrary.orgFrom 
compared with LMP2-TCR–expressing population (P  .001;
Figure 4B). In contrast, central memory cells were significantly
more frequent in the WT1-TCR–expressing population (P  .001)
in both recipients of TCR-Td A2Kb and TCR-Td B6 stem cells.
An increased frequency of effector memory T cells in the
WT1-TCR–expressing population (compared with the frequency
of LMP2-TCR–expressing effector memory T cells) was only
observed in mice reconstituted with A2Kb stem cells (P  .05) but
not those reconstituted with B6 stem cells (P 	 not significant;
Figure 4B). Therefore, antigen presentation by hematopoietic cells
promoted the differentiation of WT1-specific T cells into effector
memory phenotype cells. At the time of the phenotypic analysis,
the percentage donor chimerism of the CD3 cells (including
antigen-presenting cells) in the B63 A2Kb transplant recipients
showed between 92% and 97% donor cells (data not shown).
It is therefore possible that the small number of residual A2Kb
antigen-presenting cells contributed to, or was sufficient for, the
development of central memory and effector memory phenotype cells
in the mice transplanted with B6 stem cells.
Within the WT1-specific T cells, the TCR-low population
contained primarily memory phenotype cells, whereas the TCR-
high population contained both naive and memory phenotype
T cells (Figure 4C). Together, these observations suggested that
naive phenotype T cells differentiated into memory phenotype cells
by a mechanism that involved TCR triggering, which resulted in
TCR down-modulation and up-regulation of the CD44 activation
marker. It is possible that the lymphopenic environment of
transplanted mice facilitates the generation of WT1-specific memory
T cells, although this environment does not promote LMP2-specific
memory T-cell development.
WT1-specific T cells display antigen-specific effector function
without vaccination
We explored whether WT1-specific T cells, and more specifically
the memory phenotype T cells, were able to display antigen-
specific effector function. In vivo cytotoxicity assays revealed
strong antigen-specific killing activity in A2Kb mice transplanted
with WT1-TCR–transduced A2Kb stem cells or B6 stem cells
(Figure 5A). In contrast, no antigen-specific killing was observed
in mice transplanted with LMP2-TCR–transduced stem cells,
although the number of peripheral T cells expressing the LMP2-
TCR or WT1-TCR was similar (Figure 5A). Ex vivo, the WT1-
specific T cells isolated from both A2Kb3 A2Kb and B63 A2Kb
transplanted mice displayed antigen-specific proliferation (Figure
5B), IL-2 and IFN-
 production (Figure 5C, B63 A2Kb not
shown), whereas LMP2-specific T cells displayed no antigen-
specific functions (Figure 5B-C). These data indicated that the
phenotypic differences between WT1-specific and LMP2-specific
T cells correlated with the ability of WT1-specific T cells to display
antigen-specific effector function without prior vaccination.
Figure 2. WT1 specific T cells are selected in the thymus. (A) FACS analysis of thymocytes isolated from A2Kb mice transplanted with linA2Kb BM stem cells transduced
with the lentiviral WT1-TCR vector. Thymocytes were stained with antimurine CD3, CD4, and CD8 antibodies together with anti–human V2.1 to detect the WT1-TCR  chain.
SP indicates single positive; DP, double positive; and DN, double negative. Representative plots from a total of 8 mice are shown. (B) Percentage of murine thymocytes
expressing the WT1-TCR as detected by anti–human V2.1 antibody at each stage of thymic selection was determined by FACS analysis after gating on DN, DP, or
SP populations. A total of 8 transplanted A2Kb3 A2Kb mice were analyzed.
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To test the in vivo function of WT1-specific memory phenotype
T cells, cell transfer experiments were performed to generate mice
lacking naive phenotype cells. T cells were purified from A2Kb
mice transplanted with WT1-TCR-transduced B6 stem cells and
then adoptively transferred into irradiated secondary A2Kb-
transgenic recipients. The secondary recipients were unable to
generate “new” WT1-specific T cells in the thymus, which was
expected to result in the loss of naive phenotype cells and in the
persistence of memory phenotype T cells. The analysis of LNs,
spleen, and BM of the secondary recipients 10 weeks after transfer
demonstrated a loss of the CD44lowCD62Lhigh naive phenotype
T cells with high TCR expression level and persistence of
CD44highCD62Lhigh memory phenotype T cells expressing reduced
TCR and elevated CD8 (Figure 6A-B). In transiently lymphopenic
hosts, the WT1-specific T cells converted more efficiently into
memory phenotype cells than the WT1-TCR negative control
Figure 3. WT1 specific T cells persist in the periphery. (A) FACS analysis of peripheral T cells in spleen, LNs, and BM of A2Kb Tg mice killed 11 weeks after transplantation
with TCR-transduced Lin A2Kb BM stem cells. Mice received untransduced stem cells (top row), WT1-TCR-transduced stem cells (middle row, n 	 8), or
LMP2-TCR–transduced stem cells (bottom row, n 	 5). Viable lymphocytes were stained with anti-CD3, and anti–human V2.1 (WT1-TCR) and anti–human V13
(LMP2-TCR) antibodies before FACS analysis. Percentages of V2.1 and V13 cells in total CD3 cells are indicated. (B) FACS analysis of splenocytes isolated from A2Kb
Tg mice transplanted with LinA2Kb BM stem cells transduced with the lentiviral WT1-TCR or LMP2-TCR vector. Splenocytes were stained with anti–murine CD3, CD4, and
CD8 antibodies together with anti–human V2.1 and anti–human V13. (C) Cell surface CD3/TCR complex expression levels in peripheral T cells were determined by FACS
analysis after staining with anti-CD3, and anti–human V2.1 and anti–human V13 antibodies. CD3/TCR expression levels of the WT1-TCR (self-reactive) and the LMP2-TCR
(non–self-reactive) were compared with endogenous polyclonal T cells derived from transplanted stem cells (V2.1 and V13, respectively). Data are mean  SD of CD3
mean fluorescence intensity (MFI; n 	 8 mice for WT1-TCR and n 	 5 mice for LMP2-TCR). *P  0.05, 1-way ANOVA. **P  .01, 1-way ANOVA. (D) Modulation of TCR
and/or CD8 expression was determined by FACS analysis of peripheral T cells of spleen, LNs, and BM stained with anti-CD8, and anti–human V2.1 (WT1-TCR, n 	 8) and
anti–human V13 (LMP2-TCR, n 	 5) antibodies. After gating on viable CD3 cells, percentages of TCRhi and TCRlo populations are indicated. All recipient mice were A2Kb
and received TCR-Td A2Kb stem cells.
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T cells expressing endogenous TCRs (Figure 6B left panel).
Cytotoxicity experiments in the secondary hosts demonstrated
efficient WT1-specific effector function, which correlated with
robust WT1-specific proliferation ex vivo (Figure 6C). This clearly
demonstrated that the CD44high/CD62Lhigh memory phenotype
T cells were capable of displaying antigen-specific effector func-
tion without prior vaccination.
WT1-specific T cells accumulate in the BM without impairing
stem cell function
Considering that BM resident stem/progenitor cells express low
levels of WT1, we explored whether WT1-specific T cells accumu-
lated in the BM of mice transplanted with A2Kb stem cells.
Analysis of the donor T-cell compartment showed an increased
percentage of WT1-specific T cells in the BM compared with LNs
and spleen (Figure 7A). In contrast, analysis of LMP2-TCR
transplanted mice demonstrated no enrichment of LMP2-specific
T cells in the BM compared with LNs and spleen of these mice
(Figure 7A). It was possible that the accumulation of WT1-specific
T cells was the result of selective recruitment and proliferation of
memory phenotype T cells to the BM, as shown in other studies.35
However, analysis of WT1-specific T cells showed that the relative
frequency of naive and memory phenotype cells was similar in BM
compared with spleen and LNs (data not shown). This suggests that
the observed accumulation in BM of WT1-specific T cells, but not
LMP2-specific T cells, was primarily driven by the specificity and
not the memory phenotype of WT1-T cells.
Finally, we examined whether the presence of WT1-specific
T cells resulted in damage to the stem/progenitor cells in the BM of
transplanted mice. BM was harvested from WT1-TCR transplanted
mice and from control mice, followed by transplantation into
myeloablated secondary recipients to measure long-term reconsti-
tution of hematopoiesis. Analysis revealed that both myeloid and
lymphoid lineages were efficiently reconstituted by BM isolated
from donors transplanted with WT1-TCR–transduced stem cells,
demonstrating that WT1-specific T cells did not impair the
functional competence of the hematopoietic progenitor/stem cells
(Figure 7B). However, T-cell engraftment was slower in the
experimental mice compared with control mice (P  .01). It is
possible that lentiviral vector-driven TCR expression in developing
thymocytes alters the kinetics of T-cell repertoire selection and
T-cell reconstitution in the thymus of transplanted mice.
Figure 4. Peripheral WT1-specific T cells differentiate into memory T cells without vaccination. (A) CD44 and CD62L expression on gated TCR-expressing (TCR) and
gated TCR peripheral T cells as determined by FACS analysis after staining with anti–murine CD44 and CD62L antibodies. Similar staining patterns were observed for both
splenocytes and LN (shown here). (Top and middle panels) Resentative plots from A2Kb Tg mice transplanted with A2Kb stem cells transduced with the WT1-TCR (top panel,
n 	 8) or the LMP2-TCR (middle panel, n 	 5). (Bottom panel) Representative plots from A2Kb Tg mice transplanted with B6-derived stem cells transduced with the WT1-TCR
(n 	 8). (B) Summary data of naive (CD44low, CD62Lhigh), CM (CD44high, CD62Lhigh), and EM (CD44high, CD62Llow) T-cell frequencies in transplanted mice expressing
WT1-TCR or LMP2-TCR. ***P  .001. **P  .01. A2Kb3 A2Kb or B63 A2Kb as indicated in the figure. (C) Phenotypic analysis of gated WT1-TCRhi and WT1-TCRlo
peripheral T-cell populations in A2Kb recipients after transplantation with TCR-Td B6 stem cells, after staining with anti–murine CD44, CD62L, and CD8 antibodies. ns indicates
not significant.
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Figure 5. WT1 specific T cells display peptide-specific effector function. (A) In vivo cytotoxicity of CFSE-labeled peptide-loaded target cells. A2Kb Tg mice, 11 weeks after
transfer of BM stem cells transduced with the WT1-TCR (top panel, n 	 7 A2Kb3 A2Kb, n 	 5 B63 A2Kb) or LMP2-TCR (bottom panel, n 	 4 A2Kb3 A2Kb) were
intravenously injected with a 1:1 mix of relevant: irrelevant peptide-loaded A2Kb Tg splenocytes, differentially labeled with CFSE (WT1-TCR is specific for WT126 peptide, and
LMP2-TCR is specific for CLG peptide). Eighteen hours later, splenocytes of injected animals were harvested and analyzed by FACS to identify CFSE-labeled cells.
Representative plots are shown. Control untreated A2Kb Tg mice were injected with CFSE-labeled peptide-loaded target cells. Summary data of in vivo cytotoxicity assays are
shown on the right. Percentage antigen-specific cytototoxicity was calculated as described in “In vivo cytotoxicity assays.” ***P  .001. (B) Ex vivo proliferation of splenocytes
from mice previously transplanted with WT1-TCR and LMP2-TCR-transduced A2Kb or B6 BM stem cells. Splenocytes were stimulated for 5 days with 100M relevant
or irrelevant peptide. CFSE-labeled splenocytes were analyzed by FACS for CFSE dilution after anti–human V2.1 or V13 antibody staining. A representative plot
of pWT126-specific proliferation is shown on the left. Summary data of ex vivo proliferation assays using T cells harvested from mice transplanted with WT1-TCR
(n 	 8 A2Kb3 A2Kb, n 	 3 B63 A2Kb) and LMP2-TCR (n 	 5 A2Kb3 A2Kb) transduced BM stem cells is shown on the right. **P  .01, ***P  .001. (C) Splenocytes
harvested from A2Kb mice transplanted with WT1-TCR and LMP2-TCR-transduced A2Kb BM stem cells were stimulated ex vivo with 100M relevant or irrelevant peptide for
5 days. ELISAs were performed to detect antigen-specific IFN-
 and IL-2 secretion. ns indicates not significant.
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Discussion
We have used TCR gene transfer into HSCs to analyze the thymic
development and peripheral function of T cells specific for a WT1
peptide presented by HLA-A0201. In this approach, populations of
stem cells carrying distinct gene insertions give rise to mature
T cells, thus avoiding possible founder effects of transgenic mice
because of insertion of the transgene at a single genomic site.
Further, in this model, the TCR-expressing cells represent only a
small proportion of the whole T-cell repertoire providing an
environment of polyclonal competition that contributes to the
survival and maintenance of the peripheral T-cell pool.36
The WT1-specific TCR used was derived from high avidity
human allorestricted CD8 T cells that efficiently recognize
WT1-expressing human leukemia cells without impairing the
function of human hematopoietic stem/progenitor cells.23 In this
study, the TCR was not deleted in the thymus but successfully
selected into the single-positive CD8 lineage. Although some
studies have demonstrated thymic WT1 expression, we found that
the expression was high in the mesothelial lining but not in the
epithelial stroma of the thymus, in agreement with previously
described WT1 expression in cells with dual mesenchymal and
epithelial properties, such as mesothelium, renal podocytes, and
testicular Sertoli cells.37 Our data indicate that physiologic
WT1 expression does not prevent selection of a high-avidity
WT1-specific human TCR.
Unexpectedly, in our study, WT1-specific T cells did not display
signs of self-antigen–induced tolerance but instead differentiated
spontaneously into fully functional memory phenotype T cells.
Previous studies have clearly demonstrated that lymphopenia-
induced proliferation can result in the differentiation of naive
T cells into memory phenotype T cells,38,39 and such cells can
display antigen-specific effector function. However, this effect was
transient, as antigen-specific effector function was only detectable
during a time period of 12 to 31 days after T-cell transfer into
Figure 6. WT1-specific memory phenotype T cells display antigen specific effector function. (A) T cells were purified from A2Kb mice transplanted with
WT1-TCR-transduced B6 BM stem cells and used for adoptive transfer into irradiated secondary A2Kb Tg recipient mice (n 	 4). At 10 weeks after transfer, CD8/TCR
expression of the transferred T cells was determined by FACS analysis of splenocytes, LNs, and BM after staining with antimurine CD8 and antihuman V2.1 antibodies,
respectively. (Left panel) The TCR and CD8 profile of the T cells before transfer. (Right panel) The profile 10 weeks after transfer. Percentage of TCRhi and TCRlo populations
are shown after gating on total CD3 cells. (B) Analysis of the naive/memory phenotype of gated WT1-TCR (V2.1) T cells from spleen, LNs, and BM 10 weeks after
adoptive transfer was determined by FACS analysis after staining with anti-CD44 and CD62L antibodies. (Left panel) The naive/memory phenotype of gated WT1-TCR T cells
in LNs. (C) In vivo cytotoxicity experiments were performed in A2Kb Tg secondary recipients 10 weeks after adoptive transfer of T cells. Mean percentage killing of
CFSE-labeled relevant peptide-loaded splenocytes from 3 mice is shown on the left. Ex vivo proliferation of WT1-TCR and WT1-TCR T cells after stimulation with relevant
peptide was determined by FACS analysis for CFSE dilution after staining with antihuman V2.1 antibodies.
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lymphopenic hosts.39 Although there are some similarities between
our model and lymphopenia-induced memory phenotype induction,
there are also important differences. In our stem cell transplantation
model, thymic development generates a polyclonal T-cell popula-
tion that reconstitutes the peripheral compartment. In this situation,
the majority of non–WT1-specific T cells do not develop a memory
phenotype, whereas a large proportion of the WT1-specifc T cells
differentiate into memory T cells that maintain the ability to display
antigen-specific effector function for several months after the
initial stem cell transplantation. The reconstitution of a lym-
phopenic periphery after stem cell transplantation is similar to the
generation of a peripheral T-cell repertoire in newborn mice, where
adoptive T-cell transfer has previously demonstrated that
lymophopenia-induced proliferation promoted memory phenotype
development in approximately 20% of a transferred polyclonal
T-cell population.40 It was also shown that 2 monospecific TCR
transgenic T-cell populations did not proliferate in the newborn
hosts, suggesting that these TCRs, such as the TCRs of 80% of the
polyclonal T cells, were not stimulated sufficiently by endogenous
MHC/peptide ligands to trigger proliferation and memory develop-
ment. These findings in neonates are very similar to our findings of
T-cell reconstitution after stem cell transplantation. However, we
found that the self-specific WT1-TCR was more effective than the
polyclonal endogenous TCRs or the non–self-specific LMP2-TCR
in differentiating into memory phenotype cells.
Our data are compatible with the proposal that chronic stimula-
tion by self-antigen triggered the spontaneous differentiation of
WT1-specific T cells into persisting memory cells. Unfortunately,
both WT1 knockout mice as well as inducible tissue-specific
knockout animals are not viable.41 Thus, it is not possible to
perform stem cell transplantation experiments in a WT1-deficient
host to unequivocally prove that WT1 is the self-antigen driving the
generation of central memory T cells.
Although specificity for self-antigen has been suggested to play
a role in the generation of natural central memory phenotype cells,
experimental evidence to support this has not yet been described.18
A population of memory phenotype T cells was found in germ-free
mice, suggesting that exposure to microbial antigens is not essential for
their development.19,20 Typically, the number of natural memory pheno-
type T cells increase with age,18 which is similar to our observation
that over time the frequency of WT1-specific T cells increased
relative to the frequency of WT1-negative T cells (data not shown).
A recent report demonstrated that, although natural memory
phenotype T cells rapidly up-regulated CD69 on encountering
peptide antigen in vivo, this did not correlate with in vivo cytokine
production.19 The lack of detectable effector function led the
authors to propose the term “virtual memory cells.” In contrast, the
WT1-specific T cells were not “virtual memory cells” as they
readily displayed in vivo cytotoxicity. A possible explanation for
this difference is that the cytotoxic effector function is more readily
triggered than in vivo cytokine production. Alternatively, it is
possible that the natural memory phenotype population contains
less differentiated virtual memory cells as well as more differenti-
ated T cells capable of full antigen-specific effector function. It is
tempting to speculate that the generation of virtual memory T cells
is primarily driven by homeostatic proliferation, as suggested by
Haluszczak et al,19 whereas the generation of more differentiated
memory T cells involves additionally TCR stimulation, as sug-
gested by the observed TCR down-modulation in WT1-specific
memory T cells.
The analysis of TCR- usage showed that naive and natural
memory phenotype T cells in young mice used similar TCR-
variable gene segments.40 Our study extends this observation by
demonstrating that T cells expressing identical TCR sequences can
be present in both compartments. The data presented here are
supported by a recent study in healthy human volunteers showing
that both the naive and memory phenotype compartments con-
tained WT1-specific T cells.15 In patients with WT1-expressing
malignancies, the frequency of naive phenotype cells was reduced,
whereas memory phenotype T cells were increased. Whether this
shift was the result of priming and differentiation of naive T cells or
to the stimulation and expansion of memory phenotype T cells is
currently not clear. The HLA transgenic model described here
provides an opportunity to dissect which of the WT1-specific
T-cell populations responds more effectively when encountering
WT1-expressing malignancies or WT1-containing vaccines. It is
conceivable that the antigen dose and the costimulatory signals for
Figure 7. WT1 specific T cells accumulate in the BM without impairing stem cell
function. (A) Donor T cells (CD45.1) were analyzed in the spleen, LNs, and BM of
A2Kb Tg mice transplanted with BM stem cells transduced with the WT1-TCR (n 	 8)
or the LMP2-TCR (n 	 5) at 12 weeks after transplantation. The percentage of
CD45.1 donor T cells expressing V2.1 (WT1-TCR) or V13 (LMP2-TCR) was
determined by FACS analysis. (B) Hematopoietic engraftment in secondary C57Bl/6
recipients (CD45.2) after transplantation of BM cells from A2Kb Tg mice that were
previously transplanted with A2Kb BM stem cells (CD45.1) transduced with the
WT1-TCR (n 	 10). Peripheral blood of secondary recipients was stained with
antimurine CD45.1, CD3, B220, and CD11b to identify donor hematopoietic cells,
donor T cells, donor B cells and donor granulocytes, respectively. The peripheral
blood analysis was done at weeks 3, 4, 8, and 12 after second transplantation.
Control C57Bl/6 recipients received BM stem cells from untreated A2Kb (CD45.1) Tg
mice (n 	 5). Percentage of donor-derived cells are shown after gating on total
granulocytes, B cells, and T cells, respectively. *P  .05, **P  .01, ***P  .001. ns
indicates not significant.
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the productive vaccination of naive T cells are different from the
conditions required for optimal triggering and expansion of the
memory phenotype T cells. Thus far, immune responses triggered
by WT1 peptide vaccination were often transient and weaned soon
after the vaccination.10
The transgenic murine model will help to define optimal
conditions for WT1-directed T cell immunotherapies including
vaccination with the aim of efficiently priming naive T cells while
at the same time supporting the expansion and persistence memory
phenotype T cells.
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